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Mitochondrial DNA mutations lead to a group of diseases that are both genetically 
and phenotypically heterogeneous. The m.3243A>G point mutation is one of the 
most common and is also present in around 80% of patients with mitochondrial 
encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS), which is a 
phenotype characterised by symptoms that affect multiple systems and are either 
progressive or recessive progressive in nature. The aim of this thesis was to develop 
analysis methodologies to quantitatively characterise the structural properties of the 
brains of controls, carriers, and MELAS patients using non-invasive MRI techniques 
to then determine 
I developed robust segmentation protocols from first principles for the global 
segmentation using FSL 5.0, and also for the regional segmentation using FreeSurfer 
5.4. Global segmentation results shows that total intracranial volume may provide a 
surrogate marker for susceptibility to the onset of stroke-like episodes. Grey and 
white matter volumes showed significant difference in brain composition between 
controls and carriers despite the absence of overall brain volume differences. 
Regional segmentation highlighted that MELAS patients showed an almost global 
thinning of the cortex compared to both controls and carrier, but all carriers of the 
m.3243A>G point mutation showed significant thinning of the temporal pole and 
entorhinal cortex irrespective of the symptoms presented. 
The TBSS analysis repeated this finding of a global difference in white matter 
fractional anisotropy between carriers and MELAS patients, indicating that although 
stroke-like episodes lead to localised lesions, the degenerative effects are felt 
throughout the brain. 
The ultra-high-resolution MRI of post mortem sections highlighted the potential for 
the use of this technique in the future to allow the co-registration of MRI and 
neuropathological imaging despite the condition of the brain sections being 
suboptimal due to mounting in hydrogel. 
This study provides a protocol for the systematic, quantitative characterisation, along 
with initial data capture and analysis, of brain volumes in people harbouring the 
m.3243A>G point mutation. This can be used as a starting point to more effectively 






1. Hossain, C. L., Hall, J., Ng, Y., Bright, A., Blamire, A., Turnbull, D. M., McFarland, 
R., Gorman, G. S. (2017) ‘Identification of biomarkers in patients with mitochondrial 
disease using non-invasive imaging’, Conference Proceedings EuroMIT 2017. 
2. Hossain, C. L., Hall, J., Ng, Y., Bright, A., Blamire, A., Turnbull, D. M., McFarland, 
R., Gorman, G. S. (2018) ‘Structural analysis of m.3243A>G patients using 3D 
anatomical brain scans’, Conference Proceedings ISMRM, Paris 2018, 




List of Figures 
Figure 1. Schematic representation of the main elements of a mitochondrion. ........................ 24 
Figure 2. Classical EM image showing mitochondria as ovoid and rod-shaped structures 
(Image provided courtesy of Dr Amy Vincent). .............................................................................. 25 
Figure 3. 3D volumetric rendering of EM imagery demonstrating the large variation in 
mitochondrial shape, size and connectivity Image provided courtesy of Dr Amy Vincent). .... 25 
Figure 4. Proton spin orientations without external magnetic field (left) and with applied 
external magnetic field (right). .......................................................................................................... 38 
Figure 5. An RF pulse applied at a specific frequency imparts energy to the protons causing 
them to flip through an angle, , and precess around the axis of the external magnetic field.
 ............................................................................................................................................................... 39 
Figure 6. T1 relaxation curves for white matter (WM) (blue), grey matter (GM) (orange), and 
CSF (grey). In a T1-weighted image a short TR is used to maximise the contrast between all 
tissue types, which is better suited to carrying out volumetric analysis as tissue contrast is 
optimised. ............................................................................................................................................. 41 
Figure 7. Graph showing the increased contrast between grey and white matter, and CSF 
when using T2-weighted imaging. .................................................................................................... 42 
Figure 8. Example T1-weighted (left) and T2-weighted (right) images generated from the 
study cohort scan set for Patient 6. The difference in intensity associated with each tissue 
type and the contrast between tissues can clearly be seen......................................................... 43 
Figure 9. Example T2-FLAIR (left) and T2-weighted (right) images generated from the study 
cohort scan set for Patient 6. While the grey and white matter contrast are maintained, the 
bright CSF of the T2-weighted image is suppressed, thus making it easier to observe the 
details in and around the areas of CSF. .......................................................................................... 44 
Figure 10. A model of anisotropic diffusion of water molecules (left) and its associated 
representation by a tensor (right). .................................................................................................... 46 
Figure 11. Example slices from Patient 1 of (A) T1-weighted, (B) MD, and (C) FA. ................. 47 
Figure 12. Schematic diagram of the route of the inferior longitudinal fasciculus joining the 
temporal and occipital poles. ............................................................................................................ 48 
Figure 13. Flow chart showing breakdown of articles identified through a systematic search 
(1st January 1980 to 26th October 2017) before and after the application of the exclusion 
criteria. .................................................................................................................................................. 53 
Figure 14. Breakdown of papers that have quantitative analysis by subject matter. Papers 
may appear in more than one category depending on the study conducted. ........................... 54 
Figure 15. Histogram of a high resolution 1mm3 voxel structural MRI scan. The separated 




Figure 16. Histogram of a thick-slice T1SE scan using 3mm slices through the brain. The 
CSF can clearly be seen with a much lower intensity, but there is no clear separation 
between GM and WM intensity grouping, although some contrast may be observed. ........... 94 
Figure 17. Single slices taken from a high-resolution (1mm3 voxels) scan (A) and a thick-slice 
scan (4mm slice thickness with 1mm2 pixels) (B).  The differences in the contrast between 
grey and white matter are very clear and cannot be improved from the images above using 
contrast enhancement techniques. .................................................................................................. 95 
Figure 18. Image showing the interference of a bias field in the assessment of pixel intensity 
in the form of regular peaks across the slice histogram. .............................................................. 96 
Figure 19. Single slice examples of GM segmentation output from manual (B), FSL 5.0 (C), 
and SPM12 (D) segmentation, with original T1 image also provided as a reference (A). The 
grey matter in the manual segmentation is shown in yellow. In the FSL and SPM images, the 
grey matter is shown in a red-yellow colour scheme in which the yellow areas represent high 
levels of confidence (0.95-1.0), and the red areas represent areas of lower confidence. ...... 99 
Figure 20. Output volumes of global segmentation of grey matter for FSL, manual, and 
SPM12 segmentation showing the similarity in volumes between the FSL and manual 
segmentation techniques. ............................................................................................................... 100 
Figure 21. Single slice examples of WM segmentation output from manual (B), FSL 5.0 (C), 
and SPM12 (D) segmentation, with original T1 image (A) also provided as a reference. The 
dark blue regions in the FSL and SPM images represent regions of lower confidence in the 
classification of the white matter. ................................................................................................... 100 
Figure 22. Output volumes of global segmentation of grey matter for FSL, manual, and 
SPM12 segmentation showing the similarity in volumes between the FSL and manual 
segmentation techniques. ............................................................................................................... 102 
Figure 23. Output volumes of global segmentation leading to TICVs for FSL, manual, and 
SPM12................................................................................................................................................ 103 
Figure 24. (A) 2D presentation of the definition of total intracranial volume, (B) 3D model of 
the total intracranial volume of the brain shown in the MRI in (A) ............................................ 108 
Figure 25. (A) 2D presentation of the definition of total parenchymal volume, (B) 3D model of 
the total parenchymal volume of the brain shown in the MRI in (A). Note that the definition of 
the cerebellum is relatively poor, this is due to the small size of the detailed structure leading 
to blurring due to the partial volume effect. .................................................................................. 109 
Figure 26. Images taken from ImageJ showing the cut-off position for the cerebellar 
measurements. ................................................................................................................................. 110 
Figure 27. Breakdown showing individual z scores of the carrier and MELAS participants 




size compared to a healthy population. The red dashed line denotes a z score of -3, below 
which only 0.15% of the control population will lie. ..................................................................... 115 
Figure 28. Plot of BMI against TICV, showing graphically the overall lack of correlation 
between BMI and TICV, and that ‘outliers’ with high BMIs are present in both the carrier and 
MELAS patient groups. .................................................................................................................... 116 
Figure 29. 3D model of the TPV of a MELAS patient brain that has undergone significant 
atrophy throughout the brain. The differences between this and the healthy brain in Figure 
1Figure 25 (B). .................................................................................................................................. 117 
Figure 30. Plot of age and gender corrected z scores comparing the relative TPV between 
the carrier and MELAS groups. The two carriers with relative TPVs in the smallest 2.5% of 
the population are highlighted. ........................................................................................................ 119 
Figure 31. Graph showing two examples of patients with MELAS showing a rapid longitudinal 
change of brain volume over time with the healthy population mean and 95th percentile limits 
derived from the meta-analysis paper: M. Vågberg et al., PLOS One, 17 Jan 2017: 5878 
(3102 Female) healthy individuals. ................................................................................................ 120 
Figure 32. Plot of z scores of GM volumes normalised to TICV for the carrier and MELAS 
patient groups. ................................................................................................................................... 123 
Figure 33. Plot of z scores of relative WM volumes for the carrier and MELAS patient groups.
 ............................................................................................................................................................. 125 
Figure 34. Graph of carrier GM:WM z scores showing that some carriers have a normal ratio, 
while others show large reductions in GM volumes compared to the control group, which 
appear to dominate the statistical analysis carried out. In a group-wise analysis, the control 
group have a significantly larger grey to white matter ratio (p = 0.003). .................................. 126 
Figure 35. z scores of cerebellar volumes corrected for age, gender, and head size. .......... 128 
Figure 36. Visual representation of the Desikan-Killiany Cortical Parcellation Atlas in an 
inflated brain ...................................................................................................................................... 136 
Figure 37. z scores of the cortical thickness by lobe of the carrier and MELAS patient groups, 
corrected for head size, age, and gender. .................................................................................... 141 
Figure 38. z scores for the cortical thickness of each sub-region, averaged across the sub-
region, of the frontal lobe. ................................................................................................................ 142 
Figure 39. z scores for the cortical thickness of each sub-region, averaged across the sub-
region, of the parietal lobe. .............................................................................................................. 143 
Figure 40. z scores for the cortical thickness of each sub-region, averaged across the sub-
region, of the occipital lobe. ............................................................................................................ 144 
Figure 41. z scores for the average cortical thickness of each sub-region of the temporal 




Figure 42. TBSS output showing the regions in which carriers have a significantly higher FA 
than patients with MELAS. The mean FA skeleton is shown in green. The regions indicate a 
significant difference between the Carrier and Patient groups with a confidence limit of over 
95%. .................................................................................................................................................... 154 
Figure 43. Documented characteristics of lesions seen in patients with mitochondrial disease. 
A.I. shows normal cellular layers in the temporal cortex while A.II. and A.III. show loss of 
neuronal cells and tissue necrosis. B.I. and B.II. show severe astrogliosis. C.I. and C.II. show 
tissue inflammation. [Images courtesy of Dr N. Z. Lax] .............................................................. 160 
Figure 44. Images of a mouse cerebellum obtained using the CLARITY technique combined 
with immunofluorescent staining and also the use of confocal microscopy (red scale bar = 
100 μm). Reproduced with permission from Phillips (2015). ..................................................... 161 
Figure 45. Basic representation of a perfect magnetisation inversion recovery to demonstrate 
the array requirement to contain an exponential set of inversion times to cover both the 
negative and positive magnetisation regions equally during the scan. .................................... 166 
Figure 46. Ultra-high-resolution MRI scan with 39µm x 39µm x 125 µm voxels using a brain 
section from a non-lesioned area of brain from a patient with the m.3243A>G point mutation 
after mounting it in hydrogel. .......................................................................................................... 168 
Figure 47. Ultra-high-resolution MRI scan with 39 µm x 39 µm x 125 µm voxels using a brain 
section from a non-lesioned area of brain from a patient with the m.3243A>G point mutation 
after mounting it in hydrogel. .......................................................................................................... 169 
Figure 48. Ultra-high-resolution MRI scan with 40 µm x 40µ x 125 µm voxels using a brain 
section from a lesioned area of brain from a patient with the m.3243A>G point mutation after 
mounting it in hydrogel. ................................................................................................................... 170 
Figure 49. Quantitative T1 map showing the variation of T1 (in seconds) in a post mortem 
section of fixed brain tissue after mounting in hydrogel from a non-lesioned area of brain from 
a patient with the m.3243A>G point mutation. ............................................................................. 171 
Figure 50. Quantitative T1 map showing the variation of T1 (in seconds) in a post mortem 
section of fixed brain tissue after mounting in hydrogel from a lesioned area of brain from a 
patient with the m.3243A>G point mutation. ................................................................................ 171 
Figure 51. Screen capture of the FSL BET GUI (reproduced here with the permission of the 
FMRIB FSL Development Group, Oxford University). ................................................................ 222 
Figure 52. Screen capture of the FSL FAST GUI (reproduced here with the permission of the 





List of Tables 
Table 1. Typical water ADC values in a healthy population (Helenius et al., 2002). These 
ADC values did not vary significantly with age, gender, or hemisphere. ................................... 65 
Table 2. Published water ADC values in patients with MELAS with confirmed m.3243A>G 
point mutations (Iizuka et al., 2003; Liu et al., 2011). ................................................................... 66 
Table 3. Details of participants involved in the m.3243A>G cohort study. SNHL = 
sensorineural hearing loss; WPW = Wolff-Parkinson-White syndrome; CPEO = chronic 
progressive external ophthalmoplegia; n.d. = not detectable; MELAS = mitochondrial 
encephalomyopathy, lactic acidosis and stroke-like episodes; LVH = left ventricular 
hypertrophy; CKD = chronic kidney disease stage 4/5 ................................................................. 84 
Table 4. Detailed histories and MRI scan notes for all patients with MELAS with histories of 
stroke-like episodes. L = left; R = right; Bilat = bilateral; P = parietal; T = temporal; O = 
occipital; F = frontal; Ins = insular. ................................................................................................... 85 
Table 5. Description of the post mortem brain sections used in the high-resolution MRI work 
in Chapter 9. * = defined macroscopically. ..................................................................................... 86 
Table 6. Grey matter volumes derived using each of FSL, SPM12, and manual 
segmentation. All values are given in cm3. ..................................................................................... 99 
Table 7. Results of the 2-sample t-test to assess whether there are group differences 
between FSL, SPM12, and manual segmentation methods for grey matter. ............................ 99 
Table 8. White matter volumes derived using each of FSL, SPM12, and manual 
segmentation. All values are given in cm3. ................................................................................... 101 
Table 9. Results of the 2-sample t-test to assess whether there are group differences 
between FSL, SPM12, and manual segmentation methods for white matter. ........................ 101 
Table 10. TICVs derived using each of FSL, SPM12, and manual segmentation. All values 
are given in cm3. ............................................................................................................................... 102 
Table 11.Results of the 2-sample t-test to assess whether there are group differences 
between FSL, SPM12, and manual segmentation methods for TICV. ..................................... 103 
Table 12. Absolute TICVs for control, carrier, and MELAS groups. Male TICVs are above the 
double line, female TICVs are below the double line for each of the groups. ......................... 113 
Table 13. 2-sample t-test to ascertain whether the differences in overall head size (TICV) 
between groups are statistically significant. ................................................................................. 114 
Table 14. Spearman Rho correlational values for some of the commonly referred to 
measures in mitochondrial disease. Strong correlation can be considered to be present for 
Spearman Rho values of around ±0.8 and upwards. .................................................................. 116 




Table 16. 2-sample t-test to ascertain whether the differences in normalised TPV between 
groups are statistically significant. ................................................................................................. 119 
Table 17. Grey matter volumes normalised to TICV for each of the control, carrier, and 
MELAS groups. ................................................................................................................................. 122 
Table 18. Results from a 2-sample t-test showing significance, or otherwise, of the 
differences between the groups. .................................................................................................... 123 
Table 19.White matter volumes normalised to TICV for each of the control, carrier, and 
MELAS groups. ................................................................................................................................. 124 
Table 20. Results from a 2-sample t-test showing significance, or otherwise, of the 
differences between the groups. .................................................................................................... 124 
Table 21. Cerebellar volumes normalised to TICV for each of the control, carrier, and MELAS 
groups. ............................................................................................................................................... 127 
Table 22. Results from a 2-sample t-test showing significance, or otherwise, of the 
differences between the groups. .................................................................................................... 127 
Table 23. Output regions from the FreeSurfer aparc.stats files grouped by lobe. ................. 137 
Table 24. List of outputs from the aseg.stats file. ........................................................................ 138 
Table 25. Table showing the cortical thickness (the average of the right and left hemisphere) 
for each lobe by lobe region, as detailed in Table 23. ................................................................ 139 
Table 26. Tables showing the outputs of a paired t-test for each lobe, and between each of 
the control, carrier, and MELAS groups. ....................................................................................... 140 
Table 27. Results of the 2-sample t-test for all of the areas of the temporal lobe. ................. 146 
Table 28. Table of GEMS scan parameters used to obtain the structural T1 MRIs of post 
mortem brain sections. .................................................................................................................... 164 
Table 29. Scanner settings to run the GEMSIR Look-Locker scan to measure the quantitative 
T1 values of the post mortem brain sections. .............................................................................. 165 
Table 30. Showing the average T1 values for each layer of the cortex in each post mortem 






List of Equations 
Equation 1. Equation for spin excess where N = total number of spins in the sample, ħ = 
Planck’s constant / 2π, ω0 = Larmor frequency, k = Boltzmann’s constant, and T = 
temperature in Kelvin. ........................................................................................................................ 38 
Equation 2. Equation describing the longitudinal relaxation time, T1, where Mz = measured 
magnetisation in the z direction, M0 = maximum magnetisation value, TR = relaxation time. 40 
Equation 3. Definition of the transverse relaxation time, T2, where Mxy = measured transverse 
magnetisation, M0 = maximum magnetisation value, TE = echo time. ....................................... 41 
Equation 4. Equation for the estimation of ADC values where I1 = signal at lower b-value, I2 = 
signal at higher b-value, b = b-value, and ADC = apparent diffusion coefficient. ..................... 45 
Equation 5. Equation describing the calculation of mean diffusivity (MD) ................................. 46 
Equation 6. Equation describing the calculation of fractional anisotropy, where 𝜆 = one third 
of the trace of the tensor. ................................................................................................................... 47 
Equation 7. The equation used to carry out the calculation of the z score for an individual, 
where, x = individual value, 𝑥 = group mean of the control group, SD = standard deviation of 
the control group. .............................................................................................................................. 111 
Equation 8. The equation used to carry out the calculation of the z score for a group, where x 
= individual value, 𝑥 = group mean of the control group, SD = standard deviation of the 







AD  Alzheimer’s Disease 
ADC  Apparent diffusion coefficient 
ASL  Arterial spin labelling 
ATP  Adenosine tri-phosphate 
BET  Brain extraction tool 
BMI  Body mass index 
CKD  Chronic kidney disease 
CNN  Convolutional neural network 
CNS  Central nervous system 
COX  Cytochrome c oxidase 
CPEO  Chronic progressive external ophthalmoplegia 
CSF  Cerebrospinal fluid 
DICOM Digital imaging and communications 
DKI  Diffusion Kurtosis Imaging 
DNA  Deoxyribonucleic acid 
DTI  Diffusion tensor imaging 
DWI  Diffusion-weighted imaging 
DW-MRS Diffusion-weighted magnetic resonance spectroscopy 
EEG  Electroencephalography 
ETC  Electron transport chain 
FA  Fractional anisotropy 




FSL  FMRIB Software Library 
GABA  Gamma-aminobutyric acid 
GEMS Gradient echo multi-slice 
GEMSIR GEMS inversion recovery 
GLM  General linear matrix 
GM  Grey matter 
GUI  Graphical user interface 
IVF  In-vitro fertilisation 
LVH  Left ventricular hypertrophy 
MD  Mean diffusivity 
MEG  Magnetoencephalography 
MELAS Mitochondrial encephalopathy, lactic acidosis and stroke-like episodes 
MIDD  Maternally inherited deafness and diabetes 
MPRAGE Magnetisation prepared rapid acquisition gradient echo 
MR  Magnetic resonance 
MRA  MR Angiography 
MRC  Medical research council 
MRI  Magnetic resonance imaging 
MRS  Magnetic resonance spectroscopy 
MS  Multiple sclerosis 
mtDNA Mitochondrial DNA 
NIfTI  Neuroimaging informatics technology initiative 




NMDAS Newcastle Mitochondrial Disease Scale for Adults 
OXPHOS Oxidative phosphorylation 
PET  Positron emission tomography 
POLG  Polymerase γ (gamma) 
POLRMT Mitochondrial RNA polymerase 
PRESS Point resolved spectroscopy 
RNA  Ribonucleic acid 
ROI  Region of interest 
ROS  Reactive oxygen species 
RVI  Royal Victoria Infirmary, Newcastle upon Tyne 
SD  Standard deviation 
SIENA Structural brain change analysis tool 
SNHL  Sensorineural hearing loss 
SNR  Signal to noise ratio 
SPACE Sampling perfection with application optimised contrasts using different 
flip angle evolutions 
SPECT Single photon emission computed tomography 
SPM  Statistical parametric mapping 
STEAM Stimulated echo acquisition mode 
T1W  T1-weighted 
T1W_SE T1-weighted spin echo 
T2W  T2-weighted 




TBSS  Tract-based spatial statistics 
tCho  Total choline 
tCr  Total creatine 
TE  Echo time 
TFAM  Transcription factor A 
TFB2M Transcription factor B2 
TI  Inversion time 
TICV  Total intracranial volume 
TLE  Temporal lobe epilepsy 
tNAA  Total N-acetyl acetate 
TPV  Total parenchymal volume 
TR  Repetition time 
tRNA  Transfer RNA 
UMDF  United mitochondrial disease foundation 
VDAC  Voltage dependent anion channels 
VBM  Voxel-based morphometry 
VOI  Volume of interest 
WM  White matter 





Acknowledgements ........................................................................... i 
Author’s Declaration ........................................................................ iii 
Abstract ....................................................................................... iv 
Publications ................................................................................... v 
List of Figures ................................................................................ vi 
List of Tables .................................................................................. x 
List of Equations ............................................................................ xii 
Abbreviations ............................................................................... xiii 
Chapter 1. Introduction ..................................................................... 20 
1.1 Mitochondrial Disease ................................................................... 20 
1.1.i Mitochondria ............................................................... 22 
1.1.ii Neuropathology ........................................................... 28 
1.1.iii Human Mitochondrial Genetics and DNA Mutations ................. 30 
1.1.iv Current Treatment and Prevention Strategies for Neurological 
Symptoms 35 
1.2 Magnetic Resonance Imaging .......................................................... 36 
1.2.i Basic Principles of Magnetic Resonance Imaging.................... 37 
1.2.ii Structural MRI ............................................................. 40 
1.2.iii Diffusion Tensor Imaging (DTI) ......................................... 44 
1.2.iv Arterial Spin Labelling (ASL) ................................................... 49 
1.3 Thesis Aims and Scope .................................................................. 50 
Chapter 2. Magnetic Resonance Imaging of individuals harbouring the 
m.3243A>G point mutation ................................................................ 52 
2.1 Introduction ................................................................................ 52 
2.2 Aims.......................................................................................... 52 
2.3 Methods ..................................................................................... 52 
2.3.i Paper Selection ........................................................... 52 
2.3.ii Literature Search Strategy............................................... 53 
2.4 Data Extraction and Analysis ........................................................... 54 
2.5 Results ...................................................................................... 55 
2.5.i Use of MRI in the study of mitochondrial disease in patients with the 
m.3243A>G point mutation ............................................................ 55 
2.5.ii Case Studies, Cohort Studies, and Reviews .......................... 55 
2.5.iii Volumetric Studies........................................................ 61 
2.5.iv DWI and DTI Studies ..................................................... 62 




2.6 Findings from non-m.3243A>G research ............................................. 64 
2.6.i ADC values ................................................................ 64 
2.6.ii Alternative theories for restricted diffusion ............................ 69 
2.6.iii Quantification and mechanisms of atrophy ............................ 70 
2.6.iv Abnormal connectivity .................................................... 71 
2.6.v Individualised approach to scanning and mapping ................... 72 
2.7 Discussion/Conclusions ................................................................. 73 
Chapter 3. MRC Participant Cohort and Post Mortem Brain Sections ........... 82 
3.1 Participant Cohort ......................................................................... 82 
3.2 Post mortem brain sections ............................................. 86 
3.3 Sample Size, Power, and Correcting for Multiple Comparisons .... 86 
Chapter 4. Software Accuracy Assessment and Validation for quantitative 
volumetric analysis ......................................................................... 88 
4.1 Introduction ................................................................................ 88 
4.2 Aims and Methods ........................................................................ 91 
4.2.i Initial File Preparation .................................................... 91 
4.2.ii Comparison of 2D thick-slice and 3D anatomical scan types ....... 92 
4.2.iii Manual Segmentation .................................................... 96 
4.2.iv Automated Segmentation................................................ 97 
4.3 Results ...................................................................................... 99 
4.3.i Manual vs Automated Global Tissue Segmentation ................. 99 
4.4 Discussion/Conclusions ................................................................ 103 
Chapter 5. Volumetric analysis of global volumes .................................. 105 
5.1 Introduction ............................................................................... 105 
5.2 Aims ........................................................................................ 106 
5.3 Methods and Materials .................................................................. 107 
5.3.i Carriers and patients with MELAS.................................... 107 
5.3.ii MRI Scans ............................................................... 107 
5.3.iii Segmentation ........................................................... 107 
5.4 Results ..................................................................................... 112 
5.5 Discussion ................................................................................. 128 
5.6 Conclusions and Further Work ........................................................ 133 
Chapter 6. Regional analysis of volumetric and cortical thickness data ....... 134 
6.1 Introduction ............................................................................... 134 
6.2 Aims ........................................................................................ 134 
6.3 Methods .................................................................................... 135 
6.3.i Carrier and Patients with MELAS ............................................. 135 




6.3.iii Regional Segmentation ....................................................... 135 
6.4 Results ..................................................................................... 139 
6.5 Discussion ................................................................................. 146 
6.6 Conclusions ............................................................................... 149 
Chapter 7. Tract-based spatial statistical analysis in individuals with the 
m.3243A>G point mutation .............................................................. 151 
7.1 Introduction/Hypothesis ................................................................ 151 
7.2 Methods .................................................................................... 152 
7.2.i MRI DTI Scanner Protocol ..................................................... 152 
7.2.ii TBSS Protocol .................................................................. 152 
7.3 Results ..................................................................................... 153 
7.4 Discussion ................................................................................. 154 
7.5 Considerations for Future Work....................................................... 155 
Chapter 8. 7 T MRI ultra-high-resolution scanning and quantitative T1 mapping 
of post mortem brain sections .......................................................... 157 
8.1 Introduction ............................................................................... 157 
8.2 Methods and Materials .................................................................. 163 
8.2.i Structural Imaging ....................................................................... 164 
8.2.ii Quantitative T1 mapping ................................................................ 165 
8.3 High Resolution Structural Imaging .................................................. 167 
8.4 Quantitative T1 mapping ................................................................ 170 
8.5 Discussion ................................................................................. 173 
Chapter 9. Final Discussion ............................................................. 177 
9.1 MRI studies of the brain ................................................................... 177 
9.1.i Volumetric ....................................................................... 177 
9.1.ii TBSS ............................................................................ 181 
9.1.iii Ultra-high-resolution MRI scanning ......................................... 182 
9.2 Implications of this study ................................................................. 184 
9.3 Study Limitations ........................................................................... 184 
9.4 Concluding remarks ........................................................................ 187 
Chapter 10. References .................................................................. 189 
Appendix A – Global Segmentation Procedure Details ............................ 222 





Chapter 1. Introduction 
1.1 Mitochondrial Disease 
Mitochondria are intracellular organelles that are integral to cellular energy 
metabolism including the urea cycle, fatty acid β oxidation and the final common 
pathway for adenosine tri-phosphate (ATP) production in the mitochondrial 
respiratory chain. Mitochondrial diseases are an important group of neurometabolic 
disorders characterised by dysfunctional mitochondria that manifest marked 
genotypic-phenotypic heterogeneity. They are classified into two major groups due to 
their causative genetic aetiology: primary mitochondrial disorders (caused by point 
mutations or deletions in mitochondrial DNA (mtDNA) and nuclear mitochondrial 
disorders (caused by mutations in nuclear DNA (nDNA)). (McFarland et al., 2010). 
The point mutation m.3243A>G in the MT-TL1 gene encoding tRNALeu(UUR) is the 
most common cause of adult mtDNA disease and the most prevalent point mutation 
within the Medical Research Council (MRC) MitoCohort, a cohort dedicated to 
patients with mitochondrial disease established in Newcastle upon Tyne and now 
extended to other mitochondrial disease centres across the country, but determining 
the prevalence of the mutation in the general population is not easily achieved due to 
the heterogeneous nature of the disease (Gorman et al., 2015a). The best estimate 
of prevalence in the UK to date is provided by Gorman et al. (2015a) through a long-
term study carried out from 1990 to mid-year period of 2011, in which all adults over 
the age of 16 years with suspected mitochondrial disease in the north east of 
England were all sent to a single centre for neurology for assessment. Two minimum 
prevalence rates were determined: 20 per 100 000 for mtDNA mutations; and 2.9 per 
100 000 for nuclear mutations leading to clinically overt mitochondrial disease 
(Gorman et al., 2015a). In total, mitochondrial and nuclear DNA defects have a 
prevalence of around 1 in 4300, which makes mitochondrial disease one of the most 
common forms of inherited adult neurological disorder (Gorman et al., 2015a), and in 
addition to this, around 1 in 200 may be carrying pathogenic mtDNA mutations, which 
potentially puts mitochondrial disease high up the list of commonly inherited 
neuromuscular diseases (Gorman et al., 2015a). As of September 2018, there are 
680 mutations in mtDNA with disease associations in the human mitochondrial 
genome MITOMAP database (Lott et al., 2013; Lott, 2016), a number that will 





The prevalence of the m.3243A>G point mutation does not, however, directly 
translate into prevalence of associated phenotypes. Mitochondrial 
encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS) is often 
associated with the m.3243A>G point mutation, but only around 10% of those 
harbouring the m.3243A>G point mutation will go on to develop the MELAS clinical 
syndrome (McFarland et al., 2010). However, the m.3243A>G point mutation 
accounts for around 80% of patients manifesting with MELAS (Tuppen et al., 2010), 
making this a key mutation to study in depth to better understand the stroke-like 
episodes suffered by this patient group, which are neurologically devastating. Yet the 
heterogeneity of symptoms and lack of defined disease progression pattern makes 
treatment and prevention strategies extremely difficult to formulate and implement. 
Neuropathology of human brain tissue has provided vital insight into our 
understanding of the neurological structural end stages of the disease, and vitally has 
facilitated interrogation of potential underlying mechanisms. But these techniques are 
limited to staining and imaging of post mortem samples, and are able to provide little 
information regarding the initial changes and triggers, particularly within the brain, 
that lead to symptoms such as seizures, stroke-like episodes, and encephalopathy. 
Non-invasive neuroimaging is able to provide both structural and functional 
information about the brain in vivo and in real time. Magnetic resonance imaging 
(MRI) in particular offers a method to study high resolution structural details without 
the use of ionising radiation. To date it has been used extensively in other 
neurological diseases such as multiple sclerosis (MS), epilepsy, and various forms of 
dementia, but to date the latest developments in MRI scanning and analysis 
techniques have not been adequately brought to bear on mitochondrial disease. 
Diffusion tensor imaging is also of interest as it allows the investigation of white 
matter tracts, which form the microstructure of the brain. The technique has the 
potential to allow detection and visualisation of early, and potentially also pre-clinical, 
changes. Through the investigation of the structural and micro-structural features of 
people harbouring the m.3243A>G mutation, it is possible to add to, and provide 
supporting evidence for, clinical observations and information, and potentially 
improve the prognostic prediction for individuals, particularly for those at risk of 




The neurodegenerative nature of MELAS led to the hypothesis that by quantitatively 
analysing the brains of those carrying the m.3243A>G point mutation and comparing 
to a healthy control group it would be possible to identify regions, and properties 
thereof, that either provide more information about the mechanisms of the 
progressive nature of neurodegeneration in patients with MELAS compared to the 
relative neurological stability of non-MELAS carriers of the m.3243A>G point 
mutation, or that highlight more generic differences in those who carry the 
m.3243A>G point mutation that may then provide further information on the overall 
nature of the effects of carrying this point mutation. 
This thesis describes the work I carried out to quantitatively investigate the brain 
volumes of healthy controls and those carrying the m.3243A>G point mutation as 
both non-MELAS carriers, and those with a MELAS diagnosis. I developed robust 
segmentation protocols to provide both reliability and accuracy. The automated 
protocols were validated against manual segmentation techniques to assess 
accuracy and to justify the selection. I then used these to carry out global and 
regional segmentation to analyse, at multiple scales, what the differences were 
between the three study groups to begin to understand the effects on the brain of 
having the m.3243A>G point mutation. I decided to address the whole brain rather 
than an individual region, for example the cerebellum, due to the number of papers 
that state they have measured global effects across the brain. 
1.1.i Mitochondria 
Overview 
Eukaryotic cells contain mitochondria, which are cytoplasmic organelles. Within each 
organelle is a double-membrane structure where ATP production takes place. This is 
only one of the roles that mitochondria fulfil; they also have a number of other 
functional roles including in apoptosis, the formation of iron sulphur clusters, and 
calcium handling. Mitochondrial function is maintained through the encoding of vital 
proteins, some of which are encoded by the non-nuclear mtDNA, but the vast 
majority are actually coded by nDNA (Anderson et al., 1981). This dual source of 
protein encoding leads to mitochondria being affected by diseases caused by either 
mutations or deletions within the mtDNA, which not only affect the mitochondria 




Origins and Evolution 
There are a number of theories that have been proposed to explain the presence of 
mitochondria within mammalian eukaryotic cells (Martin et al., 2015). The most 
widely accepted theory is that proposed by Margulis (Margulis, 1971) in the form of 
endosymbiosis, defined as a mutually beneficial relationship between two organisms 
that is carried out by one of the partners ‘swallowing’ the other without digesting it. 
The fact that mitochondria contain DNA unrelated to that of the cell nucleus suggests 
supportive evidence that the mammalian eukaryotic cell began as two separate 
organisms, free-living bacteria and an ancestral host, that developed a hereditary 
symbiosis resulting in the development of mammalian cells (Margulis, 1971). The 
reasons for this endosymbiosis likely stems from the different respiration 
mechanisms of each of the organisms; the anaerobic ancestral host cell, and the 
aerobic prokaryote. This combination then allowed more efficient respiration and 
generation of ATP (Reece et al., 2011) with the host cell benefitting from the ATP 
production and the prokaryote an environment rich in metabolites. 
A second theory is the autogenous theory that proposes that a single prokaryote 
ancestor led to the development of eukaryotes through functions being 
compartmentalised through folding of the plasma membrane of the prokaryote and 
the enslavement of purple non-sulphur bacteria. This hypothesis suggests the 
evolution of mitochondria within the protoeukaryote cell when cell membranes have 
created compartments containing plasmids or vesicles of DNA that have then been 
pinched off and the endosymbionts developed into organelles because of the 
complex machinery required for protein import and the insertion of this into the inner 
membranes of protein carriers to extract energy (Cavalier-Smith, 2006). 
Structure and oxidative phosphorylation 
Mitochondria are found in every nucleated cell within the human body, with the 
exception of mature red blood cells. They are usually simplistically represented as 
rod- or ovoid-shaped double-membraned structures with a length of 1-4 µm, and a 
diameter of 0.5-1 µm (Palade, 1952). The structure comprises the outer membrane, 
the inner membrane, which folds to form ‘cristae’, the intermembrane space, and the 
matrix (Figure 1). This classical depiction is seen in most electron microscope (EM) 
imaging due to the 2D nature of the image (Figure 2). However, this depiction is 




usually form complex networks to allow exchange of ions and molecules between 
mitochondria (Bereiter-Hahn and Voth, 1994; Chen and Chan, 2004). Mitochondria 
undergo both fusion and fission to facilitate transfer of mitochondria into daughter 
cells, to remove any mitochondria that are damaged, and may also, at least partially, 
modulate the production of ATP (Skulachev 2001). Disruption in the balance of 
fission and fusion leads to suboptimal performance of the mitochondria, which in turn 
has been linked to neurodegeneration (Chen and Chan, 2009). 
 





Figure 2. Classical EM image showing mitochondria as ovoid and rod-shaped 
structures (Image provided courtesy of Dr Amy Vincent). 
 
Figure 3. 3D volumetric rendering of EM imagery demonstrating the large variation in 
mitochondrial shape, size and connectivity Image provided courtesy of Dr Amy 
Vincent). 
The outer membrane of the mitochondrion separates the cytosol and the organelle 
and also contains in the order of 10 000 voltage dependent anion channels (VDAC), 
one of the classes of porin ion channel. Small hydrophilic molecules and ions, up to 
10 kDa in size, pass through these channels forming the exchange mechanism 




membrane, which sits between the intermembrane space and the matrix, is 
selectively permeable, only allowing water, oxygen and carbon dioxide to pass 
through, thus there are a number of transport proteins associated with the inner 
membrane to allow material to enter the matrix from the intermembrane space, and 
also to help maintain the electrochemical gradient between the two. These features 
are essential for the formation of ATP (Alberts et al., 2008). 
The mitochondrial matrix hosts most of the mitochondrial processes. The content of 
the matrix consists of numerous copies of the mitochondrial genome and along with 
the essential components for replication, transcription, and translation. Other 
processes that take place in the mitochondrial matrix are iron-sulphur cluster 
biogenesis, β-oxidation of fatty acids, and the Krebs cycle (Llopis et al., 1998). 
Mitochondria have a large number of functions, but it can be argued that the most 
crucial one is the generation of energy via oxidative phosphorylation (OXPHOS). 
ATP, the end product of this process, is generated in the inner membrane using the 
OXPHOS system, which comprises five multimeric protein complexes, and two 
electron carriers (Hatefi, 1985). 
Biogenesis 
The metabolic demand of cells does not remain constant over time, therefore the 
synthesis of mitochondria, also referred to as mitochondrial biogenesis, also does not 
occur at a constant rate, instead it is a process that is regulated to ensure adequate 
production of ATP. 
Neuronal Mitochondria 
Neurons, compared to other types of cell, demand large supplies of energy but not at 
a constant rate. Therefore, to maintain neuronal health it is required that 
mitochondria are in the right locations when they are needed. The length of neuronal 
cells and their structural complexity make the transport of mitochondria key to the 
proper functioning of the cell. To add to the navigational complexity, mitochondria are 
produced predominantly, but not solely, in the soma and so then must be transported 
out as far as the neuronal distant terminals through anterograde transport 
mechanisms (Course and Wang, 2016). 
In the same way, retrograde transport is also required for damaged mitochondria, 




either back in the soma or at the terminals, can cause oxidative stress to the neuron 
(Course and Wang, 2016). 
The multiple functions of mitochondria in neurons include calcium buffering, 
detoxifying ammonia, and production of certain steroids (Rossier, 2006), haem 
compounds (Oh-hama, 1997), heat, and ROS. They are vital to the metabolism of 
neurotransmitters glutamate and gamma-aminobutyric acid (GABA) (Kugler and 
Baier, 1992), and also send signals for apoptosis, proliferation, and cell survival 
(McBride et al., 2006). The combination of these multiple roles and the long, thin 
nature of the neuronal cell, as well as the neuron being post-mitotic, means that it is 
imperative that mitochondrial function and location is optimised. There is increasing 
evidence to indicate that if the mitochondria within neurons are not properly 
distributed to provide the correct energy amounts at the right time, that this may lead 
to neurodegenerative and neuropsychiatric disorders (de Vos et al., 2008; Morfini et 
al., 2009; Deheshi et al., 2013) as a result of physical changes to the brain 
vasculature that includes impaired blood-brain barriers and lack of vascular response 
to changing oxygen demands (Nelson et al., 2016). 
Phenotypic expression 
Mitochondria are found in all cells in the body with the exception of mature red blood 
cells, and provide localised energy production. This therefore means that mutations 
in either mtDNA or nDNA involved in the OXPHOS process, can be present in any 
part of the body, frequently leading to symptoms that affect multiple organs and 
tissues. The central nervous system (CNS) is particularly susceptible as when the 
body is at rest, the CNS will use up to 20% of all energy produced (Lax et al., 2017). 
Hence organs with high energy demands are more often affected, such as the brain, 
muscles, and the heart. However, symptoms do not occur predictably and even 
patients with identical mtDNA heteroplasmy levels and genetic mutations can present 
with symptoms varying in both type and severity. Neurological manifestations include 
seizures, stroke-like episodes, encephalopathy (altered mental state), dementia, 
atrophy, and developmental delay. Other commonly seen symptoms include 
diabetes, cardiomyopathy, ptosis, and ophthalmoplegia (McFarland et al.., 2002). 
Childhood onset of mitochondrial disease generally involves more severe symptoms 
including developmental delay and/or regression, with an increased likelihood of 




m.3243A>G mt-tRNALeu(UUR) mutation 
Around 77% of mitochondrial disease cases in adult patients result from mutations in 
mtDNA, with the most common of those being related to the m.3243A>G point 
mutation (Gorman et al., 2015a). In addition to being the most prevalent, the 
m.3243A>G point mutation is also associated with patients who experience a wide 
spectrum of symptoms. Patients with this mutation comprise around 80% of those 
that are diagnosed with MELAS; however the m.3243A>G mutation can also give rise 
to other clinical syndromes, including Leigh syndrome, chronic progressive external 
ophthalmoplegia (CPEO), maternally inherited diabetes and deafness (MIDD) or a 
cardioencephalomyopathy syndrome (Gorman et al., 2016).  
mtDNA mutations affect both the quality and quantity of respiratory-chain protein 
production (DiMauro and Schon, 2003; Taylor and Turnbull, 2005). Research 
indicates that patients with the m.3243A>G point mutation have a decreased rate of 
protein synthesis, which in turn leads to a reduction in the complexes available for 
OXPHOS, thus reducing overall energy production (Ciafaloni et al., 1992). There is 
also research to support disease onset being related to the mutant load, with higher 
mtDNA heteroplasmy levels leading to an earlier onset (Morgan-Hughes et al., 1995); 
however, it is now recognised this does not fully explain the heterogeneity in disease 
expression, onset or progression. 
1.1.ii Neuropathology 
Further to focal lesions detected macroscopically in the brains of patients with 
MELAS, microscopic neuropathological investigations are indicative of profound 
neuronal cell loss, spongiform degeneration (mainly in the white matter), glial cell 
proliferation and axonal demyelination (Lax et al., 2017). Respiratory chain 
deficiencies and decreased electron transport chain (ETC) protein expression in 
vulnerable neuronal, inter-neuronal and vascular cell populations have also been 
documented (Tanji et al., 2001; Betts et al., 2006; Lax et al., 2012b; Lax et al., 2012c; 
Lax et al., 2015). These are usually associated with high heteroplasmy1 , cellular 
loss, cortical necrosis, astrogliosis, and secondary axonal loss (Lax et al., 2017). 
                                                          





Patients with the m.3243A>G point mutation, and more specifically, those with 
MELAS, have a characteristic presence of pan-necrotic foci, which are themselves 
characterised by any combination of neuronal loss, activation of the inflammatory 
response (although the response is not massive, as in the cases of other diseases 
such as MS (Steinman, 1996; McFarland and Martin, 2007), and proliferation of 
astrocytes and capillaries (Lax et al., 2017). These foci are often described as being 
‘infarct-like’ and are most commonly observed in the cerebral cortices, both 
unilaterally and bilaterally depending on disease development, and also in the 
cerebellum. Other areas may also be affected, including the basal ganglia, thalamus, 
brain stem, and subcortical white matter (Lax et al., 2017). Calcification, particularly 
of the basal ganglia, is also a relatively common observation in neuropathological 
investigations in patients with MELAS, in addition to vacuolation, also known as 
spongiform degeneration due to the sponge-like appearance, which is observed in 
the cortex (Lax et al., 2017). 
There are a number of observed vascular abnormalities that include calcification of 
vessel walls (Sue et al., 1998; Tanahashi et al., 2000), a decrease in the 
immunoreactivity against mtDNA-encoded respiratory chain subunits (Sparaco et al., 
2003) and blood vessels that are both cytochrome c oxidase (COX)-deficient and 
have high levels of mtDNA heteroplasmy (Betts et al., 2006; Lax et al., 2012b). There 
is no specific association between COX-deficiency and the presence of lesions as 
COX-deficient blood vessel walls can be found globally throughout the brain in both 
cortical and subcortical white matter, as well as meningeal tissue (Betts et al., 2006; 
Lax et al., 2012b). In addition to COX-deficiency, the physical properties of 
mitochondria within the vasculature throughout the brain are altered as the 
mitochondria are enlarged and also aggregated (Ohama et al., 1987; Mizukami et al., 
1992; Tanahashi et al., 2000). Autophagy2 is a key process in the maintenance of the 
health of mitochondria by removing old and damaged mitochondria and the 
aggregation of enlarged mitochondria indicates that the maintenance process is 
defective as it is not working quickly enough to remove them before they start to 
accumulate (Youle and van der Bliek, 2012). 
                                                          




Post mortem neuropathological investigations show generalised cerebellar atrophy 
(Sparaco et al., 1993; Tanahashi et al., 2000; Lax et al., 2012a, Lax et al., 2017). 
Even within neurons that are preserved there is a high percentage of mutant mtDNA 
and these neurons also show severely compromised respiratory chain protein 
expression, particularly for complexes I and IV (Lax et al., 2012a; Chrysostomou et 
al., 2015).  
Aberrations in the inhibitory neurotransmission in the region of lesions are indicated 
by defects in complex I protein expression in GABAergic presynaptic terminals 
(Chrysostomou et al., 2015). Compensation mechanisms may be present in the form 
of intracerebellar synaptic remodelling of residual inhibitory synapse through 
enlargement (Chrysostomou et al., 2015). 
In patients with the MELAS phenotype, profound inhibitory interneuronal loss has 
been found in the occipital, temporal, and frontal cortices, which is accompanied by 
complex I deficiency and high levels of heteroplasmy of around 79% in residual 
neurons (Betts et al., 2006). 
1.1.iii          Human Mitochondrial Genetics and DNA Mutations 
The Mitochondrial Genome 
Multiple copies of mtDNA molecules make up the mitochondrial genome. Each 
molecule is made up of 16 569 base pairs and has two strands; an inner light (L) 
strand containing 9 genes, and an outer heavy (H) strand containing 28 genes. Of 
the 37 genes in mtDNA only 13 are used to encode mitochondrial respiratory chain 
polypeptide subunits, the other 24 are required for mtDNA translation and 
mitochondrial protein synthesis (Anderson et al., 1981).  
The mitochondrial genome has a number of distinctive properties that set it apart 
from the nuclear genome (Taylor and Turnbull, 2005), namely, mtDNA heteroplasmy, 
threshold effect and the mitochondrial genetic bottleneck. mtDNA is inherited entirely 
from the mother (Giles et al., 1980) and the copy number of mtDNA molecules varies 
depending on the type of cell and its current energy demands. The bottleneck effect 
allows successive generations to show a random, and rapid, drift of mutation, making 
the inheritance and progression of the disease unpredictable. To add to the 
unpredictability, some heteroplasmic mtDNA mutations, such as m.3243A>G, show 




1995; Rajasimha et al., 2008; Stewart and Chinnery, 2015). Finally, it is also known 
that mtDNA replication occurs independently of the cell cycle (Bogenhagen and 
Clayton, 1977). The key mtDNA properties are discussed in the rest of this section in 
relation to mitochondrial disease. 
Transcription and Translation 
Transcription is the initial process that occurs in gene expression and involves 
making a copy of a DNA sequence to create an RNA molecule. There are three sites 
where mtDNA transcription is initiated, with one promoter for the light strand and two 
for the heavy strand. Two of the promoters cover almost all of the coding regions, 
with one of the H strand promoters covering a much shorter transcript. 
There are three proteins, mitochondrial RNA polymerase (POLRMT), transcription 
factor A (TFAM), and transcription factor B2 (TFB2M), that have been shown to be 
essential for transcription initiation and formation of the mitochondrial transcription 
initiation complex (Falkenberg et al., 2002; Shi et al., 2012; Yakbovskaya et al., 
2014). The process is begun with the binding of TFAM close to the promoter site to 
fold mtDNA. This then allows POLRMT to be recruited and bound to the promoter 
region as well as the TFAM. The POLRMT is also changed in shape through this 
process, which then allows TFB2M to bind to the incomplete pre-initiation complex to 
complete it (Yakubovskaya et al., 2014). 
Mitochondrial genome translation has a number of features that separate it from 
nuclear genome translation, but it still follows the recognisable steps of canonical 
initiation, elongation, and termination (Smits et al., 2010) within mitoribosomes, the 
mitochondrial equivalent to the protein-rich nucleolar ribosomes (O’Brien, 2003). 
Impairment of the mitochondrial transcription and translation processes due to either 
mitochondrial or nuclear DNA genetic mutations usually leads to malfunctioning of 
the proteins encoded by mtDNA, which results in dysfunction of the entire respiratory 
chain, although there are some nuclear genetic defects that only affect the translation 
of individual mitochondrial-encoded proteins (Boczonadi and Horvath, 2014). The 
resultant effect of mitochondrial proteins that are defective is that ATP production is 
lower than required, which has the knock-on effect of an overall energy deficit within 





mtDNA replication has its own cycle that is independent from the nuclear DNA and 
cell cycles. This independence has led to the term ‘relaxed replication’ being coined 
(Bogenhagen and Clayton, 1977; Birky, 1994). In post-mitotic cells, such as neurons, 
the turnover of mtDNA is much slower than is found in cells that are actively dividing 
(Wang et al., 2009). In fact, there is some evidence to indicate that neuronal mtDNA 
synthesis may take up to 20 hours (Calkins and Reddy, 2011). The exact mechanism 
for mtDNA replication has yet to be agreed upon, but the most popular current 
models are the asynchronous, or strand-displacement, model (Holt and Reyes, 
2012), and the synchronous, or strand-coupled, model (Brown, 2005). 
In the asynchronous/strand-displacement model polymerase gamma (Polγ) is 
believed to carry out replication of mtDNA solely using one mechanism, which 
involves a few proteins and two priming events (Holt and Reyes, 2012). Synthesis of 
the leading strand DNA starts at an exact location and synthesis goes around about 
two thirds of the way before the synthesis of DNA is started on the ‘lagging’ strand, 
which although believed to be coated with protein for many years, it has now been 
proposed that it is RNA instead (Holt and Reyes, 2012). 
In contrast, the synchronous, or strand-coupled, model involves bidirectional 
synthesis of DNA through the formation of replication forks in the directions of both 
the leading- and lagging- strand (Brown et al., 2005). 
Maternal Inheritance and the Bottleneck Effect 
mtDNA is inherited wholly through the maternal germline (Giles et al., 1980). Paternal 
mtDNA is destroyed, with mechanisms being species-specific and are known to take 
place both pre- and post-fertilisation (Sato and Sato, 2013). In mammals there is 
selective proteasomal degradation for paternal mtDNA destruction (Kaneda et al., 
1995; Sutovsky et al., 1999). 
Any pathogenic mtDNA mutations carried by a mother will be transmitted to any 
children she may have, however there is a significant amount of variability in the 
extent of the transmission to the next generation (Taylor and Turnbull, 2005). The 
existence of this variability may in part explain the phenotypic heterogeneity amongst 
patients carrying the same genetic defect (Chinnery et al., 1997), for which the 




mtDNA molecules is reduced by around 1000 times between oocyte and embryo 
(Chinnery et al., 2000; Floros et al., 2018). The exact mechanisms underlying the 
genetic bottleneck are still being debated, but it is relatively widely accepted that 
during embryonic development the rapid mtDNA replication is one of the key factors 
(Cree et al., 2008). Recent work by Floros et al. (2018) has shown that low levels of 
mitochondrial mutations are present within the primordial germ cells (PGCs) in 
healthy embryos, and that evidence of selection against mutated mtDNA variants is 
seen in these despite the heteroplasmy levels being below the threshold 
conventionally considered to be required for a change in biochemical properties. This 
work also indicates that the mtDNA bottleneck may be less stringent in human 
embryonic somatic cells and that selection against mutated mtDNA in these tissues is 
less effective, which perhaps indicates that there is some sort of selection advantage 
to this (Floros et al., 2018). Mutations that are not removed by this mechanism will be 
characterised by heteroplasmy level shifts within the space of a single human 
generation, which explains the extreme variation in phenotype seen in family lines 
that have inherited mitochondrial disorders (Floros et al., 2018). This new evidence of 
mtDNA selection provides further insights into the factors that dictate the level of 
pathogenic mutations, such as inheritance patterns for some mtDNA defects, in 
addition to the effects of random genetic drift (Brown et al., 2001; Floros et al., 2018). 
mtDNA Mutagenesis and Repair Mechanisms 
mtDNA is susceptible to acquiring defects for two major reasons; its close proximity 
to the electron transport chain (ETC), and also its compact structure. mtDNA has also 
been shown to have less robust repair mechanisms compared to nuclear DNA 
(Clayton, 1982), which leads to an order of magnitude higher mutation rate than 
chromosomal DNA (Brown et al., 1979). The proximity of reactive oxygen species 
(ROS) production sites under normal OXPHOS conditions also has a negative impact 
on mtDNA integrity. 
DNA strand breaks can lead to a variety of mtDNA defects, including point mutations, 
deletions, insertions, and duplications (el-Khamisy and Caldecott, 2007; Kasparek 
and Humphrey, 2011). There is also the possibility of replication errors or modified 
nucleotides being incorporated (Kamiya, 2003, Boesch et al., 2011). The normal 
ageing process can also cause somatic mtDNA mutations to be acquired, and even 
environmental conditions can trigger ancient genetic variants to occur as part of an 




The repair mechanisms used in mtDNA repair are, in general, similar in nature to 
nuclear ones (Larsen et al., 2005) and include direct reversal (Yasui et al., 1992), 
base excision repair (Stierum et al.., 1999), mismatch repair (Mason et al.., 2003) 
and single-strand break repair (Hegde et al., 2012). Mitochondria have also evolved 
a unique repair mechanism where damaged mtDNA fractions are degraded and 
replaced by replicated segments of the healthy genome (Gross and Rabinowitz, 
1969).  
mtDNA Heteroplasmy and the Threshold Effect 
There are multiple copies of mtDNA within each cell, which means that a mixture of 
wild type and mutant mtDNA are able to co-exist within the same cell. This concept is 
called heteroplasmy and is the basis for the theory of the ‘threshold effect’, in which it 
is theorised that if the mutant mtDNA exceeds a certain percentage, this then leads 
to the presentation of a particular phenotype (Larsson and Clayton, 1995). In addition 
to heteroplasmy, it is also possible to have a homoplasmic state if all mtDNA 
molecules within a cell are either wild type or mutant (Taylor and Turnbull, 2005). 
The levels of heteroplasmy are not constant over time and are affected by random 
genetic drift3 through the process of clonal expansion4 (Elson et al., 2001). Clonal 
expansion allows for the mutant genome to be selectively multiplied, which then 
leads to higher heteroplasmy levels in post-mitotic tissue (Weber et al., 1997). The 
threshold effect is a key concept in explaining the presentation of a phenotype, but in 
itself is complex as the actual heteroplasmy threshold varies between individuals, 
tissue type within an individual, and also between mutation types. Studies indicate 
that for tRNA point mutations that the threshold effect occurs at around 90% 
heteroplasmy, but for single large-scale mtDNA deletions the threshold effect is much 
lower at around 60% (Rossignol et al., 2003). Tissue specific thresholds also vary in 
the type of deficiency they are sensitive to, with mitochondria in the brain having a 
lower threshold for complex I deficiency, when compared to other organs, and 
muscle mitochondria being more susceptible to complex IV defects (Rossignol et al., 
1999). 
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1.1.iv     Current Treatment and Prevention Strategies for Neurological 
Symptoms 
Overall there is a lack of treatments that are effective, thus leaving clinicians with few 
options once patients have presented with symptoms. Pharmacological treatments 
have generally been found to have either low efficacy or high toxicity in patients with 
mitochondrial disease (Horvath et al., 2008), with the exception of patients with a 
coenzyme Q10 deficiency. Non-pharmacological strategies for treating mitochondrial 
disease include diet modification along with exercise (Tarnopolsky, 2016; Ratnaike et 
al., 2012; Murphy et al., 2012; Gorman et al., 2016), and also strategies for 
preventing the transmission of mitochondria between generations (Gorman et al., 
2015b). 
Symptomatic Therapy 
There are a number of relatively common neurological symptoms in m.3243A>G 
patients, which include seizures and stroke-like episodes, encephalopathy, cognitive 
dysfunction, dementia and ataxia. The neurological symptoms are characterised by a 
number of changes within the brain, such as lesions, global neurodegeneration, and 
global atrophy. Treatment for seizures usually comes in the form of anticonvulsants, 
with valproate being one a commonly used anti-epileptic drug. While this has 
generally been shown to provide effective seizure treatment, it has been associated 
with fulminent liver failure, mainly in polymerase γ (POLG) patients, and therefore 
clinicians advocate against its use (Stewart et al., 2010). L-arginine has also been 
used in patients with MELAS to reduce the severity of acute stroke-like episode 
symptoms and to prevent recurring stroke-like episodes when in the chronic phase 
and its use is recommended by the United Mitochondrial Disease Foundation 
(UMDF) (Yoneda et al., 2012), however evidence to support the routine use of L-
arginine is still lacking. 
Through ongoing monitoring and clinical care of patients, which is complex and 
multidisciplinary, there are several therapeutic strategies that have been investigated, 
but very few that are directly aimed at slowing, or preventing, neurological symptoms, 
particularly the neurodegenerative symptoms. In addition to anticonvulsants, anti-
depressants have also been trialled, as mood disorders are a possible symptom in all 




Additional treatment approaches 
In addition to the traditional symptomatic therapy, there are a number of additional 
treatment possibilities that are also worth mentioning. These are: upregulation of 
mitochondrial proliferation for enhanced mitochondrial biogenesis to increase the 
numbers of wild-type mtDNA, which are able to assist in compensating for the 
mutated mtDNAs even though production of these are increased as well; increasing 
mitophagy through the use of rapamycin; the use of mildly hypoxic environments that 
could potentially restore locomotor function; novel gene therapy approaches that 
include targeting of mutated mtDNA for digestion, prevention of transmission of mice 
mtDNA haplotypes, and reducing oocyte heteroplasmy levels, which may offer an 
alternative to replacing mitochondrial DNA in the prevention of transmission of 
mitochondrial diseases through the maternal line (Gorman et al., 2016). 
Prevention of mitochondrial disease 
The gold standard for mitochondrial disease is the prevention of mutation inheritance 
and recently prevention strategies to mitigate the transmission of serious 
mitochondrial disease have been developed (Gorman et al., 2015b; Zhang et al., 
2017). As all mtDNA is inherited from the mother, the use of pro-nuclear transfer can 
be used, which essentially removes the mtDNA of the mother and replaces it with 
healthy mtDNA from a donor (Craven et al., 2010), or alternatively spindle transfer 
can be carried out in which the nuclear DNA of the oocyte can be transferred to a 
donor oocyte without the transfer of the mitochondrial DNA (Zhang et al., 2017). 
There are also additional reproductive choice options available for women with 
mtDNA mutations to have children via egg donation, or to have the option of either 
pre-implantation genetic diagnosis if conception is through in-vitro fertilisation (IVF), 
which totally eradicates the risk except, or prenatal diagnosis. These techniques 
allow the chances of having severely affected children to be reduced, but these also 
may involve decisions about termination and neither pre-implantation genetic 
diagnosis nor prenatal diagnosis are of benefit for women who have high levels of 
heteroplasmy (Steffann et al., 2006), or for those women who have mutations that 
are homoplasmic.  
1.2 Magnetic Resonance Imaging 
Magnetic resonance imaging (MRI) is a technique that allows non-invasive imaging 




disadvantages. The main disadvantage is that all output images are dependent on 
the MR scanner sequence used and so this must be carefully selected to ensure 
contrast may be observed between the desired tissues, for example between a 
tumour and healthy brain tissue. However, as MRI is sensitive to a range of brain 
tissue properties, it is possible to investigate a number of different brain properties 
using the same equipment, but varying the scan sequences chosen. MRI may be 
used to investigate both structural and functional aspects of the brain making it a 
powerful tool in brain research both in a healthy population and also to probe how 
disease affects the brain. 
1.2.i Basic Principles of Magnetic Resonance Imaging 
The basic concepts behind how MRI works are rooted in quantum mechanics, but it 
is possible to gain an understanding of these by using analogies in a more easily 
understandable classical mechanical system. In this section I will introduce the 
essential aspects of structural and diffusion MRI, consider how typical images are 
acquired, and also describe some of the standard clinical observations that are made 
in patients with mitochondrial disease. 
Proton Spin and its Manipulation 
The human body is made up of around 75-80% water. Within each water molecules 
are two hydrogen atoms, and each hydrogen atom contains one proton. It is the 
inherent properties of these protons that make MRI possible. A proton can be thought 
of as a charged ball, spinning on an axis, although in the quantum world ‘spin’ is not 
a literal term. The ‘right hand rule’ then dictates that this ball then also has an 
associated magnetic moment with a defined size and direction. Normally, proton spin 
direction will be random, and there will be zero net magnetisation. In an MRI scanner 
a strong magnetic field is present and this causes the protons to align with that field. 
Once aligned, the nuclei can exist in two possible states; low energy in which the 
proton is aligned with the field, and high energy in which the proton is aligned against 
the field. If there is no further change of field it is found that there are slightly more 
protons aligned with the applied field compared to against it. Overall, this creates a 





Figure 4. Proton spin orientations without external magnetic field (left) and with 
applied external magnetic field (right). 
When in the presence of an externally applied magnetic field, there are fractionally 
more protons in the low energy state so when the magnetic moments are added 
together, they do not fully cancel each other out. This slight excess of protons in the 
low energy state is known as the ‘spin excess’. This excess is very small, for example 
when the magnetic field is 3 Tesla (one of the most common magnetic fields found in 
clinical MRI machines) the spin excess is only around 3 in 100 000 (Equation 1). At 
first glance it does not seem likely that there will a measurable signal. However, there 
are of the order of Avogadro’s number (6.022 x 1023) of protons in only 24.7 grams of 
brain tissue, assuming that the brain is made up of approximately 73% water. 
Therefore, the net magnetisation then becomes measurable.    




Equation 1. Equation for spin excess where N = total number of spins in the sample, 
ħ = Planck’s constant / 2π, ω0 = Larmor frequency, k = Boltzmann’s constant, and T 
= temperature in Kelvin. 
The properties, and manipulation, of the net magnetisation vector is key to the 




The application of an external magnetic field alone is not enough to create a 
measurable signal, therefore an additional RF pulse must be applied, using a 
transmission coil, to temporarily shift the orientation of the protons so they precess 
around the axis of the applied magnetic field. 
 
Figure 5. An RF pulse applied at a specific frequency imparts energy to the protons 
causing them to flip through an angle, , and precess around the axis of the external 
magnetic field. 
The RF pulse must be applied at a specific frequency, known as the Larmor 
frequency, for the proton to absorb the energy and shift from its original orientation 
with the precise frequency scaling with the strength of the applied static magnetic 
field. The duration of the pulse then dictates how far from the original orientation the 
proton moves (Figure 5), which is known as the ‘flip angle’, . Detection coils are 
placed around the area of interest on the body in which a current is created via 
electromagnetic induction. This current provides the magnetic resonance (MR) 
signal. The angle through which the pulse tips the spins is not maintained over time 
and the protons eventually return to their original alignment with the external field and 
lose their phase cohesion, a process known as relaxation. 
There are two relaxation processes that are important in image formation. These 
processes are described by the time-constants T1 and T2. The T1 constant describes 
the spin-lattice relaxation, which is the loss of energy from the protons to the 
surrounding material. The T2 constant describes the spin-spin relaxation, which 




of these processes happen at the same time, but images are weighted to one or the 
other by setting the RF pulse sequence appropriately. The differences in the 
structural properties in the tissues allow good contrast in both T1 and T2-weighted 
images, but where pathological changes, such as lesions in patients with 
mitochondrial disease, are present one of the modalities often provides better 
contrast between the pathology and the healthy tissue. This is possible because the 
T1 process takes longer than the T2 process. It should also be noted that the T1 
relaxation time is significantly affected by the strength of the external magnetic field, 
while the T2 relaxation time is relatively independent of it. 
The contrast within an image is dictated by the physical properties of the tissue, with 
more solid tissue having distinct T1 and T2 values as compared to tissue with more 
fluid in it. 
1.2.ii Structural MRI 
Anatomical Scans 
Most clinicians are familiar with the most commonly used clinical MRI sequences that 
produce anatomical scans with contrasts derived from either T1 or T2 weighting. By 
using multiple radiofrequency pulses within a single scan with specific repetition 
times (TR), the measured signals can be optimised for the type of contrast being 
looked for, whether that is contrast between healthy tissue types, for example grey 
and white matter, or contrast between damaged tissue, for example healthy grey and 
white matter, and a lesioned area (Figure 6). This method of creating an image uses 
the relative difference between the relaxation times of different tissues and therefore 
provides a qualitative ‘snapshot’ rather than a true measure of the T1 and T2 values 
for each tissue visible on the scan, although quantitative scan protocols are available. 
To appreciate the differences between these two weighting types and their clinical 
relevance we shall first consider the longitudinal relaxation time, T1.  




Equation 2. Equation describing the longitudinal relaxation time, T1, where Mz = 






Figure 6. T1 relaxation curves for white matter (WM) (blue), grey matter (GM) 
(orange), and CSF (grey). In a T1-weighted image a short TR is used to maximise the 
contrast between all tissue types, which is better suited to carrying out volumetric 
analysis as tissue contrast is optimised. 
Using short TR and echo time (TE) values weights the imaging to T1, which provides 
good contrast, particularly between grey and white matter, and this is key if 
volumetric analysis is to be carried out as there needs to be as clear a distinction as 
possible between the tissue types. The T1 of a specific tissue is defined as the time 
taken for the signal to increase to around 67% of its final value. 
Next, we shall consider the transverse relaxation time, T2. 




Equation 3. Definition of the transverse relaxation time, T2, where Mxy = measured 





Figure 7. Graph showing the increased contrast between grey and white matter, and 
CSF when using T2-weighted imaging. 
To weight an image to T2, long TR and TE values are selected for the scan, with the 
T2 value of a tissue or fluid being defined as the time taken for the signal to drop to 
around 33% of its starting value. The difference between tissue and cerebrospinal 
fluid (CSF) signal in T2-weighted imaging allows for better contrast to be seen 
between healthy tissue and lesioned regions in the brains of patients with 
mitochondrial disease. However, the brightness of the CSF can cause some 
problems with image interpretation as it is sometimes not clear whether an area is 
lesioned, or if it is an area appearing to be particularly bright where it is not expected 
to be, which occurs due to partial volume effects, particularly in images with large 
voxels as each voxel can contain signal from more than one tissue or fluid. 
The differences between the weighting types can be best appreciated by inspecting 





Figure 8. Example T1-weighted (left) and T2-weighted (right) images generated from 
the study cohort scan set for Patient 6. The difference in intensity associated with 
each tissue type and the contrast between tissues can clearly be seen. 
These anatomical scans can show obvious changes to tissues, but this still relies on 
the skill and experience of a neuroradiologist to identify and interpret. The visual 
interpretation of these images is also entirely qualitative and therefore also 
subjective. When attempting to assess something like atrophy, the definition of the 
amount of atrophy that has occurred is highly problematic as the volume loss occurs 
three-dimensionally but is assessed using two-dimensional slices. The classical 
changes seen in patients with the m.3243A>G point mutation are the appearance of 
lesions, associated with stroke-like episodes, and also atrophy. While these 
observations may assist clinicians in assessing the effect and impact on the patient 
of these changes to the brain, they do nothing to explain the underlying mechanisms 
and do not provide a predictive capability prior to the onset of stroke-like episodes or 
global atrophy. 
T2 Fluid-attenuated Inversion Recovery (FLAIR) 
T2 FLAIR is an MR imaging technique in which the usually bright CSF is suppressed 
by utilising even longer TR and TE values, thus improving the image contrast within 
the image for the other tissues present. This is achieved by setting the inversion time 
(TI) to be equal to the time taken for the CSF signal to equal zero. This effectively 
nulls the normal CSF signal, while allowing abnormal tissues to remain bright within 




and size of lesions within the brain and improves the ability to delineate between 
CSF and lesions, which are often difficult to distinguish in a standard T2 image. 
 
Figure 9. Example T2-FLAIR (left) and T2-weighted (right) images generated from the 
study cohort scan set for Patient 6. While the grey and white matter contrast are 
maintained, the bright CSF of the T2-weighted image is suppressed, thus making it 
easier to observe the details in and around the areas of CSF. 
1.2.iii Diffusion Tensor Imaging (DTI) 
Diffusion Weighted Imaging (DWI) 
In contrast to the qualitative imaging techniques described in Section 1.2.ii, there are 
also quantitative magnetic resonance techniques that have been developed to look at 
the pattern of water diffusion within the brain at a microscopic level. Although it has 
been possible to measure the self-diffusion of molecules using magnetic resonance 
since 1965 (Stejskal and Tanner, 1965), it was not until 1990 that it was employed in 
a clinical setting to interrogate the brain to ascertain where local water diffusion 
patterns had been disrupted during ischaemic stroke (Neil, 2008). 
To obtain a diffusion image the location of the water molecules within the brain are 
encoded using one magnetic gradient pulse, then applying a second magnetic 
gradient pulse after a delay of around 60 ms to locate them again. Water molecule 
movement in the time between the two gradient pulses leads to attenuation of the 
MR signal due to diffusive processes, which then allows quantitative information 




calculated. The value is known as the diffusion coefficient and provides an average 
measure of how far the water molecules move due to Brownian motion. The scans 
are diffusion-weighted, and by modifying the diffusion times it is possible to, at least 
partially, target the specific environment in which the water molecules are moving, for 
example intracellular compartments. The environment within which a water molecule 
is moving is important as a freely moving water molecule will have a different pattern 
of movement to one moving in a more structured environment. A structured 
environment restricts molecular movement and so is termed the apparent diffusion 
coefficient (ADC). 
To carry out this type of scan additional parameters have to be set. The first of these 
is the b-value. This defines the strength and duration of the gradient. Most diffusion 
scans that are used to estimate ADC use b-values between 0 and 1000 s/mm2. To 
calculate an estimate of the ADC values Equation 4 is used. 
𝐼2
𝐼1
=  𝑒(−𝑏.𝐴𝐷𝐶) 
Equation 4. Equation for the estimation of ADC values where I1 = signal at lower b-
value, I2 = signal at higher b-value, b = b-value, and ADC = apparent diffusion 
coefficient. 
Principles of DTI 
Diffusion tensor imaging (DTI) is a more robust extension of DWI and allows 
quantification of localised water molecule diffusion properties within the highly 
structured environment of the brain where there are both intra- and extracellular 
barriers that are encountered by a diffusing water molecule. In an unstructured 
environment the movement of a water molecule can be described by a sphere, but in 
a structured environment the movement is then modelled as an ellipsoid as diffusion 





Figure 10. A model of anisotropic diffusion of water molecules (left) and its 
associated representation by a tensor (right). 
To mathematically define the ellipsoid a number of measurements of water diffusion 
are required in multiple directions that are distributed throughout the three-
dimensional space, and a diffusion tensor model applied to their analysis. The 
application of the diffusion tensor model allows the production of orthogonal 
measurements in the x, y, and z planes, and the magnitudes of these are the 
eigenvalues λ1, λ2 and λ3. By combining the direction and magnitude the overall 
direction and movement of the water molecules can be described using the 
eigenvectors v1, v2, and v3. In the white matter of the brain the myelinated axons run 
in a specific direction and water moves most freely in this direction, and is restricted 
across the axons. Therefore, the largest eigenvector will run parallel to the axon. The 
eigenvector values can then be used to calculate rotationally invariant diffusion 
values throughout the brain volume. Examples of the types of measure include the 
mean diffusivity (MD), as defined in Equation 5, which is a measure of isotropy, and 
the fractional anisotropy (FA), as defined in Equation 6, which is a measure of 
diffusion restriction. FA values can be anything from 0, totally isotropic, to 1, total 
anisotropy. 
𝑀𝐷 =  
𝜆1 +  𝜆2 +  𝜆3
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Equation 6. Equation describing the calculation of fractional anisotropy, where 〈𝜆〉 = 
one third of the trace of the tensor. 
 
Figure 11. Example slices from Patient 1 of (A) T1-weighted, (B) MD, and (C) FA. 
Figure 11 shows the different types of information available using different scan 
types. The T1-weighted image shows the familiar brain tissue with grey matter being 
darker grey, white matter a lighter grey, and CSF being almost black. The central 
mean diffusivity image can indicate regions of the brain that have altered diffusion 
properties showing up as brighter regions within the darker grey and white matter 
regions, which have very similar MD. The FA image highlights the pathways of the 
white matter tracts, which can also be presented in a colour version showing the 
different orientations of the fibres. 
It has been proposed that the diffusion patterns of water molecules in the brain may 
provide additional information about the underlying microstructure of the tissue 
(Nucifora et al., 2007; Lebois, 2014). In particular, a technique, known as 
tractography, uses patterns of local anisotropy to define the orientation of white 
matter tract pathways. FA has been of some interest in studies of patients with 
mitochondrial disease and recent studies have shown microstructural changes to 
white matter tracts that appear to be unique to a specific phenotype, and possibly 
genotype but many more studies would be required to fully assess this as no post 
mortem neuropathological correlates have yet been established (Virtanen, 2011; 
Rocca, 2011). Perhaps of most interest is the study that looked at a group of 




group. The main finding was a decreased FA in the inferior longitudinal fasciculus 
(see Figure 12) (Virtanen, 2011), which correlates to clinical observations of the 
symptoms experienced by many m.3243A>G patients relating to the areas of the 
brain linked by this particular tract. 
 
Figure 12. Schematic diagram of the route of the inferior longitudinal fasciculus 
joining the temporal and occipital poles. 
Perhaps one of the most useful aspects about FA is that the relevant scans can be 
taken in vivo and so tissue structures in living patients can be mapped. With the 
information available from the eigenvectors a virtual map of white matter tracts can 
be rendered in three dimensions, also known as tractography. These maps may then 
potentially highlight whether the white matter tracts have been disrupted in some 
way, for example showing evidence of shearing after traumatic brain injury (Gold and 
Lipton, 2008). 
DTI Analysis Techniques 
MD and FA values that are obtained using DTI are measures of water molecule 
movement within the brain and are hypothesised to differ in different tissue types 
(Jeurissen et al., 2012). A single value for the whole brain would be meaningless as 
this would average together all tissue types, including any areas of pathology, and 
although there may be an indication of the presence of pathology from the absolute 
value provided, there would be no information about the size, location, or structural 
nature, so a number of techniques have been developed to break down the analysis 




The most prevalent technique is to register DTI data with a conventional T1- or T2- 
weighted scan and then to place ROIs for which mean MD and FA values can then 
be extracted. These values can then be compared within regions, between regions, 
and also between patient and control groups (Levin et al., 2008, Matsushita et al., 
2011, Newcombe et al., 2011, Niogi et al., 2008).  
An increasingly popular method of data analysis is to automatically segment scans 
into tissue types, grey matter (GM), white matter (WM), and CSF, to then obtain 
mean values for each one; or to use a software program to carry out tractography to 
define and map the white matter tracts (Chu et al., 2010, Goetz et al., 2004, Hong et 
al., 2009, Newcombe et al., 2011).  
For analysis to be meaningful between individuals or groups, differences in size and 
head geometry between individuals must be compensated for. To achieve this, scans 
are translated into “standard space”, which maps the test brain onto an ‘ideal’ brain 
that has been averaged from many scans so that the test brain aligns with the 
reference brain and thus regions can be more accurately defined. This then facilitates 
a direct comparison between specific brain regions. However, there are some 
research groups that advocate the use of patient space, or real space, instead to 
provide a more accurate determination of the values being measured in each 
individual (Aribisala et al., 2011). 
1.2.iv Arterial Spin Labelling (ASL) 
ASL works on the principle that the water in blood can be magnetically labelled. The 
water in the blood just below the area that is to be imaged is given a magnetic label 
by applying a 180° RF inversion pulse. Over time this magnetically labelled water 
exchanges with tissue water, thus altering the properties of the water within the 
tissue as the magnetically labelled water has an inverted spin. This exchange 
reduces the overall magnetisation of the tissue which then also reduces the MR 
signal and the associated image intensity. This process is then repeated without the 
magnetic labelling step to create a control image. The labelled image is then 
subtracted from the control image to produce an image showing the perfusion within 
the tissue and also reflects the volume of arterial blood that is delivered to the 




1.3 Thesis Aims and Scope 
Mitochondrial diseases are a collection of heterogeneous diseases in which 
symptoms may occur in any tissue, with age of onset varying across the lifespan with 
few clear indicators of the underlying mechanisms that trigger the presentation of 
symptoms. Despite the advances of understanding in terms of genotypes, 
phenotypes, and disease end-state neuropathology, there is still a large gap in 
mitochondrial disease knowledge in terms of reasons for susceptibility to neurological 
symptoms, the early mechanisms of these, and thus also any early warning 
biomarkers that may be used to develop and utilise preventative treatments. 
The main aims of this thesis were to develop, validate, and utilise cutting edge MRI 
analysis techniques to non-invasively investigate the volumetric properties of the 
brains of carriers and patients with MELAS with a confirmed m.3243A>G genetic 
diagnosis against a healthy control group to ascertain whether there are identifiable 
biomarkers for susceptibility to stroke-like episodes. The outputs are as defined 
below: 
• Identification and validation of an accurate and repeatable automatic 
segmentation protocol. 
• Analysis of global brain volumes in the form of whole brain, grey matter, and 
white matter. 
• Analysis of regional brain volumes in the form of cortical thicknesses. 
• Basic analysis of white matter tracts using tract-based spatial statistics applied 
to DTI scans. 
• Looking beyond single mode imaging to assess the challenges associated 
with registering ultra-high-resolution MRI with CLARITY images. 
Within the analysis of all of the above areas, there are a number of underpinning 
themes. These themes are the clinically relevant outputs that will assist clinicians in 
understanding mitochondrial disease better in terms of progression and prognosis. 
These themes are: 
• Determining those at risk of stroke-like episodes using risk biomarkers. 
• Tracking the disease trajectory from the point at which a specific mutation is 




• Providing insights into the evolution of underlying mechanisms of stroke-like 
episodes and their development over time. 
• Identifying any potentially easy-to-measure biomarkers, or surrogate 
biomarkers that may potentially be used in clinical practice. 
The scope of the thesis was to not only utilise the analysis techniques, but also to 
assess them for validity in this particular field. The patient cohort was made up of 17 
individuals, some of who had experienced stroke-like episodes, patients with MELAS 
(n = 7), and those who had not, carriers (n = 10). In addition, there was also a control 





Chapter 2. Magnetic Resonance Imaging of individuals harbouring 
the m.3243A>G point mutation 
2.1 Introduction 
Patients with mitochondrial disease may have any one of a large number of 
mitochondrial genetic defects, either in the form of point mutations or large-scale 
deletions (McFarland et al., 2010). The most common genetic mutation is the 
m.3243A>G point mutation, which makes up around a third of all genetic diagnoses 
within the mitochondrial disease patient and family populations (Gorman et al., 
2015a). Although many of the phenotypes associated with the m.3243A>G point 
mutation, such as MELAS and MIDD, have been relatively widely discussed in the 
literature (El-Hattab et al., 2015; Zhang et al., 2015; Nelson, 2017), m.3243A>G as a 
standalone genotype, and the prediction of symptoms and the long-term prognosis 
prior to symptom onset, has not. There are a number of neurological symptoms that 
are associated with this genotype that have been well characterised (McFarland et 
al., 2010), but there are yet to be reliable biomarkers identified to allow the probability 
of CNS symptom development to be assessed. 
2.2 Aims 
This chapter systematically reviews the use of MRI scans and the associated 
analysis techniques in the characterisation of the brains of patients harbouring the 
m.3243A>G point mutation and also considers relevant research carried out in other 
diseases that provides evidence to highlight methods that should be considered for in 
depth research into the mechanisms and processes of the development and clinical 
presentation of neurological manifestations of symptoms in patients harbouring the 
m.3243A>G point mutation. 
2.3 Methods 
2.3.i Paper Selection 
Published clinical studies were identified using the following criteria: adult patients, 
defined as >18 years old; a genetic diagnosis of the m.3243A>G point mutation; have 
had a brain MRI; additional descriptors, including ‘stroke-like episodes’ and ‘MELAS’ 
were also used to identify relevant papers. The reason for only including adults within 
this literature search is due to the adult-only composition of the study cohort and the 




Additional papers from research into other diseases, and also other techniques, were 
identified via the more general search terms: ‘lesion detection’; ‘lesion measurement’; 
‘metabolite ADC’; ‘water ADC’; ‘brain MRI’. 
2.3.ii Literature Search Strategy 
Searches were carried out using online literature databases; PubMed, Scopus, and 
Web of Science. Publication dates from 1st Jan 1980 through to 26th October 2017 
were included in the search. This wide date range was chosen to cover the main 
development period of MRI and its use in clinical practice. Articles in English, French, 
and German were included, and any duplicate articles were excluded. Reporting of 
patients in multiple papers was not considered to be an issue unless the findings in 
each were contradictory. The following keywords were used for searches: 
‘m.3243A>G’, ‘A3243G’, ‘brain’, ‘MRI’, ‘adult’, ‘MELAS’. 
Non-m.3243A>G paper searches were carried out using the same literature 
databases using search terms: ‘lesion’, ‘MRI’, ‘ADC’, ‘atrophy quantification’, 
‘abnormal connectivity’. Papers were selected for the relevance to research into 
m.3243A>G neurological symptoms, along with the quality of methodology and 
insights provided into non-m.3243A>G disease. 
 
Figure 13. Flow chart showing breakdown of articles identified through a systematic 





Volumetric Studies 3 (46 Patients) 
DWI/DTI Studies 1 (15 Patients) 
Other – including SWI and ASL 0 
 
Figure 14. Breakdown of papers that have quantitative analysis by subject matter. 
Papers may appear in more than one category depending on the study conducted. 
An additional 22 papers were identified through a wider scope literature search and 
investigation of citations that covered research outside m.3243A>G, but provided 
additional information and evidence to allow a more in depth understanding to be 
formed of the current MRI research into the effects of the m.3243A>G point mutation 
on the brain. This was a search that utilised both systematic searching of databases, 
but also utilisation of reference lists within those papers that were identified as adding 
relevant information to the discussion of topics identified within the MRI in 
mitochondrial disease papers. 
2.4 Data Extraction and Analysis 
The selected articles were arranged by cohort type, with further categorisation 
carried out to identify the type of MRI scan and analysis used in each of the papers 
with regards to the investigation and understanding of the brains of patients with the 
m.3243A>G point mutation. Case studies are defined as papers that discuss one, or 
more, specific individual patients, while cohort studies are papers that discuss 
patients as a group and report group characteristics rather than characterise the 
individual.  
To provide an overview of the findings to date a meta-analysis was attempted. The 
data collected showed that this would not be possible as the sample sizes for each 
possible parameter was very small, generally numbering less than 10, and with data 
coming from a maximum of n = 3 papers per parameter. Therefore, quantitative 
analysis was not possible due to the predominance of observational findings and, in 
many cases, small sample size. Therefore, analysis of papers will consist of a 






2.5.i Use of MRI in the study of mitochondrial disease in patients with the 
m.3243A>G point mutation 
The search terms yielded a total of 793 articles within the electronic databases 
selected. Of these, 20 articles described 31 patients in case studies, which are 
defined as papers discussing specifics of each individual.  There were also 14 
articles describing 182 patients in cohort studies, defined as papers discussing group 
characteristics of the participants, along with five relevant reviews containing 
overviews of MRI findings and use of MRI in patients with mitochondrial disease with 
the m.3243A>G point mutation. It is perhaps interesting to note that datasets for only 
211 patients harbouring the m.3243A>G point mutation have ever been published, 
and yet if the prevalence estimate from Chapter 1 is used, along with the m.3243A>G 
point mutation making up around a third of that number, there are approximately 670, 
000 people with the m.3243A>G point mutation. 
Application of the search criteria led to a large number of papers being removed from 
the analysis. Around half of these were papers using paediatric subjects, while the 
rest were removed due to insufficient information being contained within the paper to 
be of any value to a larger study. In many cases an MRI scan was mentioned either 
in the abstract or methods, but no image was presented, nor was the scan 
discussed, or alternatively it was simply stated that the MRI scan did not show 
anything of interest. These papers also made no statement of the scan sequence 
used, or the scanner type. n = 7 papers were removed due to there being no 
verification of the genetic mutation of the patient(s) in question, thus making it 
impossible to know whether the paper is relevant to a study of purely patients with 
the m.3243A>G mutation. 
2.5.ii Case Studies, Cohort Studies, and Reviews 
Case Studies 
The 20 case study papers covered a total of 31 individuals, 12 of these utilised T2-
weighted MRI scans, of which three carried out longitudinal follow-ups over time 
periods ranging from three weeks to 12 months (Apostolova et al., 2005; Bi, et al., 
2006; Choi et al., 2012; Clark et al., 1996; Fabrizi et al., 1996; Hanna et al., 1997; 




31 individuals covered in these studies, the dominant observations were the 
presence of temporal and occipital lobe lesions, in 15 and 14 individuals respectively. 
Seven were reported with lesions within the parietal lobe, and only two with lesions in 
the frontal lobe. Of the 18 symptoms reported, three were reported in around a third 
of cases, which were headaches, epileptic seizures, and aphasia, with the others 
only being reported for a couple of individual cases, most of which were reported due 
to their unusual presentation. This collection of reporting backs up the anecdotal 
clinical reports of temporal and occipital lesions being the most common. There was 
also approximately even reporting of cortical and cerebellar atrophy (in eight and nine 
patients respectively), however it was rare that both types of atrophy were reported in 
a single individual. Seven of the studies utilised apparent diffusion coefficient (ADC) 
mapping techniques (Bi et al., 2006; Choi et al., 2012; Kolb et al., 2003; Ohshita et 
al., 2000; Oppenheim et al., 2000; Tzoulis et al., 2009; Uehara et al., 2014) to 
analyse the diffusion properties of water in the brain and the findings were somewhat 
contradictory as equal reporting was given for both increases and decreases of ADC 
associated with lesions caused by stroke-like episodes. The Tzoulis et al. (2009) 
paper did however suggest that these differences are due to the time between the 
stroke-like lesion forming and the measurement being made as they monitored the 
lesions in their patient over time and noted a change from a decrease in ADC to an 
increase in ADC compared to healthy controls over time (see Section 2.6.i for further 
discussion of the literature ADC values), four studies utilised ASL to analyse the 
perfusion properties of the brain (Ikawa et al., 2013; Li et al., 2017; Tsujikawa et al., 
2012; Uehara et al., 2014). All four found that in acute lesions there was 
hyperperfusion, and two also noted that in old lesions hypoperfusion was seen. 
Ikawa et al. (2013) and Li et al. (2017) noted regions of hyperperfusion in a total of 
five patients prior to their next stroke-like episode, so these patients already had a 
history of stroke-like episodes and were being actively monitored. Tsujikawa et al. 
(2012) also noted an interesting case in which hyperperfusion was observed in the 
contralateral cerebellum to the location of the lesion, which then resolved over time 
no lesion was noted in the cerebellum itself. The final case study used MR 
angiography (MRA) (Minobe et al., 2015) and observed increased vasodilation within 







The 14 cohort studies involved a total of 182 patients who had MRI scans as part of 
the study and ranged in sample size from 3 up to 33 patients with m.3243A>G 
related mitochondrial disease. Some of the studies contained a mixed genotype 
cohort and only where patients with the m.3243A>G point mutation could be 
separated out were the studies deemed to be valid for use in this review. All bar two 
of the cohort studies utilised structural MRI scans to analyse the patient brains 
qualitatively by eye (Abe et al., 2004; Iizuka et al., 2002; Iizuka et al., 2003; 
Majamaa-Voltti et al., 2006; Sue et al., 1998; Suzuki et al., 1996; Tatlisumak et al., 
2016; Tschampa et al., 2013; Tsujikawa et al., 2016; Virtanen et al., 2011; Chinnery 
et al., 2000; Fromont et al., 2009).  
In the qualitative observations there was a slightly different weighting to the reporting 
of the location of lesions with equal numbers being reported in all of the temporal, 
occipital, and parietal lobes. Interestingly there were 12 reported cases of having a 
confirmed m.3243A>G point mutation with symptoms such as headaches and 
epileptic seizures, but with MRI scans that were reported as looking normal. In terms 
of symptoms, reporting of stroke-like episodes (58 individuals), epileptic seizures 
(33), and cognitive impairment (38 individuals) dominated the cohort literature. 
The differences seen between the case studies and the cohort studies is likely to be 
due to the selection of ‘interesting cases’ for the case studies, while the cohort 
studies perhaps used patient groups that are more representative of the patient 
population as a whole, although the patient selection is heavily weighted towards 
those with MELAS or histories of stroke-like episodes.  
Four of the studies had a longitudinal element to them in addition to the main case 
study, but timeline details were only given in one of these (Abe et al., 2004; Iizuka et 
al., 2002; Iizuka et al., 2003; Majamaa-Voltti et al., 2006) and although they did 
describe the progression of the lesions in the patients that were followed up in terms 
of size and location, most often beginning in the temporal lobe and spreading 
unilaterally, without timelines associated with those it is impossible to begin to 
ascertain whether there are any patterns in terms of lesion development.  
Five studies looked at water ADC mapping techniques (Abe et al., 2004; Iizuka et al. 




that ADC values were decreased in acute lesions, but Liu et al. (2010) also 
investigated non-lesioned areas compared to controls and found the ADC values to 
be elevated (further discussion of ADC values can be found in 2.6.i).  
Of these cohort studies, three carried out voxel-based morphometry (VBM) to 
statistically volumetrically compare the brains of those with stroke-like episodes, to 
carriers, and to controls (Tsujikawa et al., 2016; Virtanen et al., 2011; Haast et al., 
2018), but only one of those actually presented a full quantitative presentation of their 
results that included actual values in addition to statistical comparisons (Virtanen et 
al., 2011). The regions highlighted by Tsujikawa et al. (2016) were the left superior 
parietal lobe, the right precuneus, the right middle temporal gyrus, and the bilateral 
posterior lobes of the cerebellum, which were significant in all four of their patients 
with MELAS, and found in three, one, two, and five of their carrier group respectively. 
In contrast Virtanen et al. (2011) found the predominant changes between their 
control and patient groups in the occipital lobes and the cerebellum, with no apparent 
dominance in either hemisphere. All three of the papers found significant differences 
between the control and patient group grey matter volumes, although Haast et al. 
(2018) did not find a significant difference between their controls and their ‘low 
heteroplasmy’ group. 
The paper by Virtanen et al. (2011) provided a methodology that was well-described 
and repeatable, with the measures being clearly defined and also quantified. In the 
analysis conducted in this paper, the patients were all consolidated into a single 
group that included both carriers and patients with a history of stroke-like episodes 
and significant atrophy. The paper reported the patient group to have significantly 
less grey matter than the control group. 
The cohort studies mostly consisted of patient groups with a mixture of clinical 
histories and within each group there were patients with, and without, histories of 
stroke-like episodes (Majamaa-Voltti et al., 2006; Suzuki et al., 1996; Tatlisumak et 
al., 2016; Tschampa et al., 2013; Tsujikawa et al., 2016; Virtanen et al., 2011; 
Chinnery et al., 2000; Fromont et al., 2009). Most of these clearly defined the number 
of patients that were included who had histories of stroke-like episodes (Tsujikawa et 
al., 2016; Virtanen et al., 2011; Chinnery et al., 2000; Fromont et al., 2009), but some 
did not (Majamaa-Voltti et al., 2006; Suzuki et al., 1996; Tatlisumak et al., 2016; 




addition to this, only around half of the cohort studies papers included a patient table 
with information such as symptoms, age at diagnosis, age at first stroke-like episode, 
and so on.  
Comparison and Discussion of Case and Cohort Studies 
The vast majority of the reporting is from clinical sources and there is a heavy 
emphasis within the case studies of ‘interesting cases’. The trend of publishing these 
‘interesting’ case studies has now almost ceased, and there is now a much larger 
emphasis being placed on cohort studies to attempt to gain a more in depth 
understanding of the neurological, and in particular the neurodegenerative, 
symptoms experienced by patients with the m.3243A>G point mutation, whether they 
have suffered from stroke-like episodes or not.  
All reported case studies within this review, except one case study presentation of a 
patient with MIDD (Kobayashi et al., 2005), were of patients who had suffered from a 
stroke-like episode, or who had lesions reported on their MRI scans. Therefore, the 
vast majority of case studies reported some type of lesion being present on the MRI 
scans. Unfortunately the details of when the stroke-like episodes occurred in relation 
to the date of the MRI scan were not reported in the majority of cases, with only 
seven of the case studies (Bi et al., 2006, Clark et al., 1996; Ikawa et al., 2013; Kolb 
et al., 2003; Li et al., 2017; Tsujikawa et al., 2012; Tzoulis et al., 2009) and 3 of the 
cohort studies (Abe et al., 2004; Iizuka et al., 2003; Liu et al., 2010) providing 
timelines relative to the first recorded stroke-like episode within the study timeline. 
The studies that included structural MRI scans provided clinical observations of the 
general location, and in the case of the longitudinal studies, the spread or 
development of lesions, but the longitudinal studies carried out no further analysis of 
the images to provide information about the size of the lesions present, the lesion 
location, the shape or coverage of the lesion, details of the size changes of the 
lesion, or any other observations about the longitudinal changes that occurred. 
The seven case and cohort studies that captured longitudinal structural data simply 
captured observational comments and cannot be combined to provide further 
information about the longitudinal progression of stroke-like episodes (Bi et al., 2006; 
Clark et al., 1996; Kitamura et al., 2016). The only structural longitudinal aspect of 




2006; Clark et al., 1996; Fabrizi et al., 1996; Hanna et al., 1997; Kim et al., 2016; 
Kitamura et al., 2016; Kobayashi et al., 2005; Majamaa-Voltti et al., 2006), with three 
of the papers observing significant, but unquantified, atrophy over time in the regions 
of the lesion formation (Bi et al., 2006; Liu et al., 2010; Majamaa-Voltti et al., 2006). 
Cortical laminar necrosis was reported by some of the longitudinal studies (Bi et al., 
2006; Majamaa-Voltti et al., 2006) even though cortical laminar necrosis is a 
pathological diagnosis and there have yet to be imaging correlates established. With 
a combined sample size of seven the data presented states that up to half of 
lesioned areas caused by stroke-like episode lesions will show cortical laminar 
necrosis, however this should be read as the T1-weighted images showing 
hyperintensities in the grey matter surrounding lesions.  
Atrophy is another measure that is frequently commented upon in the selected case 
studies. All of these studies only made qualitative visual assessments of the 
presence, and extent, of the atrophy. These most commonly qualitatively described 
atrophy in the region of the lesions, in addition to descriptions of both cerebellar (Kim 
et al., 2016; Kobayashi et al., 2005) and brain stem (Kobayashi et al., 2005) atrophy.  
One of the difficulties of studying patients with mitochondrial disease who do not 
have significant symptoms is identifying them. One method that may be of use to 
increase the cohort of people with the m.3243A>G point mutation is to look in other 
disease groups including diabetes (Tatlisumak et al., 2016) or ischaemic stroke 
(Tschampa et al., 2013). While these studies are relatively rare, they indicate that 
m.3243A>G point mutation carriers could make up 15 - 45 patients per thousand 
within the diabetic and stroke patient groups (Suzuki et al., 1996; Tatlisumak et al., 
2016). These results indicate that the prevalence of the m.3243A>G point mutation 
within the general population may be somewhat higher than currently thought and 
these patient groups may provide a useful clinical insight into the differences in 
symptomatic presentation between those who are carriers, and those who are 
diagnosed with phenotypes, such as MELAS, due to their more extreme symptoms. 
Comments on Review Papers 
Relevant reviews identified in this process are few, and are also somewhat varied in 
nature (Goodfellow et al., 2012; Haas et al., 2004; Malhotra et al., 2016; Parry et al., 
2003; Saneto et al., 2008). One review discusses the use of MRI in MELAS only to 




stated to be headaches, seizures, acute neurological deficits, which agrees with both 
the case and cohort study findings in this review, and the associated lesions seen on 
MRI (Goodfellow et al., 2012). The four reviews concentrating on imaging modalities 
provided a lot of information about the imaging techniques available, but in general 
there are only a couple of useful published papers providing data to allow any sort of 
assessment of the usefulness of each technique to be made (Haas et al., 2004; 
Malhotra et al., 2016; Parry et al., 2003; Saneto et al., 2008). The main findings 
include the use of T2-weighted FLAIR images for effect visual assessment of the 
location and size of lesions associated with stroke-like episodes as well as 
highlighting the potential for techniques such as quantitative T1-mapping. The papers 
also only summarise the observations from the papers they have reviewed without 
acknowledging that these are specifically related to the occurrence of stroke-like 
episodes in the form of lesions and significant atrophy, and also fail to add any 
additional value to the original research either through a meta-analysis, or by stating 
what the observations mean for either a patient group focus (Haas et al., 2004; 
Malhotra et al., 2016), or for mitochondrial disease in general, for which the other two 
papers discusses the use of imaging techniques in the diagnosis of the disease 
(Parry et al., 2003; Saneto et al., 2008). The most important observation made in 
these imaging papers is that to date there is still no pathonomic correlation between 
specific neuroimaging changes seen in the brain and the genetic defects present in 
patients with mitochondrial disease (Saneto et al., 2008). 
2.5.iii Volumetric Studies 
There are three cohort studies that state they have carried out quantitative volumetric 
analysis on high resolution MRI scans (Tsujikawa et al., 2016; Virtanen et al., 2011; 
Haast et al., 2018). Tsujikawa et al. (Tsujikawa et al., 2016) and Haast et al. (Haast 
et al., 2018) carried out VBM on their scans, which although strictly speaking is a 
quantitative analysis technique, the results presented were simple a statement of the 
brain areas that were highlighted as having statistically significantly different volumes 
between the patient groups. Tsujikawa et al. (2016) split patients into those with, and 
without, documented stroke-like episodes, while Haast et al. (2018) split their patient 
group by degree of blood heteroplasmy with a low heteroplasmy group (<23%) and 
high heteroplasmy group (≥23%), with no justification for splitting the patient group in 
this manner, although examination of the presented data by eye appears to indicate 




finding correlation between hearing loss symptoms in patients with MIDD and 
heteroplasmy, all other papers have found a lack of strong correlation, which further 
adds to the questions arising from this choice of patient grouping.  
The second quantitative volumetric analysis paper to be considered (Virtanen et al., 
2011) utilised both segmentation and VBM analysis methods to ascertain whether 
there were significant volumetric differences between the patient and control groups. 
In this study the patient group was kept as a single group containing both those with, 
and without, a history of stroke-like episodes. The number of patients with histories of 
stroke-like episodes was not stated, but it was stated that nine of the patients were 
neurologically asymptomatic. The lack of patient information means that is it also 
unknown how many were of short stature, and therefore have smaller heads, which 
would bias the patient results. The results showed that there was significantly smaller 
volumes of grey matter in patients compared to controls (after normalisation for head 
size) and that these were concentrated in the occipital pole region and the 
cerebellum (Virtanen et al., 2011). The methodology used was clearly stated and 
could easily be repeated by any other group. The results were also presented as 
quantitative outputs, which could allow simple comparison to output from other 
studies if the scan type and parameters are suitably matched. However, it needs to 
be stated that the grouping of patients into a single group and the lack of attention to 
additional patient details means that this research is highly biased towards patients 
with histories of stroke-like episodes and significant atrophy. 
2.5.iv     DWI and DTI Studies 
Seven case studies looked at the ADC properties of water in the brains of patients 
who had suffered stroke-like episodes (Bi et al., 2006; Choi et al., 2012; Kolb et al., 
2003; Ohshita et al., 2000; Oppenheim et al., 2000; Tzoulis et al., 2009; Uehara et 
al., 2014). The presented results of these were that around half found restricted 
diffusion, identified through the observation of a reduction in ADC values, (Bi et al., 
2006; Choi et al., 2012; Tzoulis et al., 2009) in and around lesions, while the other 
half found increased diffusion (Kolb et al., 2003; Ohshita et al., 2000; Oppenheim et 
al., 2000; Uehara et al., 2014). Those finding restricted diffusion postulated that in the 
region of a lesion vasogenic oedema was occurring, while those finding increased 
diffusion postulate that cytotoxic oedema is the dominant mechanism within a lesion. 




conclusions to be reached about whether the difference in reported diffusion 
characteristics are due to the timing of the scans in relation to the stroke-like episode. 
Two cohort studies have been carried out that provide more details about the nature 
of changes in water ADC (Iizuka et al., 2003; Liu et al., 2010). The cohort study 
comparing the water ADC values between lesioned and non-lesioned areas found 
that the values were lower in lesioned areas (0.7 - 1.2 x 103 mm2/s) than apparently 
non-affected areas (0.9 - 1.7 x 103 mm2/s), and therefore that diffusion was more 
restricted in the lesions than in the surrounding tissue (Iizuka et al., 2003). The study 
also found that the mean ADC values in normal appearing regions with no previous 
lesions were lower than in previously affected regions (0.9 – 1.1 x 103 mm2/s, 
compared to 1.2 – 1.7 x 103 mm2/s) (Iizuka et al., 2003). In a second scan taken five 
days after the stroke-like episode the newly appearing lesions were measured as 
having water ADCs of 0.73 – 0.89 x 103 mm2/s compared to 0.92 – 0.98 x 103 mm2/s 
in normal appearing regions (Iizuka et al., 2003). The other cohort study solely 
looked at water ADC values in the apparently normal areas of the brain of patients 
with lesions and compared these to controls (Liu et al., 2010). This paper found that 
water ADC values in patients with MELAS were significantly higher across ten 
regions of the brain than in the control group, with the overall average water ADCs 
being 0.793 ± 0.054 x 103 mm2/s for the patients with MELAS and 0.740 ± 0.038 x 
103 mm2/s for the controls. This paper also noted that other studies (Ohshita et al., 
2000; Wang et al., 2003) looking at water ADC values have traditionally taken the 
water ADC values from non-lesioned parts of the brain as the ‘normal’ value to 
compare the lesioned values against (Liu et al., 2010). Traditional explanations for 
the formation of lesions were discussed, along with the possibility of the combination 
of impaired cerebral perfusion with the increased neuronal metabolic rate leading to 
disruption of the OXPHOS process and then on to neuronal death in the lesioned 
regions (Liu et al., 2010). There are also a number of pathological assumptions that 
have been made to justify the use of water ADC as an MRI marker for the presence 
of oedema, either cytotoxic or vasogenic, and also to attempt to explain the local 
cellular conditions.  
One of the cohort studies (Virtanen et al., 2011) carried out analysis of DTI data in 
addition to the volumetric analysis that was also carried out. Again, the patient group 
was kept in a single group to compare against the control group with not enough 




analysis was carried out using tract-based spatial statistics (TBSS) and the results 
indicated that significant differences in fractional anisotropy (FA) were seen in a 
number of areas, but the most significant being along the length of the inferior 
longitudinal fasciculus approximately connecting the occipital and temporal poles 
(Virtanen et al., 2011).  
2.5.v Additional MRI protocols 
ASL was used in four case studies to investigate perfusion within the brains of 
patients suffering from stroke-like episodes (Ikawa et al., 2013; Li et al., 2017; 
Tsujikawa et al., 2012; Uehara et al., 2014), with two of those papers (Ikawa et al., 
2013; Li et al., 2017) claiming that ASL maps may show hyperperfusion up to 3 
months prior to the onset of a stroke-like episode. One further paper utilised MRA to 
look at the vascular system during a stroke-like episode and found vasodilation of the 
cerebral arteries, which then reverted to normal as the symptoms reduced in severity 
(Li et al., 2017). All of these papers utilised patients who had already had a stroke-
like episode and were therefore being actively monitored, with some being scanned 
at 3 month intervals, allowing the longitudinal tracking of perfusion. However, none of 
the papers had scanned a patient prior to the first presentation of a stroke-like 
episode, and therefore the observations made cannot be assumed to be an initial 
indicator of a stroke-like episode. 
2.6 Findings from non-m.3243A>G research 
2.6.i ADC values 
With a number of m.3243A>G research papers looking at water ADC, some further 
information was sought on this parameter, particularly due to the often-contradictory 
results presented. 
Specifically looking at water ADC values to begin with, it is known that although water 
is almost omnipresent throughout both the microscopic and macroscopic brain 
tissues, it is for this very reason inherently non-specific (Shepherd et al., 2012). In 
addition to this ubiquity, there is also work that has been carried out by Lampinen et 
al. (2017) and Reisart et al. (2017), which claims that the exact diffusion properties 
and coefficients of water in the various cellular environments are not yet accurately 
known, and therefore diffusion measurements of water in the brain offer little solid 




division between the intra- and extracellular components of a diffusion signal. In 
addition to these issues, there is also the problem that there are a number of different 
models utilised in order to quantify the diffusion properties of water in the brain, and 
all of which incorporate a large number of assumptions within them (Shepherd et al., 
2012). 
It therefore seems obvious that water alone is unlikely to ever provide a complete 
picture of all cellular environments of interest within the brain. If metabolite ADCs are 
also used, the combination of all of these could provide detailed insights to the 
microstructure of the brain in vivo (Shepherd et al., 2012). 
To further undermine the usefulness of water ADC, Table 1 and Table 2 show ADC 
values that have been quoted in the literature.  
 
Tissue type Average value (x10-3 
mm2/s) 
Range (x10-3 mm2/s) 
Cortical grey matter 0.89 ± 0.04 0.78-1.09 
Deep grey matter 0.75 ± 0.03 0.64-0.83 
White matter 0.70 ± 0.03 0.62-0.79 
Table 1. Typical water ADC values in a healthy population (Helenius et al., 2002). 





Tissue type (mixture of 
GM and WM) 
Average value (x10-3 
mm2/s) 
Range (x10-3 mm2/s) 
Lesioned (2-5 days post 
stroke-like episode) 
 0.7 – 1.2 
Contralateral to lesion – 
previously unaffected 
 0.9 – 1.1 
Contralateral to lesion – 
previously affected 
 1.2 – 1.7 
Normal appearing  0.92 – 0.98 
Average across the brain MELAS 0.79 ± 0.05 
Control 0.74 ± 0.04 
 
Table 2. Published water ADC values in patients with MELAS with confirmed 
m.3243A>G point mutations (Iizuka et al., 2003; Liu et al., 2011). 
The values provided in the literature show that in general the ADC values found in 
any patient with a history of stroke-like episodes are higher than those in healthy 
controls. This may be indicative of global changes that occur in association with 
stroke-like episodes. 
Although diffusion-weighted magnetic resonance spectroscopy (DW-MRS) 
measurements to ascertain metabolite ADCs are highly challenging, if accurate 
metabolite diffusion data are acquired, it can then be combined with geometric and 
computational modelling to provide unique information about specific types of cells 
and the microstructure in the tissue of the brain both in healthy and diseased brains 
(Shepherd et al., 2012). 
Now addressing metabolite ADCs specifically in ischaemic regions of the brain, there 
are a number of papers that have begun to tackle research in this area. 
One of the earliest papers to look at metabolite ADCs in ischaemic regions of the 
brain is Wick (1995) and used a rat model. Metabolite ADCs were measured over an 
80-minute period, with ischaemia being induced after 20 minutes, and lasted for 20 




ischaemic attack. ADCs were recorded for water, total N-acetyl aspartate (tNAA), 
total creatine (tCr), total choline (tCho), and myo-inositol. 
The water ADC value initially decreased, but gradually returned to its starting value 
by the time the final measurement was made. In contrast, all of the metabolite ADCs 
initially decreased, then returned to their starting value for a very short period of time, 
and then decreased again, indicating that the cellular changes were not as simple as 
water moving between the cellular environments, and also perhaps that there are 
some permanent cellular changes are induced as part of the process (Wick, 1995). 
To support this finding, Abe et al. (2000) also carried out DW-MRS measurements of 
metabolite ADCs during the early stages of focal ischaemia in rat brains to observe 
the temporal changes that occur. ADCs for water, tNAA, tCr, and tCho were 
measured over a period of 2 hours. The main findings are that all ADC values 
dropped immediately within the ischaemic regions and were then followed, after a 
delay, by decreases in all ADCs of the non-ischaemic region and the metabolite 
ADCs in the contralateral hemisphere, thus indicating that although the ischaemic 
region was well defined, that there was a global effect observed (Abe et al., 2000). 
Liu et al. (2011) have carried out a study of metabolite ADCs in patients with MELAS 
who were all interictal, and therefore had well-established lesions within their brains 
(Liu et al., 2011). This study was carried out on in vivo brains, and examined the 
metabolite ADCs of tNAA, tCho, and tCr. In this study all of the metabolites were 
found to have significantly higher ADCs both in lesioned and non-lesioned areas than 
the control group (Liu et al., 2011). 
Looking more in depth at the diffusion properties of water within the brain shows that 
there is a dependence of ADC on the diffusion time with longer diffusion times 
showing a decrease in water ADC, thus indicating more restricted movement of the 
water molecules, which is then theorised to be predominantly attributed to the 
intracellular environment (Branzoli et al., 2013). Shorter diffusion times are therefore 
theorised to be predominantly associated with diffusion in extracellular space and 
larger ADCs (Branzoli et al., 2013). In reference to metabolite ADCs, this paper 
suggests that their diffusion is not dictated by the cell size, type, and associated 
structure, but also by additional compartmentalisation on a sub-cellular level along 
with varying distributions of metabolites in either a ‘free’ or a ‘bound’ state. It is also 




could also affect the quantitative measurement of metabolite diffusion (Branzoli et al., 
2013). 
Metabolite ADCs appear to offer a great level of information about their cellular 
environments, but there are yet more factors that have to be considered, and one of 
these is that metabolite ADCs are different in grey and white matter, which 
considering their different cellular makeups should be expected (Deelchand et al., 
2017). When defining volumes of interest (VOIs) within which to measure metabolite 
diffusion, there are cross-term effects that must be considered and which are directly 
proportional to the volumes of grey and white matter within the VOI. To add further 
complexity to the cross-term factor, some scan sequences are more greatly affected 
than others, with the examples of STEAM5 and PRESS6 sequences being given in 
this case as examples of scan sequences that are affected to a greater and lesser 
extent respectively (Deelchand et al., 2017).  
In real terms, metabolite diffusion measured in grey matter is found to be significantly 
more restricted than in white matter and therefore any VOI containing multiple types 
of tissue must therefore have cross-term effects considered for absolute values to be 
valid along with relative values compared to other VOIs within the same brain or 
VOIs from the same region in a different subject (Ercan et al., 2015; Kan et al., 
2012). 
One of the reasons for the attraction of measuring metabolite diffusion properties is 
because, on the whole, metabolites are confined within cells, and are not found in the 
extracellular environment (Najac et al., 2016). The location of metabolites can further 
be determined through experimentation with diffusion times. By varying diffusion 
times from very short (a few milliseconds) up to over a second it can be seen that 
there is no dramatic dependence upon these, thus indicating that the majority of the 
metabolites found within cells in the brain are actually within the long fibres of cells 
rather than the cell bodies (Najac et al., 2016; Valette et al., 2018). This metabolite 
distribution reflects the distribution of mitochondria within the neuron as although 
mitochondria start in the soma they then travel along the fibres to provide localised 
energy production for each part of the cell, only returning to the soma to be repaired 
or recycled (Lin and Sheng, 2015). The lack of dependence on short diffusion times 
                                                          
5 STEAM – Stimulated echo acquisition mode, is a 90° - 90° - 90° slice selective pulse sequence. 
6 PRESS – Point resolved spectroscopy, is a 90° - 180° - 180° slice selective pulse sequence, which is less 




also indicates that metabolites are also not dominantly transported by active 
mechanisms around the cell (Valette et al., 2018). 
This predilection for metabolites to be in the long fibres of cells also means that there 
is an age-dependency of their ADCs as neuronal cell properties change significantly 
over time losing dendritic length, surface area, volume, diameter, and spine numbers 
and density (Zheng et al., 2012). Therefore, metabolite ADCs decrease as the brain 
ages, while in contrast water ADCs are not significantly affected (Zheng et al., 2012). 
It is also stated that neuronal apoptosis could begin as soon as 30 minutes after the 
onset of ischaemia, with a peak occurring between 24 and 48 hours, and at 
timescales longer than 48 hours the lesion is considered to be fully mature and 
necrotic. 
While this technique appears to offer a method to gain in-depth insight into the 
microstructure of the brain in patients carrying the m.3243A>G point mutation, the 
scanning protocols are not yet routinely available on clinical scanners and so could 
not be utilised within this study, but should definitely be considered in the planning for 
any future work. 
2.6.ii Alternative theories for restricted diffusion 
Changes in dendritic morphology, which could be caused either by age or ischaemia, 
may decrease the internal neuronal space across a number of dimensions, in which 
metabolite diffusion may occur, which then leads to the decrease of metabolite ADCs 
(Zheng et al., 2012). In addition to the morphological changes already described, it is 
also stated that apoptotic neurons are smaller in size than healthy neurons, which in 
itself could account for an overall decrease in metabolite ADCs while the water ADC 
is able to return to normal (Zheng et al., 2012).  
One theory about long term changes in metabolite ADCs is in the case of a chronic 
(necrotic) lesion, there is liquefaction of the neuronal debris, which then reduces the 
viscosity of the extracellular space. The number of apoptotic neurons also decreases, 
which could then result in a net increase of metabolite ADCs over time assuming that 
apoptosis ceases, which could provide an explanation for the relapsing/remitting 
nature of mitochondrial disease. However, this would require a large-scale 




In high grade gliomas, there is another alternative mechanism for the production of 
reduced metabolic ADCs proposed. In these gliomas there is the possibility of the 
presence of volume reduction caused by hypoxia within the glial cells, with an 
associated shift of cytoplasmic water (Gadda et al., 2016). 
One final theory for the reduction of metabolite ADCs actually comes from the study 
of lesions in patients with POLG (Tzoulis et al., 2016). It was found in these lesions 
that there was a significant increase in the cerebral vascular density, which was more 
pronounced in regions of chronic neurodegeneration, in other words, within lesions 
as identified on structural T1 and T2 FLAIR MRI scans. The vascular density 
correlated with the severity of the neuronal loss, but it was also observed in acute 
lesions and so either occurred very quickly, or was an ongoing process prior to the 
full development of the lesion and associated stroke-like episode (Tzoulis et al., 
2016). These results suggest that in patients with mitochondrial disease that at least 
some lesions do not have ischaemia as a contributing factor to the pathogenesis of 
either chronic neurodegeneration or acute lesions, particularly in POLG 
encephalopathy and that these lesions are more likely to reflect energy production 
insufficiency driven in large part by underlying seizure activity (Tzoulis et al., 2016). 
2.6.iii Quantification and mechanisms of atrophy 
Quantifying atrophy is not necessarily a straightforward task, but a large study carried 
out into the quantification of atrophy in Alzheimer’s Disease (AD) attempted to 
identify reliable methods to quantify the progression of atrophy in this patient group. 
A number of methods were proposed, all looking at the quantitative measure of 
atrophy, however the methods proposed were more designed to quantify the overall 
rate of atrophy in patients with AD, rather than to quantify the rate of progression in a 
single patient and also only considered atrophy progression over short timescales of 
up to a year (Cash et al., 2015). The paper found that there were large differences 
between the proposed techniques in terms of the number of samples required for the 
technique to work, but the smallest sample sizes stated for a trial that has a 
subsequent 12-month monitoring period is 242 for the full brain. It should also be 
stated that these techniques were designed to be able to identify volume changes 
down to around 1%. 
It has also been observed in patients with temporal lobe epilepsy (TLE) that there is 




et al., 2016). The patients with TLE have MRIs that appear normal, in terms of lesion 
presence, and also in patients both with and without hippocampal sclerosis. This 
appears to suggest either a separate atrophy process, or one that is due to sub-
clinical activity within the temporal lobe (Alvim et al., 2016). Interestingly, it has been 
noted that some patients with AD suffer so-called ‘silent’ seizures and spikes in the 
hippocampus during sleep (Lam et al., 2017), which indicates that seizure activity 
during sleep may be a factor in apparent seizure-less atrophy processes. One area 
that does not appear to have been studied in any detail is the effect of seizure control 
on the rate of atrophy, with no papers having been found addressing this question, 
either qualitatively or quantitatively, within the current literature. 
TLE research has also employed quantitative segmentation techniques to assess 
differences between patient and control populations in very large cohorts (Whelan et 
al., 2018) and have found patterns of atrophy associated with each of the epilepsy 
subgroups identified within the patient population. In addition to this definition of 
atrophy patterns, other work has shown that grey matter atrophy is networked, which 
may also be linked to seizure frequency and aetiology (Coan et al., 2014) and which 
may provide some insights into the mechanisms of seizure-related atrophy in patients 
with mitochondrial disease. 
2.6.iv      Abnormal connectivity 
The previous example of ongoing atrophy without seizure activity may perhaps be 
linked to the findings of work that has been carried out into looking at the 
hippocampal-thalamic wiring in patients with medial temporal lobe epilepsy, which 
shows enhanced connectivity per hippocampal voxel (Freund et al., 2012). This study 
found pronounced enhancement of connectivity between the sclerotic hippocampus 
and the ipsilateral thalamus in patients with either left or right TLE compared to a 
control group. The differences were most apparent in the number of absolute fibres 
and was most pronounced when correcting for hippocampal volume (Freund et al., 
2012). It was also noted in this study that the increased connectivity also negatively 
correlated with cognitive performance on a number of executive function tasks. 
A further study has also been carried out in patients with TLE using connectivity-
based segmentation to determine the connectivity patterns of the thalamus to 
ipsilateral cortical regions; occipital, parietal, prefrontal, precentral, postcentral, and 




volume of the ipsilateral hippocampus and entorhinal cortex. There was also a 
preferential volumetric loss of the thalamic segment connected to the temporal lobe 
(Keller et al., 2014). 
Further analysis also showed that the thalamotemporal segment volume significantly 
correlated with the volume of ipsilateral, but not contralateral, mesial temporal 
structures, which indicates that the degree of thalamic pathology is related to the 
extent of mesial temporal lobe damage in TLE (Keller et al., 2014). 
Research has also been carried out in patients with Parkinson’s Disease with, and 
without, hallucinations to attempt to pinpoint the regions involved in this 
phenomenon. Despite previous assumptions that the mesial temporal lobe is 
involved, this work showed that the hallucinations in these patients are actually 
related to disruption of the visuoperceptual pathway (Goldman et al., 2014). The 
areas that were shown to have a significant relationship to hallucination severity 
were: left inferior parietal lobule; left cuneus; right lingual gyrus; and right precentral 
gyrus. These affected regions play essential roles in both primary and secondary 
visual processing and visuoperceptual functions (Ungerleider and Mishkin, 1982). 
The secondary visual pathway is of most interest relating to mitochondrial disease 
patients, and particularly the disruption to the lingual gyrus, and their hallucinations 
as the pathway is involved in object recognition and movement detection and from 
anecdotal clinical reports appears to correlate with the types of visual hallucination 
experienced by patients with mitochondrial disease (unpublished data). 
Unfortunately, to date there has not been a cohort study formally investigating the 
nature of hallucinations and any related changes in the microstructure of the brain in 
patients with mitochondrial disease to allow any further analysis of this phenomenon. 
2.6.v Individualised approach to scanning and mapping 
There is ongoing work to develop a robust method for lesion segmentation utilising 
shape priors from both offline and online learning (Shepherd et al., 2012). The 
technique combines radial shape parameterisation combined with machine learning 
techniques from the field of non-linear time series analysis and offers the potential for 
quantifying the volume of a lesion (Shepherd et al., 2012). This could provide a 
robust method for assessing the location, size, and spread of a lesion over time. 
Taking an individual approach further into the future and considering the 




Cantor-Rivera et al. (2016) propose the use of patient-specific mapping to allow 
addressing clinically relevant individual pathologies, thus facilitating a detailed 
patient-specific automated quantitative assessment using MRI scans. For each 
genotype, phenotype, or disease, it is theorised that it is possible to carry out 
baseline imaging to then identify and define regions of interest that can then be 
interrogated for volumetric, relaxometry, and diffusion features that may differ from 
healthy control groups. Direct comparison of these regions with healthy control 
groups can then identify and provide visualisation of any significant differences in 
specific regions of clinical interest and importance through the use of individual 
feature maps (Cantor-Rivera et al., 2016). 
2.7 Discussion/Conclusions 
There are a number of learning points that can be taken away from this literature 
review to improve both the way MR research is carried out in patients with the 
m.3243A>G point mutation, and also to improve and increase the awareness that is 
required to ensure that all relevant research is taken into consideration when stating 
that a parameter appears to be of significance in indicating a neurodegenerative 
process is either about to occur, or is occurring. 
The early literature predilection for reporting on case studies of patients who have 
already suffered from stroke-like episodes means that there is only piecemeal, 
inconsistent information regarding the following research parameters:  
• The exact symptoms and their durations, or timelines, during a stroke-like 
episode 
• Subsequent reporting of disease progression, for example the formation of 
lesions within the affected area of the brain, which migrate over time in many 
cases and are not constricted by vascular boundaries 
• The rapid atrophy that occurs in a large number of cases, although the 
proportion in which this happens is still completely undefined 
The sum total of the information from this style of reporting on individual cases is not 
enough to provide any real insight into the causes and mechanisms of the onset of 
stroke-like episodes. 
The consistent reporting of lesions being more common in the temporal and the 




stroke-like episodes, and therefore should be of greatest interest for more in-depth 
analysis, particularly in those carrying the m.3243A>G point mutation but who have 
not yet suffered a stroke-like episode.  
Despite these initial clues, identifying a suitable technique to interrogate whether 
these mechanisms are in progress, and at what stage they are at, is something of a 
guessing game. The aim of this type of reporting should be to create a clinical 
database of symptoms, and the number, and progression, of patterns, to establish 
whether there are any specific markers to allow definition of which of these a patient 
may be likely to experience. 
Despite the move to larger cohort studies there is a clear lack of standardisation in 
the way that patient information is analysed. Of the three papers claiming to have 
carried out quantitative analysis of their patients, two simply carried out VBM and 
stated the areas found to have a statistically significant difference in volume without 
providing justification of what they considered to be statistically significant or why, 
with absolutely no consideration of what may be clinically significant. This was also 
reflected in the lack of attempt to explain what the volumetric difference might mean 
in terms of the symptoms suffered by patients, or why the m.3243A>G point mutation 
would affect these areas in both carriers and patients (Tsujikawa et al., 2016; Haast 
et al., 2018). In addition to this, the methodology that was used in each of these was 
far from being reproducible, and in Haast et al. (2018), there was also an 
unexplained and unjustified split in the patient group made by blood heteroplasmy 
levels, despite the only correlation between heteroplasmy and symptoms being found 
in patients with MIDD (Chinnery et al., 2000) and relating to deafness, no other 
papers have found significant correlations between heteroplasmy and individual 
symptoms. 
Table 14 also provides supporting evidence for the lack of correlation between 
heteroplasmy level and susceptibility to stroke-like episodes. In addition to the points 
already mentioned there is also a lack of timeline reporting for both cross-sectional 
and longitudinal studies for the time elapsed between the presentation of a stroke-
like episode and the subsequent imaging, which means that the information 
presented cannot be analysed in a meaningful way to then provide additional 
information within a clinical setting relevant to the onset of stroke-like episodes. This 




showing that water ADC changes over time (Tzoulis et al., 2009), but there has yet to 
be any definition of timelines, or variations of these, within the MRI literature for 
mitochondrial disease. 
There are a number of theories for the underlying mechanism of stroke-like-episodes 
that include mitochondrial cytopathy, mitochondrial angiopathy, non-ischaemic 
neurovascular cellular mechanism, or even some combination of any of these (Koga 
et al., 2010; Lax et al. 2012) and it is clearly an important task to identify which of 
these it may be; however there have been no MRI correlates for any of these 
established for patients with the m.3243A>G point mutation that may provide an early 
warning that a stroke-like episode will occur in the future. There has also been no 
reported work on attempting to establish the order in which subclinical seizure 
activity, activation of rapid atrophy, formations of lesions, and clinical presentation of 
stroke-like episodes occur, or if they do in fact occur in a specific order. In addition to 
the cellular mechanisms previously mentioned, there are also mechanisms by which 
subclinical seizure activity occurs, which may alter the underlying white matter 
structure, or general connectivity, which then exert influences over other processes. 
Therefore, while it is important to understand the formation and development of 
stroke-like episodes on a cellular level, I have identified a distinct need to identify 
potential non-invasive imaging biomarkers indicating an underlying susceptibility that 
exists prior to a stroke-like episode reaching clinical significance as otherwise it will 
never be possible to formulate effective treatments that could stop the occurrence of 
stroke-like episodes rather than attempting to limit the devastating effects they have 
on the brain once they have occurred. However, it is acknowledged that any 
biomarkers are likely to be identified through more in-depth longitudinal research into 
all of the microstructural parameters that may be measured through non-invasive 
imaging. 
It should also be noted that in MS tCr ADCs potentially indicate problems with energy 
regulation and that the primary attempt at treatment would be to rectify this (Zhu et 
al., 2009). The same could be true for all mitochondrial disease, as the regulation of 
energy production should be seen as the optimum treatment. 
There is also a potential issue of either sub-clinical activity that never fully manifests 
as a stroke-like episode, or an additional unidentified process, that is significant 




severe atrophy seen in the majority of patients who have had clinical presentations of 
stroke-like episodes.  
In addition to this, there is work that was carried out in the mid-1990s that indicates 
that there are fundamental changes to the intracellular environment in the presence 
of oedema and that permanent regional damage to the cells is caused within 20 
minutes (Wick, 1995). This highlights that in order to identify the optimal method for 
predicting stroke-like episode susceptibility requires a multi-disciplinary approach that 
includes pinning down at least some of the pathological correlates of stroke-like 
lesions. It has been questioned whether cellular swelling alone can account for all 
water ADC changes in tissue that is assumed to be ischaemic (Wick, 1995). In fact, a 
number of papers have gone on to investigate the ADC of various metabolites, which 
allows the separation of extra- and intracellular diffusion coefficients, as normally 
metabolites are only found within cells, such as neurons and glial cells (Wick, 1995; 
van der Toorn et al., 1996; Valette et al., 2018). The main outcomes of these studies 
was that although the water ADC returned approximately to normal, metabolite ADCs 
of N-acetyl-aspartate, myo-inositol, creatines, and cholines, all showed persistent 
changes, and in addition to this, in post mortem pathological tests nuclear chromatin 
showed clumping, mitochondrial swelling was frequently observed, and dilation of the 
endoplasmic reticulum was found in astrocytes, thus indicating that there may be 
some fundamental intracellular changes that take place when a region of the brain is 
ischaemic (Wick, 1995; van der Toorn et al., 1996; Valette et al., 2018). These 
changes have been observed in stroke animal models and indicate that in only a 20-
minute global transient ischaemia model irreversible tissue damage occurs (Wick, 
1995), and after induction of a 24 hour focal ischaemia, metabolite ADCs were so low 
that no measurement was possible, indicating that concentrations of these were 
extremely low within the ischaemic region (van der Toorn et al., 1996), which 
provides supportive evidence of energy failure. This information shows that patients 
with mitochondrial disease, with an already impaired energy production system, may 
suffer an increased rate of irreversible damage compared to patients who have 
suffered from a conventional stroke. This is an important consideration to consider 
when attempting to apply ADC as either a predictor of stroke-like episodes, or as a 
measure of the status of the lesion as the exact mechanisms causing changes to 




Cerebellar atrophy is something that is highlighted in a number of papers with 
apparently no associated cerebral atrophy, but there is no mention of the fact that the 
cerebellum has much smaller features than the rest of the brain, and therefore is 
much more susceptible to distortion and appearing to be atrophied. When the details 
of the MRI scan in Kobayashi et al. (2005) are investigated, it is found that the slice 
thickness in all of the scans was 5mm. A quick reference to either anatomy or 
neuropathology texts (Romero-Sierra, 1986; Osborn, 2013) shows that the smallest 
structures around the outer edge of the cerebellum are only a couple of millimetres in 
size. This means that they will in no way be imaged, or presented, accurately in a 
scan using 5mm thick slices. Not only will the structures appear to blur into each 
other on the image being assessed, there are also the issues of how partial volume 
effects are considered in the formation of that image, which is a particular problem 
when it comes to the accuracy of cerebellar imaging. When combined, these effects 
often lead to the appearance of the cerebellum being more atrophied than the rest of 
the brain. After identifying these as issues, I have investigated them further in 
Chapter 4. 
A parameter often quoted as being related to both lesions and atrophy is cortical 
laminar necrosis. The reporting of cortical laminar necrosis in imaging studies is 
incorrect as there has, to date, been no pathological correlation for cortical laminar 
necrosis with the cortical T1 hyperintensities observed. Data on these cortical T1 
hyperintensities, and the likelihood of their development once a lesion has formed, is 
sketchy as it is often the most severely affected patients who are commented on and 
presented, even within a group of those who have suffered from stroke-like episodes, 
so there can be no further conclusions drawn from the reporting of cortical T1 
hyperintensities to further understanding of the clinical progression of lesions. 
The Tsujikawa et al. (2016) paper was an attempt to carry out a quantitative analysis 
of the brain structure of patients with the m.3243A>G point mutation. While there may 
actually be significant volume differences in the highlighted areas of the brain, many 
of these were seen in both patient groups and so they can’t be linked with 
susceptibility to stroke-like episodes without a longitudinal study as they could just be 
a feature of changes that are seen in the brain due to the m.3243A>G point mutation. 
This paper needed an assessment of what the highlighted brain areas are 
responsible for and whether they link to any specific symptom(s) commonly seen in 




that they are related to the susceptibility and subsequent onset of stroke-like 
episodes. This paper highlights the need for interpretation and meaning to be applied 
to any, and all, quantitative analysis results as there is little, to no, benefit in merely 
stating areas of statistically significant volumetric difference in which the 
requirements for ‘significance’ are neither stated nor discussed. This opens up a 
whole new question about the analysis methods utilised as statistical significance is 
highly unlikely to be the same as clinical significance, and yet every paper only states 
results by statistical significance. This lack of discussion about clinical significance 
partly stems from the difficulty in defining it and what it means when there are 
clinically significant differences between groups, but this is a key part of ensuring that 
the research output is able to provide information that is of clinical relevance and that 
may also potentially be used in further research to investigate in more detail regions 
of the brain that may provide further answers to the question of whether someone is 
susceptible to stroke-like episodes, in the first instance, but also susceptibility to a 
broader range of symptoms could potentially also be defined. 
The Virtanen et al. (2011) paper, at first glance appears to take a much more robust 
approach to the analysis. However, the failure to separate the patients into two 
groups means that any subtle differences between the patients without a history of 
stroke-like episodes and the control group will be lost due to the very large volumetric 
changes that are seen in the brains of patients who have experienced stroke-like 
episodes and have suffered from significant and rapid atrophy after these. I have 
identified and demonstrated the importance of this separation in globally in Chapter 
5, and regionally in Chapter 6. The diffusion results in this paper are interesting as 
they appear to indicate significant differences in the diffusion properties of the inferior 
longitudinal fasciculus between the patient and control groups. It would be of great 
interest to see whether this difference is seen only in the stroke-like episode patient 
group, or if it is seen in all, or a subset of, patients without a history of stroke-like 
episodes. The results of the TBSS analysis are of more interest than the volumetric 
results as they appear to indicate a significant difference in the diffusion properties of 
the inferior longitudinal fasciculus, which connects the occipital and temporal poles. 
This white matter tract route is of particular interest as there is anecdotal clinical 
evidence that the temporal and occipital lobes are particularly susceptible and are 
usually the locations of the first onset of stroke-like episodes. The migration of 




no comprehensive analysis of the nature and route of lesion migration due to the lack 
of longitudinal scan data. The high level of clinical anecdotes for the temporal lobe 
being the site of the first stroke-like episode indicate that the inferior longitudinal 
fasciculus should be the subject of further investigation, along with the temporal lobe 
itself. Their methodology is well-presented and makes sense as a process as I 
independently formulated this same methodology through validation of the 
segmentation software and techniques available, and have found that it is the only 
one to provide true quantitative outputs, allowing clinically relevant analysis to be 
carried out rather than purely statistical analysis, which does not in any way provide 
information about the clinical relevance or significance of differences that have been 
found between control, carrier, and patient groups. 
Correct interpretation of results is also absolutely vital and an example of how 
incorrect interpretation can be misleading can be found in the Haast et al. (2018) 
paper. In a number of places significant correlation is stated, but the correlation 
values do not support these statements. Inspection of the data presented shows that 
some of the correlational values provided are significant, in other words, likely to be 
accurate with 95% probability, but significance of the correlational value does not 
equate to significant correlation. This appears to have been misinterpreted 
throughout the paper with correlation values of 0.3 and below being stated as 
showing significant correlation (Haast et al., 2018). Although smaller correlation 
values are often accepted in biological sciences as showing a significant correlation, 
the smallest value for this to be the case is usually around 0.5 at the lowest, with 
most using 0.6. Therefore, any clinical significance postulated regarding the link 
between heteroplasmy and symptomatic presentation within the Haast et al. (2018) 
paper must be treated with caution and the size and significance of the correlational 
value clarified and confirmed. A number of correlation values have been determined 
to be significant, and so the values found are accurate within 95% confidence limits, 
but this does not mean that the correlation is significant in itself (Haast et al., 2018). 
There are occasionally papers that comment on the efficacy of a particular treatment 
in either the prevention of future stroke-like episodes, or a lessening of post-stroke-
like episode progression of atrophy. These papers do not represent a full clinical trial, 
with a large patient cohort, in which the effects of L-arginine, or other drugs, are 




evidence for which to use a particular treatment and the value of publishing these 
has to be questioned (Ohsawa et al., 2018). 
The reviews to date, unsurprisingly, are limited by the lack of in depth published 
literature regarding patients with mitochondrial disease who have no history of 
stroke-like episodes and so generally concentrate on the observations that have 
been highlighted throughout this chapter. What these reviews do not do is to identify 
the need for in depth studies looking at patients with confirmed genetic mutations and 
deletions associated with mitochondrial disease, but who have not had any stroke-
like episodes, as without these there is very little chance of moving research forward 
to provide understanding of the changes in the brain that occur prior to a stroke-like 
episode occurring and also to be able to identify possible methods of seeing these 
changes long before the first presentation of a stroke-like episode. This, in turn, 
would then allow for the targeting of treatments to known processes, to either impede 
them, or potentially stop them altogether. 
The main takeaway point from this systematic review of the use of MRI scans in the 
study of stroke-like episodes in patients with the m.3243A>G point mutation is that, to 
date, the overwhelming majority of papers have presented observations, often of 
individual case studies, without the benefit of any sort of quantitative baseline data of 
the m.3243A>G brain prior to the onset of any stroke-like episodes. There has also 
been a distinct lack of hypotheses in the presentation of the observational data, 
barring a couple of exceptions. Although a number of brain regions have been 
highlighted as potentially being different in those carrying the m.3243A>G point 
mutation, there have been no theories proposed as to why these areas may be 
important in the development of stroke-like episodes, or why they may also be 
susceptible to the development mechanisms. 
Therefore, I have identified that in order to fully utilise any MRI scan data, whether 
that is related to the structure of the brain or its diffusion properties, there must be an 
associated investigation and attempt at explanation of why any highlighted areas are 
important for further investigation. To attempt to begin to rectify this I have identified 
the requirement to systematically collect and analyse data with respect to current 
clinical anecdotal information to put together a solid understanding of the similarities 




There is also an additional requirement to collect longitudinal scans to provide better 
information regarding the progression of changes in the brain over long time periods. 
With the recent work to identify carriers of the m.3243A>G point mutation prior to 
clinical presentation, there is the opportunity to build up a cohort of both 
asymptomatic and presymptomatic carriers, which currently cannot be differentiated 
from each other with any certainty. 
While I have acknowledged the work carried out looking at brain metabolites, further 






Chapter 3. MRC Participant Cohort and Post Mortem Brain Sections 
3.1 Participant Cohort 
Participants were sourced from the MRC Mitochondrial Disease Patient Cohort (UK), 
either locally via the mitochondrial clinical team, or via a postal invitation to suitable 
candidates already within the cohort. The cohort for this specific study were 
opportunistically utilised from within a larger m.3243A>G study. 
The inclusion criteria that had to be met for the study were: 
- ≥18 at the time of the first appointment 
- Have proven genetic disease (blood or urine mtDNA heteroplasmy levels were 
used to confirm) 
- Have high levels of heteroplasmy 
- All participants must be carriers of the m.3243A>G point mutation and either 
have the MELAS phenotype (n=7), or be an non-MELAS carrier of the point 
mutation (n=10) 
- Provide informed consent to be included in the study 
Scan details 
All cohort participants were scanned on the Siemens Achieva 3 T clinical MRI 
scanner at the Royal Victoria Infirmary (RVI), and all controls were scanned on a 
Philips Intera 3 T research MRI scanner. 
To minimise the differences due to being scanned on different scanners, the same 
3D Anatomical T1-weighted MRI scan parameters were used. In addition to this, MRI 
scans from a healthy control that had been scanned on both machines using this 
protocol were analysed to assess whether there were any significant differences in 
total intracranial, grey matter, and white matter volumes. Derived values were within 
± 1.5 % of each other, which was deemed to not be significant in relation to the 
volume changes being assessed within the study. 
Scan 1: 3D Anatomical T1-weighted 
Axial; TE: 5ms; TR: 8ms; Flip angle: 8°; voxel size 1mm3. 




TR: 9000ms; TE: 95ms; Number of averages: 2; Flip angle: 90°; b-values: 0, 1000; 
number of directions: 64 
Control Participants 
Each patient within the study cohort had at least one age- and sex- matched control 
identified. The control group was taken from the general population, but few 
demographic details were held regarding this population so it was not possible to 
match to any additional parameters of interest, such as height, BMI, lifestyle, and so 
on.  
The lack of information about the handedness of the members of both the control 
group and the cohort may introduce a confounding factor as there are various 
documented differences in brain physiology between left- and right-handed 
individuals, with a larger corpus callosum in left-handers being most often noted 
(Khosravizadeh and Teimournezhad, 2011). The produced results must therefore be 






Carriers of the m.3243A>G point mutation details 
 
Table 3. Details of participants involved in the m.3243A>G cohort study. SNHL = 
sensorineural hearing loss; WPW = Wolff-Parkinson-White syndrome; CPEO = 
chronic progressive external ophthalmoplegia; n.d. = not detectable; MELAS = 
mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes; LVH = 





Table 4. Detailed histories and MRI scan notes for all patients with MELAS with 
histories of stroke-like episodes. L = left; R = right; Bilat = bilateral; P = parietal; T = 
temporal; O = occipital; F = frontal; Ins = insular. 
  
Patient Number Stroke-like episode clinical history (date, location of lesions, other notes)
P03
10/2003 - LP, LT with report of bright objects seen in left field
03/2005 - RO
P04
No obvious lesions on MRIs, suspect encephalopathic episodes mimicking stroke-like 
episodes. Brainstem stroke was cause of death.
P05
05/2015 - RP, RT, RO
06/2015 - RO only, rest resolved
P06
01/2012 - BilatT (R>L), BilatO (L>R), LT (+ restricted diffusion) - note significant delay to 
seeking medical attention as patient was in Australia at the time. Date recorded is first 
presentation to clinic.
02/2012 - LP, with BilatT (R>L) still in evidence.
P11
01/2010 - LT
04/2010 - All resolved
06/2010 - RO (+ restricted diffusion)
06/2011 - All resolved
05/2012 - LF, LIns, BilatP, BilatT, BilatO
02/2013 - LP, LT, LO, all others resolved
07/2013 - LIns, BilatT, BilatO
P14
08/2012 - No lesions but scanned due to functional neurological problems
11/2015 - RP, BilatT (R>L), BilatO (R>L)
02/2016 - RP, BilatT (R>L), RO, others resolved
05/2017 - LP, BilatT (L>R), BilatO (L>R), LF
P15
01/2016 - RP, RT, RO





3.2 Post mortem brain sections 
Donor Details 
This section details the post mortem brain sections used in the work carried out on 
the 7 T pre-clinical scanner to obtain very high-resolution structural MRI scans and 
quantitative T1 maps of the same sections. There were 22 patient sections from 
seven patients with a variety of mitochondrial genetic diagnoses. These sections 
covered the frontal, temporal, and occipital lobes and had representative samples 
from macroscopically defined lesioned and non-lesioned regions of the left 
hemisphere of the fixed post mortem brain. There were also six post mortem brain 
sections from two controls covering the frontal, occipital, and temporal lobes. It is 
perhaps important to note that it is not common to have the clinical history of a brain 
donor for brain sections. 
 
Table 5. Description of the post mortem brain sections used in the high-resolution 
MRI work in Chapter 9. * = defined macroscopically. 
3.3 Sample Size, Power, and Correcting for Multiple Comparisons 
Clearly the sample size within this study is small and there are also multiple 
comparisons being made. To allow usable results to be generated the statistical 
hypothesis used in each case is that the comparison group of either carriers or 
patients with MELAS has a mean that is a minimum of three standard deviations 
away from the mean of the control group. This greatly reduces the number of 
Label Genetic defect Brain region Non-lesioned / lesioned * Length of time in fixative Status Further information
Frontal Non-lesioned 7 mnths Fixed
Temporal Lesioned 7 mnths Fixed
Occipital Lesioned and non-lesioned 7 mnths Fixed
Frontal Non-lesioned 4 years Fixed and hydrogel-embedded
Temporal Non-lesioned 4 years Fixed and hydrogel-embedded
Occpital Non-lesioned 4 years Fixed and hydrogel-embedded
Frontal Non-lesioned 4 years Fixed and hydrogel-embedded
Temporal Lesioned and non-lesioned 4 years Fixed and hydrogel-embedded
Occpital Non-lesioned 4 years Fixed and hydrogel-embedded
Frontal Non-lesioned 4 years Fixed and hydrogel-embedded
Temporal Lesioned 4 years Fixed and hydrogel-embedded
Occpital Non-lesioned 4 years Fixed and hydrogel-embedded
Frontal Non-lesioned 5 years Fixed and hydrogel-embedded
Temporal Non-lesioned 5 years Fixed and hydrogel-embedded
Occpital Non-lesioned 5 years Fixed and hydrogel-embedded
Frontal Non-lesioned 3 years Fixed and hydrogel-embedded
Temporal Non-lesioned 3 years Fixed and hydrogel-embedded
Occpital Non-lesioned 3 years Fixed and hydrogel-embedded
Frontal Non-lesioned 9 years Fixed and hydrogel-embedded
Occipital Non-lesioned 9 years Fixed and hydrogel-embedded
Frontal Non-lesioned 8 years Fixed and hydrogel-embedded
Temporal Non-lesioned 8 years Fixed and hydrogel-embedded
Occipital Non-lesioned 8 years Fixed and hydrogel-embedded
Frontal Non-lesioned 9 years Fixed and hydrogel-embedded
Temporal Non-lesioned 9 years Fixed and hydrogel-embedded


































participants required for the sample sizes used to have adequate power. By using 
specific comparisons, and not assessing every possible comparison, as is done in 
automated voxel-based morphology, to assess whether a region has a significantly 
different volume, in addition to setting the statistical hypothesis to require the test 
group mean to be at least three standard deviations below the control group mean, 
the need to carry out correction for multiple comparisons is not required as the 
probability of a group mean occurring within these parameters becomes vanishingly 
small. In addition to this, the p-value for every comparison is stated and was 
assessed during analysis for any correction requirement. 
Clearly, the statistical hypothesis used throughout this study is aimed at finding very 
large differences between groups. Therefore subtle, but consistent, differences in 
brain volumes will not be highlighted as statistically significant within this work as the 
power is not high enough to allow these to be reliably detected. The justification for 
this approach was to attempt to not only provide statistical significance, but also to 
highlight results that are of clinical significance and to ensure the power was high 






Chapter 4. Software Accuracy Assessment and Validation for 
quantitative volumetric analysis 
4.1 Introduction 
There has been a great deal of development of brain structure analysis techniques 
over the past 15 years. For many years the most commonly used tool to calculate 
brain volume, and also segmented brain volume, was the manual tracing method 
(Keller and Robert, 2009; Geuze et al., 2005). These were popular because they 
allowed the operator the surety of specificity of the selected areas, particularly on 
poor quality images. This specificity allows for absolute brain volumes to be 
calculated more easily than for automated methods (Keller and Roberts, 2009). 
However, there are a number of disadvantages to using this method including the 
time burden to manually trace the sections, and operator wobble when tracing along 
boundaries, which can cut off areas desired for inclusion and include areas desired 
for exclusion (Keller and Roberts, 2009). A much faster manual method of calculating 
brain volume is to use the stereological point counting method (Keller and Roberts, 
2009) in which areas are selected by superimposing a grid of points over the image 
and deselecting those that are not relevant to the area of interest (Garcia-Fiñana et 
al., 2003; Garcia-Fiñana et al., 2009; Roberts et al., 2000). There is one final 
significant drawback of using manual methods, and that is the requirement for 
expertise in neuroanatomy, particularly for volumetric analysis of specific brain 
components, so despite manual methods offering greater specificity, they are often 
not used due to lack of expertise in neuroanatomy and also the difficulty of achieving 
high inter-rater reliability (Keller and Roberts, 2009). 
There are a huge number of papers that have been published over the last 15 years 
detailing various different pieces of software and methods for carrying out semi-
automated and automated volume and segmentation analysis (Keller and Roberts, 
2009; Ashburner and Friston, 2000; Ashburner and Friston, 2001; Bookstein, 2001; 
Freeborough et al., 1997; Smith et al., 2004; Smith et al., 2002; Taylor et al., 2014). 
One thing is very clear, there are many different approaches employed when it 
comes to non-manual MRI analysis. This causes a number of problems in that results 
produced by different pieces of software are rarely directly comparable. This was 
demonstrated by the author by carrying out segmentation of the same set of brain 




values. Therefore, there needs to be a good level of understanding of what a piece of 
software is outputting. Previous literature may be used as a guide to the type of 
processing to use so that new results may be compared to those previously 
published. 
Most current automated processing of brain MRIs uses a reference set of healthy 
brains, the composition of which is important if a true population norm is to be 
established, which is used to create a ‘standard’. The brain under investigation is 
then compared against the standard using either physical characteristics (FMRIB, 
2015) or statistical techniques (Friston, 2007). This comparison to a standard based 
on a group means obtaining absolute values for parameters such as brain volume, 
ventricle size, etc., is not a reasonable aim for individual scans but identifying group 
trends is. However, obtaining relative changes over time for an individual is a 
reasonable activity as they are only referenced to themselves and not to a group 
standard. In summary, there is no standard automated method of processing MRIs, 
which causes a number of reproducibility issues.  
In general, manual stereological analysis is considered to be more suited to 
individual cases, whereas the statistical nature and use of atlases makes automated 
processing more suitable for comparing groups of cases (Roberts et al., 2000). 
Understanding of the different analysis techniques and how they can best be used is 
vital to ensure accurate and reliable information is output from any analysis. There 
are very few papers that have directly compared the output of manual, semi-
automated/region of interest and fully automated volumetric analysis (Good et al., 
2002; Keller et al., 2002) so it is difficult to know how the different techniques 
compare to each other, particularly with respect to the type and quality of images that 
are being used for the analysis. It is key, however, to remain consistent in the type of 
analysis method used for a particular measurement so that results are repeatable 
and comparable (Good et al., 2002). 
The method of processing is irrelevant if the images that are being worked with are 
not of a high enough quality in terms of resolution of features and contrast between 
tissues of interest. Irrespective of processing method, poor images will not provide 
robust, accurate volumetric analysis or segmentation (Keller and Roberts, 2009; 




Despite a high level of interest in carrying out quantitative analysis of MRI scans 
within both the clinical research and the analysis tool development communities, 
there is a lack of quality assurance standards to provide standardised information 
about the accuracy, repeatability, and reliability of the various softwares available. 
There are a number of softwares that have been validated for very specific regions of 
the brain, most notably the hippocampus, amygdala, and corpus callosum (Mulder et 
al., 2014; Velasco-Annis et al., 2018), and some that have been validated for 
repeatability (Yang et al., 2016), but to date I have not been able to find any that 
been validated for global segmentation volumetric accuracy, as opposed to 
repeatability, with the results published in open literature. 
One of the underlying reasons for this is due to the speed of development of MRI 
analysis techniques with the research community moving to convolutional neural 
networks (CNNs) and the complex architectures required to carry out the deep 
learning processes required for increased accuracy, and also greatly increased 
speed (van Ginneken, 2018). This rapid development leaves little time for methods to 
be developed to the point where they have been quality assured for the purposes of 
clinical use, which is not helped by the use of bespoke software on the scanners 
themselves (Block, 2018). However, to reach the point of having a clinical use, the 
techniques first have to demonstrate a clinical value, which is likely to require a 
greater level of collaboration between the developers of these techniques and the 
clinicians who would be the ones using the outputs (Schmeirer et al., 2018).  
Clinicians are keen to move forwards from the technology that is currently available, 
should robust quantitative outputs providing useful and clinically relevant information 
be developed, and agree that an iterative process is for development is likely to be 
the most effective method of producing software and techniques that are fit for 
purpose, and also disease specific as each disease has different requirements from 
MRI (Schmeirer et al., 2018). 
In addition to all of the issues mentioned above, it is also the case that MRI scanners 
have not been developed as quantitative measurement devices, and each vendor 
has come up with different methods to achieve each type of scan so there is no easy 
way to standardise between scanner types (Chenevert, 2018). 
This current state of affairs means that to carry out quantitative analysis on clinical 




takes up a lot of human effort as well, but also has no absolute accuracy limits 
provided, which are vital should any software be considered for use within a clinical 
setting. 
The lack of standards relating to quantitative analysis of structural scans makes any 
quantitative project difficult, and therefore to allow my confidence to be established in 
my quantitative results, I carried out a time-consuming validation exercise to 
ascertain the most suitable segmentation software, as well as starting to gain an 
understanding of some of the intrinsic limitations of the quantitative outputs provided 
by the software. 
The final justification for carrying out this type of validation is because there are 
inherent issues in attempting to segment a combination of healthy and diseased 
brains using the same atlas, and so there needs to be careful assessment of how the 
diseased brains are segmented by the software. An alternative approach has also 
been developed in which multiple atlases are used that are specific to the group 
being analysed, in terms of age, disease type, and any other significant factors that 
may affect the segmentation. 
4.2 Aims and Methods 
The most commonly available MRI scan type are thick-slice clinical scans used by 
radiologists to visually identify any abnormalities on the scans. However, for 
quantitative analysis there are issues with attempting to segment from this type of 
scan, and high-resolution anatomical scans are required. 
The aims of this section are to carry out a validation exercise on the segmentation 
software commonly used in the volumetric analysis of brain MRI scans to assess the 
following: 
Aim 1: To demonstrate why global tissue segmentation cannot be carried out on 
thick-slice scans. 
Aim 2: To compare manual vs automated segmentation of global volumes of GM, 
WM, and CSF. 
4.2.i Initial File Preparation 
All files to be segmented were first converted from the digital imaging and 




(NIfTI) files using the DICOM to NIfTI file conversion capability within the MRIcroGL 
MRI viewing software (Rorden and Brett, 2000). Bias field correction was carried out 
as part of the automated segmentation processes, and was not carried out for the 
manual segmentation as variation across the image could be compensated for by the 
person carrying out the segmentation. 
Eight 3D T1-weighted anatomical scans were selected, all from people in their 30s 
and comprising four men and four women, for segmentation. Six of the scans were 
from healthy controls, and two scans were selected from the carrier group who did 
not have any visible lesions or histories of stroke-like episodes. 
A 2D T1-weighted spin echo (T1SE) with thick slices from a MELAS patient with no 
obvious lesions or atrophy was also selected to provide a comparison. 
4.2.ii Comparison of 2D thick-slice and 3D anatomical scan types 
To carry out tissue segmentation successfully there should ideally be a discernible 
difference in the intensity of each class of tissue, identified by the presence of a clear 
peak in the histogram output. These peaks can be spread by factors including noise 
in the image, motion artefacts, bias field effects, partial volume effects, in addition to 
true within class variation (Smith et al., 2004). This spreading effect can lead to the 
mislabelling of voxels, which may lead to a significant distortion of the results if any of 
the contributing factors are particularly strong (Smith et al., 2004). 
The easiest method of assessing the size of the effect of the confounding artefacts is 
to take a histogram of the intensities seen within the image. To demonstrate some of 
the issues a histogram from a high resolution and low resolution scan were taken and 
can be seen in Figure 15 and Figure 16. These can be obtained by opening the MRI 





Figure 15. Histogram of a high resolution 1mm3 voxel structural MRI scan. The 
separated peaks can clearly be seen for each of the different tissue types. 
Figure 15 shows the resulting histogram from a high-resolution 3D anatomical scan. 
Separation of the peaks for each of the tissue types can clearly be seen, and 
therefore it is possible to differentiate between these when looking at individual pixels 





Figure 16. Histogram of a thick-slice T1SE scan using 3mm slices through the brain. 
The CSF can clearly be seen with a much lower intensity, but there is no clear 
separation between GM and WM intensity grouping, although some contrast may be 
observed. 
Figure 16 shows the resulting histogram from a thick-slice T1SE scan using a slice 
thickness of 3 mm. Separation of the peaks for each of the tissue types can clearly 
be seen, and therefore it is possible to differentiate between these when looking at 
individual pixels on each slice of the image as they have different intensities. 
When high-resolution and thick-slice scans are compared side by side as shown in 
Figure 17, the differences in contrast are also visibly very clear. The lack of contrast 
in the thick-slice scan can only lead to large error margins for any quantitative 
volumetric segmentation, particularly when contrast is used to define the tissue 
boundaries. It should be noted that there may also be contrast differences between 
different acquisition sequences, irrespective of slice-thickness, that may also have an 
impact on the contrast, for example the use of magnetisation prepared rapid 
acquisition gradient echo (MPRAGE) or sampling perfection with application 






Figure 17. Single slices taken from a high-resolution (1mm3 voxels) scan (A) and a 
thick-slice scan (4mm slice thickness with 1mm2 pixels) (B).  The differences in the 
contrast between grey and white matter are very clear and cannot be improved from 
the images above using contrast enhancement techniques. 
The importance of bias field correction in automated segmentation can be 
appreciated if a histogram is taken of an uncorrected MRI, as shown in Figure 18. 
This shows clearly the regular peaks across the histogram, which if not corrected will 





Figure 18. Image showing the interference of a bias field in the assessment of pixel 
intensity in the form of regular peaks across the slice histogram. 
4.2.iii Manual Segmentation 
3D Slicer 4.8 (Kikinis et al., 2014; Fedorov et al., 2012) was used to carry out the 
manual segmentation of the sample brains. Each pixel was inspected and allocated 
to a tissue category using individual pixel selection. These selections were used to 
define the region of each tissue type on each slice, with the segmentation being 
driven almost completely by the intensity of, and contrast between, tissues due to my 
neurological inexperience. The majority of the segmentation was carried out in the 
sagittal and axial planes, with the coronal plane being used periodically to double 
check that areas had not been selected erroneously. 
The technique used was to segment the grey and white matter, with the deep grey 
matter being included in the grey matter volume, of the brain in a combined model, 




method was chosen to keep the segmentation time to a minimum as the CSF volume 
could easily be derived from these values. 
It took around seven to ten hours to carry out TPV segmentation of a scan to obtain 
values for TICV, and between 60 and 70 hours to carry out a grey and white matter 
segmentation. 
Once each piece of segmentation had been completed, it was built into a 3D model 
from which the volumetric values could be extracted. 
Manual segmentation was carried out three times per scan, with a gap of 4-6 weeks 
in between each segmentation to take into account intra-rater reliability between 
each segmentation attempt. The presence of any large discrepancies would be 
assessed and explained. To compare the results between the automated 
segmentation and the manual segmentation, an average of the manual segmentation 
values was taken. 
4.2.iv    Automated Segmentation 
The software selected to carry out the automated segmentation were the two most 
prevalent available. While both offer essentially the same type of global segmentation 
into grey and white matter, and CSF, they carry out this process in slightly different 
ways, which can then lead to differences in the output results. The FMRIB software 
library (FSL) FMRIB’s automated segmentation tool (FAST) (Zhang et al., 2001) is 
based on a model called the Hidden Markov Random Field (HMRF) model that uses 
the Expectation-Maximsation algorithm to optimise it (Zhang et al., 2001). The HMRF 
model is a finite mixture model and is generally considered to be more robust than 
similar models as it takes spatial information into account with respect to the mutual 
information found in local neighbourhoods to then use this information to carry out 
the segmentation of tissue into different classes (Tsang et al., 2008). In contrast the 
SPM12 segmentation algorithm is based on a unified model that carries out all three 
stages; the segmentation, correction of bias, and spatial normalisation, within the 
same model (Ashburner and Friston, 2005). Statistical parametric mapping 12 
(SPM12) also uses the Expectation-Maximisation algorithm to optimise the 
parameters that correspond to models comprising a mixture of Gaussians that each 
represent one of the tissue classes (Tsang et al., 2008). SPM12 then utilises tissue 
probability maps to transform the brain anatomy into MNI152 standard space (Tsang 




Automated segmentation protocols 
The FSL segmentation was carried out by using the following protocol on each .nii 
file: 
1. Carry out brain extraction using the FSL brain extraction tool (BET) (Smith, 
2002) with a fractional intensity setting of 0.5 that was derived from empirical 
experiments to assess the optimal value for this setting to ensure that all of the 
brain remained in the extracted file. 
2. Carry out the segmentation using FSL FAST (Zhang et al., 2001) with all 
settings left at default. 
3. Volumes were then extracted using the fslstats tool. 
The SPM12 segmentation was carried out by running the SPM graphical user 
interface (GUI) through Matlab. Using the fMRI option, which also includes the 
structural processing features, batch processing was carried out using ‘Batch’ and 
selecting the Segmentation.mat option. All of the files to be processed are then 
added to the ‘Volumes’ list. The rest of the parameters were all left on the default 
settings. The ‘get_totals.m’ Matlab script was then run on the output files c1, c2, and 
c3, which are grey matter, white matter, and CSF volumes respectively, for each of 
the scans to output the volumes. 
The segmentation output images were all visually inspected to assess the 






4.3.i Manual vs Automated Global Tissue Segmentation 
 
Figure 19. Single slice examples of GM segmentation output from manual (B), FSL 
5.0 (C), and SPM12 (D) segmentation, with original T1 image also provided as a 
reference (A). The grey matter in the manual segmentation is shown in yellow. In the 
FSL and SPM images, the grey matter is shown in a red-yellow colour scheme in 
which the yellow areas represent high levels of confidence (0.95-1.0), and the red 
areas represent areas of lower confidence. 
 
FSL SPM Manual 
HC01 673.624 796.131 658.472 
HC02 597.761 666.015 584.369 
HC03 598.417 675.354 604.856 
HC04 652.495 755.671 665.342 
HC05 660.995 769.5 650.142 
HC06 643.927 715.521 639.934 
Ca01 705.473 806.861 698.165 
Ca02 602.954 697.926 608.364 
Table 6. Grey matter volumes derived using each of FSL, SPM12, and manual 
segmentation. All values are given in cm3. 
 FSL vs SPM FSL vs Manual SPM vs Manual 
Grey 
Matter 
FSL < SPM 
p = 0.002 
No significant 
difference 
p = 0.868 
SPM > Manual 
p = 0.001 
Table 7. Results of the 2-sample t-test to assess whether there are group differences 





Figure 20. Output volumes of global segmentation of grey matter for FSL, manual, 
and SPM12 segmentation showing the similarity in volumes between the FSL and 
manual segmentation techniques. 
The results shown in Figure 19, Figure 20, Table 6, and Table 7 show that there is a 
clear, and statistically significant, difference in the end results of the segmentation 
between FSL and SPM, and also between manual and SPM. 
 
Figure 21. Single slice examples of WM segmentation output from manual (B), FSL 
5.0 (C), and SPM12 (D) segmentation, with original T1 image (A) also provided as a 
reference. The dark blue regions in the FSL and SPM images represent regions of 






FSL SPM Manual 
HC01 619.901 592.95 632.158 
HC02 549.954 480.88 555.694 
HC03 549.756 495.821 561.74 
HC04 694.186 546.148 678.144 
HC05 621.479 534.799 631.251 
HC06 607.149 494.571 615.316 
Ca01 670.943 485.613 681.196 
Ca02 556.571 425.193 568.615 
Table 8. White matter volumes derived using each of FSL, SPM12, and manual 
segmentation. All values are given in cm3. 
 FSL vs SPM FSL vs Manual SPM vs Manual 
White 
Matter 
FSL < SPM 
p = 0.002 
No significant 
difference 
p = 0.800 
SPM > Manual 
p = 0.001 
Table 9. Results of the 2-sample t-test to assess whether there are group differences 







Figure 22. Output volumes of global segmentation of grey matter for FSL, manual, 
and SPM12 segmentation showing the similarity in volumes between the FSL and 
manual segmentation techniques. 
Figure 21, Figure 22, Table 8, and Table 9 show a reversal of the findings in the grey 
matter results with both FSL and manual segmentation showing statistically 
significantly larger values than the SPM segmentation. 
 
FSL SPM Manual 
HC01 1533.8 1704.67 1536.01 
HC02 1373.16 1397.47 1371.05 
HC03 1371.71 1405.75 1387.03 
HC04 1660.81 1646.99 1639.1 
HC05 1620.8 1746.07 1602.04 
HC06 1504.05 1473.34 1501.63 
Ca01 1669.36 1538.93 1668.96 
Ca02 1419.52 1323.11 1428.61 
Table 10. TICVs derived using each of FSL, SPM12, and manual segmentation. All 








p = 0.885 
No significant 
difference 
p = 0.969 
No significant 
difference 
p = 0.855 
Table 11.Results of the 2-sample t-test to assess whether there are group 
differences between FSL, SPM12, and manual segmentation methods for TICV. 
 
Figure 23. Output volumes of global segmentation leading to TICVs for FSL, manual, 
and SPM12. 
Figure 23, Table 10, and Table 11 show that there are no statistically significant 
group differences between the different segmentation methods for the measurement 
of TICV, although Figure 23 does appear to indicate an overall better agreement 
between the FSL and manual segmentation methods. 
4.4 Discussion/Conclusions 
Due to the huge range of possible aims of automated segmentation it was not 
possible to find anything in the literature that specifically addressed the global 
volumetric accuracy of segmentation software, particularly in the presence of lesions, 




decisions made in this study with regards to the methods used to carry out volumetric 
analysis of the brain MRI scans of the participant cohort. 
It is clear from Figure 20 and Figure 22 that the FSL 5.0 and manual segmentation 
results are very similar, with the SPM12 results apparently indicating a larger volume 
of grey matter, and a smaller volume of white matter. Inspecting the segmentation 
images in Figure 19 and Figure 21 indicates that both the manual segmentation, in 
which a voxel has to be 100% defined as a single tissue type, and FSL 5.0 
segmentation define the grey/white matter boundary relatively tightly. This is in 
contrast to the SPM12 segmentation, which has a much larger gradient of tissue type 
probability at the location of any grey/white matter boundary. 
It should be noted that this selection of software for automated segmentation is only 
valid for high-resolution (1mm3 voxels or smaller) T1 anatomical scans taken on 
either a 3 T Philips Achieva or a 3 T Siemens MRI scanner using the scanning 
parameters shown in Chapter 3. Lower resolution scans, or scans of different types, 
such as T2 anatomical scans, would have to be assessed in a separate study. These 
scans were also all MPRAGE7 scans. There have been anecdotal reports than some 
radiology departments are using SPACE8 scans, which although are better for seeing 
lesions, do not provide as good a contrast between healthy tissue types (Okada et 
al., 2011) and would also have to be assessed in a separate trial to ascertain 
whether they are suitable for this type of segmentation. 
Therefore, the decision was made, on the basis of these results to utilise FSL 5.0 for 
all of the global volumetric analysis. 
  
                                                          
7 MRPAGE: fast 3D gradient echo pulse sequence using a magnetisation preparation pulse. 





Chapter 5. Volumetric analysis of global volumes 
5.1 Introduction 
The literature review carried out in Chapter 2 discusses and summarises the state of 
current research into brain MRI analysis in mitochondrial disease. Only a single 
paper by Virtanen et al. (2011) provided any volumetric results, and even then the 
carrier and MELAS patient groups were combined so the results were dominated by 
the severe atrophy seen in patients with histories of stroke-like episodes and any, 
more subtle, changes in m.3243A>G mutation carriers would have been lost.  
There are two papers in the literature that have carried out analysis of volumetric 
changes using VBM to highlight regions of significantly different volumes between 
controls, carriers, and patients with MELAS (Tsujikawa, 2016; Haast, 2018). It should 
be noted that hypotheses under test in these papers were both purely statistical in 
nature and further work would be required to establish the clinical significance, if any, 
of these differences.  
To date, the published volumetric work in mitochondrial disease is somewhat thin on 
the ground, a mere three papers to date, and the findings from these do not agree on 
the details of significant differences between their groups. This is likely to be in part 
due to the different grouping methods used between the studies, and also the 
differences in symptom groupings found within the individuals in each study. 
Therefore using this information alone it is difficult to formulate a hypothesis. Adding 
in the qualitative reporting from the case and cohort studies in Chapter 2 does at 
least provide a good starting point for formulating regions of interest as stroke-like 
episodes, and their associated lesions are most commonly seen in the temporal and 
occipital lobes, thus indicating that there may be something about the structure, and 
also the function, of these regions that lead to a susceptibility to the occurrence of 
stroke-like episodes. Therefore, there are many questions to answer regarding the 
effect of the m.3243A>G point mutation on the volumetric properties of the brains of 
people with the m.3243A>G point mutation prior to the onset of stroke-like episodes, 
and in addition to this, which of those changes cause measurable clinical changes in 
the functioning of the brain and if any of those can be used as biomarkers for 
susceptibility to the future development of other neurological symptoms or the 





This work has therefore been planned in such a way as to allow results from existing 
studies to be assessed and compared to the outputs defined here, but also to carry 
out a broader assessment of the global properties of the head and brains of those 
carrying the m.3243A>G point mutation. 
5.2 Aims 
Due to the very small amount of quantitative volumetric baselining data available for 
anyone with the m.3243A>G point mutation, the aims for this initial piece of analysis 
were: 
1. Carry out an analysis of total head size to ascertain whether the overall growth 
of people with the m.3243A>G point mutation is affected and where all carriers 
of the m.3243A>G point mutation lie within the normal distribution of head 
sizes of the healthy population. 
a. Justification for this comes from the anecdotal evidence gained from 
clinicians who regularly note that patients with MELAS seen in clinics 
are of short stature and generally have a very low body mass index 
(BMI). 
2. Analyse the head size distribution to ascertain whether head size may be 
related to the eventual onset of stroke-like episodes. 
3. Analyse grey and white matter volumes to ascertain what the differences are, 
if any, between controls, carriers, and patients with MELAS. 
a. It is hypothesised that in the MELAS patient group that atrophy will be 
the dominant measure and that all relative volumes will be significantly 
smaller than the control group. 
4. Analyse cerebellar atrophy and compare to global atrophy to ascertain 
whether the trend in case reports for reporting visual cerebellar atrophy in the 
absence of cerebral atrophy is correct, or whether it is an artefact of the visual 
inspection process. 
a. Justification for this comes from continued reporting in the literature of 
standalone cerebellar atrophy with the absence of cerebral atrophy. 
There is also disagreement within the clinical community about the 
apparent predominance of cerebellar atrophy in addition to imaging 
factors that will affect smaller structures more and that are not taken 




5.3 Methods and Materials 
5.3.i Carriers and patients with MELAS 
Seventeen participants from the MRC mitochondrial disease cohort were used for the 
TICV and total parenchymal volume (TPV) analysis. 10 of these participants were 
classed as carriers with no history of stroke-like episodes, while seven were classed 
as patients with MELAS and had a history of stroke-like episodes. Participant details 
can be found in Chapter 3. 
5.3.ii MRI Scans 
Cohort participant scans were taken on a 3 T Siemens MRI scanner. The scan 
parameters used were Gradient Echo, 3D sequence, TR = 50 ms, TE = 30 ms, FA = 
15°, with 1 mm x 1 mm x 1 mm voxels. 
5.3.iii Segmentation 
Segmentation of global tissue volumes 
Segmentation of the MRI scan images to produce the global tissue volumes was 
carried out using the FSL FAST (Zhang et al., 2001) as justified by the work carried 
out in Chapter 4 regarding the accuracy of the volumetric outputs. A detailed protocol 
and relevant screenshots can be found in Appendix 1. 
Skull stripping was carried out using the FSL BET (Smith, 2002). Fractional intensity 
threshold was set to 0.5, and ‘robust brain centre estimation’ was selected. The 
extracted brain files were each examined using FSLView to assess the accuracy of 
the brain extraction to ensure that all of the brain was present.  
Segmentation of the extracted brains was then carried out using FSL FAST (Zhang 
et al., 2001) with the outputs being partial volume maps for GM, WM, and CSF. The 
segmentation for each individual was then assessed using FSLView, loading up the 
extracted brain file and overlaying each of the segmented classifications on top to 
ensure that the segmentation was ok. The quantitative volumetric values were then 
extracted using the fslstats tool. 
Patients with MELAS with obvious lesions were excluded from this analysis due to 





This analysis used the raw values output from the FSL segmentation software that 
was validated for global tissue segmentation in Chapter 4. The definition of TICV 
using a slice from an MRI is shown in Figure 24, in which the TICV value is the 
volume encompassing all brain tissue and cerebral spinal fluid contained within the 
skull cavity with the ventral boundary being defined by the frontal and temporal lobes, 
the brain stem, and the cerebellum. The TICV includes the entire brain stem 
(Midbrain, Pons, and Medulla) and also the cerebellum. The reason for using this 
definition of the TICV is because that is how FSL segments the brain and it is also 
the definition used in Chapter 4 to validate the volumetric outputs from FSL. The 
image of the 3D model shows the relatively smooth appearance of the TICV, with no 
definition of sulci and gyri, or around the cerebellum.  
    
Figure 24. (A) 2D presentation of the definition of total intracranial volume, (B) 3D 
model of the total intracranial volume of the brain shown in the MRI in (A) 
The definition of TPV using a slice from an MRI is shown in Figure 25, in which the 
TPV value is the volume encompassing all brain matter within the skull cavity, with 
the lower limits being bounded by the frontal and temporal lobes, the brain stem, and 
the cerebellum, and excluding all CSF. The image of the 3D model shows the clear 
definition of the sulci and gyri, but also shows the lack of definition of the finer details 
of the cerebellum, which reflects the 1mm3 voxels used in these scans being around 





    
Figure 25. (A) 2D presentation of the definition of total parenchymal volume, (B) 3D 
model of the total parenchymal volume of the brain shown in the MRI in (A). Note that 
the definition of the cerebellum is relatively poor, this is due to the small size of the 
detailed structure leading to blurring due to the partial volume effect. 
The TPV was defined as consisting of all of the brain tissue within the skull cavity 
from the brain stem upwards, including the cerebellum, and excluding all CSF. 
The raw TPVs were divided by the TICVs for each individual to normalise the 
volumes to head size to remove any confounding effect of differing head sizes, which 
also removes the requirement to calculate separate means for males and females as 
any gender differences have already been taken into account. 
Segmentation of cerebellum 
The cerebellar volume for each of the controls, carriers, and patients with MELAS 
was measured using manual segmentation, with the segmentation being kindly 
carried out by Heather Thompson (BSc Biomedical Sciences, final year 
undergraduate), as a complete volume rather than attempting to segment it into grey 
and white matter. Heather carried out work to define the boundary of the cerebellum, 
and to ensure reproducibility the cut-off point was positioned at anterior edge of the 
meeting point of the pons and lingual of the superior cerebellar hemisphere and a 






Figure 26. Images taken from ImageJ showing the cut-off position for the cerebellar 
measurements. 
ImageJ software (Schneider et al., 2012) was used to carry out the segmentation and 
volumetric measurements by initially reslicing the axial scan into the sagittal plane. 
The cerebellar volume for each individual was then measured by manually tracing 
around the edge of the cerebellum on each slice in which it was visible using the 
polygon feature to create a region of interest (ROI), which could then be summed to 
provide a volumetric output. 
I analysed the volumes obtained by Heather using my methodology of utilising z 
scores, and so all analysis of the volumes was carried out by the author. The 
cerebellar volumes were normalised against TICV to remove any confounding effect 
of head size, corrected for age, and the z scores were then calculated. 
Analysis 
The raw volumetric data were input into Excel so that each control and MELAS 
patient had a gender, age, grey matter volume, white matter volume, CSF volume, 
TPV, and TICV listed for them. 
The TPV was calculated by adding together the grey and white matter volumes, and 
the TICV was calculated by adding together the TPV and CSF volume. 
For the TICV analysis, gender effects had to be taken into account as, on average, 
women have significantly smaller head sizes than men, so the groups were not only 
split into control, carrier and MELAS patient groups, but also subdivided into gender 
categories within these. The control group was used to calculate the male and female 
mean and standard deviation, which was then subsequently used in the calculation of 





𝑧 𝑠𝑐𝑜𝑟𝑒𝑖𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙 =  
(𝑥 −  ?̅?)
𝑆𝐷
 
Equation 7. The equation used to carry out the calculation of the z score for an 
individual, where, x = individual value, ?̅? = group mean of the control group, SD = 
standard deviation of the control group. 
𝑧 𝑠𝑐𝑜𝑟𝑒𝑔𝑟𝑜𝑢𝑝 =  





Equation 8. The equation used to carry out the calculation of the z score for a group, 
where x = individual value, ?̅? = group mean of the control group, SD = standard 
deviation of the control group, n = number in test group. 
The z scores for the carrier and MELAS patient individuals and groups were then 
plotted onto a graph using Excel. One of the advantages of this type of analysis, is 
that the control group are always represented on the graphical output as having a z 
score of 0, which then removes any requirement to plot any control data and provides 
an easy way to see exactly how far away, or how close, the carrier and MELAS 
patient data lies to the control group. 
The rationale behind using z scores rather than any other statistical test, is because z 
scores provide an easy to visualise statistical output relating the cohort groups to the 
normal Gaussian population, defined by the control group. Population statistics allow 
for the easy identification of participants with abnormal characteristics, particularly 
when there is clustering of participant characteristics in a region of the distribution 
that may indicate clinical relevance to either the presence of the m.3243A>G point 
mutation or symptomatic disease progression. 
The selection of the statistical hypothesis being three standard deviations was also 
chosen to take into account lifestyle factors that may also cause generalised brain 
shrinkage over time, such as drinking alcohol, smoking, and having diabetes. The 
literature shows that although these can cause relatively large amounts of brain 
shrinkage compared to healthy controls, even in severe cases of long-term 
alcoholics, smokers, and sufferers of diabetes, the mean TICVs only lie around one 




decrease in brain volume occurs over timescales of several decades, compared to 
the seven to ten years observed in patients with mitochondrial disease (Oscar-
Berman and Marinkovic, 2003; Biessels and Reijmer, 2014; Duriez et al., 2014). 
5.4 Results 
Total intracranial volume (TICV) 
Using the definitions and measurements in Section 5.3.iii, the carrier and MELAS 
patient TICVs can be presented in the form of z scores as in Figure 27. The carrier 
group as a whole have TICVs that are well within the normal distribution of the 
control group, even if the group average does lie on the low side of that normal 
distribution, however there is one carrier with a TICV that is closer to those of the 
MELAS patient group. The MELAS group shows a very different trend, with all of the 
MELAS group having TICV z scores below -2, and half of that group having z scores 
below -4, which represents a vanishingly small percentage of the population 
considering that only 0.15% of people will have head sizes with z scores of less than 







Controls Carriers MELAS 
1514.010934 1373.161132 1168.823791 
1589.222312 1588.93062 1317.752912 
1772.567801 1571.175255 1325.690229 
1669.356447 1669.092139 1343.869776 
1693.052217 1437.952649 1323.261746 
1682.62982 1508.187093 1167.453067 
1486.548344 1533.802205 1167.340458 



















Male Mean 1602.04502 1524.749815 1295.879691 
Female Mean 1426.101893 1404.41017 1157.644144 
Group Mean 1521.40442 1476.613957 1244.041361 
Table 12. Absolute TICVs for control, carrier, and MELAS groups. Male TICVs are 















p = 0.166 
Controls > MELAS 
p < 0.0005 
Carriers > MELAS 




p = 0.618 
Controls > MELAS 
p < 0.0005 
Carriers > MELAS 




p = 0.342 
Controls > MELAS 
p < 0.0005 
Carriers > MELAS 
p < 0.0005 
Table 13. 2-sample t-test to ascertain whether the differences in overall head size 
(TICV) between groups are statistically significant. 
Table 13 shows that although there is some difference between the carrier and 
control groups, this does not reach significance. It also shows that both the control 







Figure 27. Breakdown showing individual z scores of the carrier and MELAS 
participants compared to the control group (group z score of 0) showing the individual 
differences in head size compared to a healthy population. The red dashed line 
denotes a z score of -3, below which only 0.15% of the control population will lie. 
TICV and other physical attribute correlations with stroke-like episodes. 
There are some who believe that, in addition to head size, height, BMI, heteroplasmy 
levels are also appropriate biomarkers for disease severity prediction, and in 
particular the onset of stroke-like episodes. Therefore, I have also carried out a 
correlational analysis to provide further information about the measures that are often 







Table 14. Spearman Rho correlational values for some of the commonly referred to 
measures in mitochondrial disease. Strong correlation can be considered to be 
present for Spearman Rho values of around ±0.8 and upwards. 
Table 14 shows that the only measure approaching a strong correlational value is 
TICV. While height, head circumference, and BMI indicate some level of correlation, 
the values are not high enough to justify using these as surrogate measures of 
susceptibility to stroke-like episodes. The blood and urine heteroplasmy correlations 
are so low as to be meaningless in the context of predicting susceptibility to stroke-
like episodes within this cohort. 
 
Figure 28. Plot of BMI against TICV, showing graphically the overall lack of 
correlation between BMI and TICV, and that ‘outliers’ with high BMIs are present in 
both the carrier and MELAS patient groups. 




Head Circumference -0.551 0.022
Blood Heteroplasmy -0.015 0.957




Total parenchymal volume (TPV) 
This analysis used the raw values output from the segmentation software that was 
validated for global tissue segmentation in Chapter 4 and the definition of TPV as 
defined in Section 5.3.iii.  
Patient 3 was removed from this analysis due to the very large regions of lesioned 
brain tissue, which was shown to be misclassified by the FSL segmentation software. 
Figure 29 shows a manually segmented 3D model of the left hemisphere of Patient 3 
and has had the temporal lobe lesion removed for demonstrative purposes. The 
model also serves to show the physical, observable changes due to the severe, and 
rapid, atrophy experienced by patients with MELAS, which generally begins around 
the time of the first stroke-like episode, but currently the exact timing and relationship 
between the two are unclear. 
 
Figure 29. 3D model of the TPV of a MELAS patient brain that has undergone 
significant atrophy throughout the brain. The differences between this and the healthy 
brain in Figure 1Figure 25 (B). 
The rest of the individual TPVs were then corrected for age and the z scores 
calculated using the mean and standard deviation calculated from the control data 







Controls Carriers MELAS 
0.775968636 0.797584588 0.742669688 
0.75022562 0.779145269 0.690250799 
0.773852936 0.786974575 0.677451625 
0.76803736 0.778201538 0.736133233 
0.774278709 0.727115041 0.658765467 
0.74843789 0.801783727 0.699083914 
0.780928097 0.765780975 0.725224586 
0.801055467 0.751419244 0.708454824 
0.799796234 0.779411618   
0.732535587 0.723978481   
0.782019304     
0.801065187     
0.793804658     
0.782102403     
0.776312995     
0.803502072     
0.795039189     
0.792329142     
0.738292617     
0.784403918     
0.767105875     
0.785211712     
0.793455118     
0.749259618     
Mean 0.777042514 0.769139506 0.704754267 






Controls vs Carriers Controls vs MELAS Carriers vs MELAS 
No significant 
difference 
p = 0.359 
Controls > MELAS 
p < 0.0005 
Carriers > MELAS 
p = 0.003 
Table 16. 2-sample t-test to ascertain whether the differences in normalised TPV 
between groups are statistically significant. 
Table 16 shows that even after head size is corrected for by normalising to TICV, that 
there is no significant difference between TPVs of controls and carriers. Both the 
control and carrier groups show significantly larger TPVs than the MELAS group, 
indicating that the MELAS group, as a whole, shows atrophy compared to a 
population with no history of stroke-like episodes. 
 
Figure 30. Plot of age and gender corrected z scores comparing the relative TPV 
between the carrier and MELAS groups. The two carriers with relative TPVs in the 
smallest 2.5% of the population are highlighted. 
The results show a clear difference between the mutation carrier and MELAS patient 




which is indicative of the fact that all of these patients have had stroke-like episodes 
and have large amounts of atrophy. The carrier group shows that most of the group 
have relative TPVs that are well within the limits of the healthy control group, 
however there are two carriers that show relative TPVs that are much smaller than 
would be expected in healthy controls. In these cases only a longitudinal study would 
provide further information about these patients with regards to whether they either 
just have small brains for their head size that are stable, or normal sized brains for 
their head size that are undergoing atrophy. 
Longitudinal changes in TPV 
 
Figure 31. Graph showing two examples of patients with MELAS showing a rapid 
longitudinal change of brain volume over time with the healthy population mean and 
95th percentile limits derived from the meta-analysis paper: M. Vågberg et al., PLOS 
One, 17 Jan 2017: 5878 (3102 Female) healthy individuals. 
The characteristics of Figure 31 show that atrophy can be very rapid in patients with 
MELAS, although from this sample size of only two patients it is impossible to 
ascertain whether this is the most common pattern, or if there are other patterns of 




at any position along this longitudinal atrophy path, including a stable position without 
rapid atrophy. 
Grey matter (GM) and white matter (WM) 
The MELAS group had to be modified for this section of analysis as three of the 
patients with MELAS had lesions that misclassified the grey and white matter in 
around the regions of the lesions, which led to misleading value for the segmented 
volumes of grey and white matter. The three patients with MELAS with lesions visible 
on their images were therefore removed from this section of the analysis. 
The raw volumes were normalised against TICV to remove any confounding effect of 







Controls Carriers MELAS 
0.42195468 0.442474915 0.391817005 
0.387825907 0.3802001 0.366170007 
0.424226751 0.435971207 0.415581588 
0.4347478 0.437559717 0.382222188 






















Mean 0.435071261 0.413803468 0.392011206 
Table 17. Grey matter volumes normalised to TICV for each of the control, carrier, 





Controls vs Carriers Controls vs MELAS Carriers vs MELAS 
Controls > Carriers 
p = 0.014 
Controls > MELAS 
p < 0.0005 
No significant 
difference 
p = 0.148 
Table 18. Results from a 2-sample t-test showing significance, or otherwise, of the 
differences between the groups. 
Table 18 shows, perhaps unexpectedly considering the results in Table 16, which 
both the carrier and MELAS groups show significantly less grey matter relative to 
head size compared to the control group. This is despite the carrier group showing 
no significant difference to controls in the overall amount of brain tissue within the 
skull cavity. 
 
Figure 32. Plot of z scores of GM volumes normalised to TICV for the carrier and 
MELAS patient groups. 
Figure 32 shows a large variation in the amount of grey matter present in each brain 
in the carrier group, and a generally small amount of grey matter present in MELAS 





Controls Carriers MELAS 
0.333405122 0.339314938 0.284003926 
0.339113598 0.3778952 0.297147849 
0.329144104 0.334995747 0.301787721 
0.313542654 0.324947837 0.303425986 






















Mean 0.321094499 0.339441542 0.295477064 
Table 19.White matter volumes normalised to TICV for each of the control, carrier, 
and MELAS groups. 
Controls vs Carriers Controls vs MELAS Carriers vs MELAS 
Controls < Carriers 
p = 0.007 
Controls > MELAS 
p = 0.001 
Carriers > MELAS 
p = 0.001 
Table 20. Results from a 2-sample t-test showing significance, or otherwise, of the 




Table 20 shows that the carrier group has a greater amount of white matter within 
their overall brain volume than the control, thus indicating that there are significant 
differences in the structure and make-up of the brains of those carrying the 
m.3243A>G point mutation compared to those who do not. 
 
 
Figure 33. Plot of z scores of relative WM volumes for the carrier and MELAS patient 
groups. 
Combining Figure 32 and Figure 33 it is clear to see that despite the apparently 
normal TPVs of the carrier group seen in Figure 30, there are differences in the 
relative grey and white matter volumes of some of the carrier group compared to the 
control group, which consist of reduced grey matter volumes and increased white 
matter volumes that are then combined to show TPVs within the healthy control 
group range. In contrast, the MELAS patient group show the expected characteristics 





Grey matter to white matter ratio (GM : WM) 
To further demonstrate the differences between the control and carrier group the 
grey to white matter ratio was also looked at. The MELAS patient group was 
removed from this analysis due to atrophy being clearly dominant in the grey and 
white matter analysis. 
 
Figure 34. Graph of carrier GM:WM z scores showing that some carriers have a 
normal ratio, while others show large reductions in GM volumes compared to the 
control group, which appear to dominate the statistical analysis carried out. In a 
group-wise analysis, the control group have a significantly larger grey to white matter 
ratio (p = 0.003). 
Figure 34 highlights that within the carrier group there are significant differences 
between individuals, highlighting the unpredictable and heterogenous nature of 
mitochondrial disease. 
Cerebellum 
The cerebellum has often been quoted as showing atrophy in isolation to the rest of 




the results presented here looking at whether these are true observations, or if it is at 
least partly an observational illusion caused by the size of the structures being 
imaged. 
 
Control Carrier MELAS 
0.078941965 0.07659084 0.063425455 
0.087887881 0.102796734 0.073324641 
0.076128189 0.086966868 0.096025239 
0.077978649 0.090514664 0.062220314 
0.072934541 0.063494541 0.061169576 
0.081545279 0.091640262 0.076044036 













Mean 0.079004882 0.080931771 0.071563037 
Table 21. Cerebellar volumes normalised to TICV for each of the control, carrier, and 
MELAS groups. 
Controls vs Carriers Controls vs MELAS Carriers vs MELAS 
No significant 
difference 
p = 0.538 
Controls > MELAS 
p = 0.028 
No significant 
difference 
p = 0.136 
Table 22. Results from a 2-sample t-test showing significance, or otherwise, of the 
differences between the groups. 
Table 22, combined with observations from Figure 35, again shows the large 




indicates that some carriers, in addition to a reduced grey matter volume, also have 
either a smaller cerebellum, or one that has undergone some atrophy. 
 
Figure 35. z scores of cerebellar volumes corrected for age, gender, and head size. 
Comparing Figure 35 to Figure 32 and Figure 33 shows that in this group of patients 
with MELAS and carriers that cerebellar atrophy does not occur in isolation and in 
most cases reflects the atrophy state of the rest of the brain. 
5.5 Discussion 
The heterogeneous nature of mitochondrial disease makes it very difficult to predict 
disease progression for any individual patient. Despite a large amount of anecdotal 
clinical evidence, I identified that, at the time of writing, the head sizes of patients 
with MELAS has not yet been quantitatively investigated, and theorised that the 
overall growth of carriers and patients with MELAS may provide some sort of insight 
into their overall prognosis. Examining Figure 27 clearly shows that the MELAS 
patient group, who have suffered stroke-like episodes, all have head sizes more than 
two standard deviations away from the control group mean. This means that these 
patients with MELAS have head sizes that sit in the bottom 2.5% of the population. 




developmental factor associated with the m.3243A>G point mutation, however, as 
the carrier group in general have head sizes that sit well within the control group 
normal range, this indicates that there is either a threshold, or an additional 
mechanism that is exceeded or present in carriers of the m.3243A>G point mutation 
who go on to develop stroke-like episodes. 
Looking back at the correlation data in Section 5.3.iv, it can clearly be seen in  
Table 14 that TICV and BMI are not equivalent as measures of possible susceptibility 
to stroke-like episodes as there is a much stronger correlation between TICV and 
stroke-like episodes than between BMI and stroke-like episodes. 
While it has been shown that blood, urine, and muscle heteroplasmy levels are 
correlated (Grady et al. 2018), what has not yet been established is whether these 
are either correlated, or representative, of heteroplasmy levels within the brain. The 
blood-brain barrier could provide an effective isolation mechanism to prevent the 
heteroplasmy levels in the blood from taking on a correlational component from the 
brain. It could easily be hypothesised that heteroplasmy levels within the brain could 
provide significant insights into both the current status, and the future prognosis, of 
the brains of those carrying the m.3243A>G point mutation. Localised, and unilateral, 
thinning of the cortical thickness, and in particular the thinning of the temporal pole, 
could point to significant differences in heteroplasmy levels between hemispheres of 
a single brain, and possibly even between regions, however the observed 
progression of lesions across boundaries implies a mechanism to facilitate this, which 
may well be associated with the local heteroplasmy characteristics. 
While TICV does not provide any information about the mechanisms in play that 
define who is susceptible to stroke-like episodes, it does provide a simple measure, 
using the MRI method described here that could effectively highlight those people 
carrying the m.3243A>G point mutation who are more likely to develop stroke-like 
episodes at some point, which would allow them to be more closely monitored and 
potentially benefit from more timely interventions due to this. Substituting head 
circumference for TICV has been suggested as an alternative method, however a 
basic literature search has revealed that there are no equivalent head circumference 
percentile charts for adults, and the Tanner growth charts are not suitable (Busby et 
al, 1992). One paper attempts to derive percentiles, but uses a Turkish population, 




(Örmeci et al, 1997). Papers using either UK, or comparable, populations, show 
correlation values of 0.28 to 0.39 for males and 0.53 for females (Bale et al, 1991; 
Nguyen et al, 2012), and so height and head circumference do not appear to be 
strongly correlated and therefore the current approach of combining head 
circumference with height to generate percentiles within population norms is not 
suitable to provide a substitute for TICV. Head circumferences for each of the 
m.3243A>G population within this study were also assessed for correlation with 
stroke-like episodes, and it came out at a similar correlation to BMI, see Table 14 for 
details, thus showing there is some level of correlation, but not one that is strong 
enough to use a predictor. 
The abnormally small TICVs seen in the MELAS patient group also indicate that the 
effects of having the m.3243A>G point mutation is not just about the development of 
stroke-like episodes or brain shrinkage due to atrophy, and highlights that there are 
developmental factors in play from birth that appear to influence whether someone 
with the mutation is going to be susceptible to stroke-like episodes or not. To fully 
understand the effects of having the m.3243A>G point mutation it is going to take a 
multi-disciplinary approach to understand exactly how the point mutation affects 
someone right from the OXPHOS chain, through to global effects throughout the 
body and the brain. 
Within the systematic review in Chapter 2, I highlighted papers that carried out and 
reported on visual measures of atrophy within their patient populations (Iizuka et al., 
2002; Majaama-Volti, 2006; Sue, 1998; Tschampa et al., 2013; Tsujikawa et al., 
2016) and also that there currently does not exist any robust quantitative measure of 
atrophy to replace this. I have used the fact that once someone has finished growing, 
their head, and therefore also their TICV, does not change during their adult life to 
provide a stable volumetric reference against which atrophy may be effectively 
measured. In contrast to the complex analytical methods to assess atrophy put 
forward in the MIRIAD atrophy challenge (Cash et al., 2015), and also to the 
somewhat variable performance of completely automated measure of longitudinal 
brain volume changes (Durand-Dubief et al., 2012), I have defined a simple measure 
of total brain atrophy that is calculated by using global segmentation of brain tissue to 
provide a volumetric measure of brain tissue, that can then be normalised to the 
TICV to give the proportion of the TICV filled with brain tissue. In this case I used all 




and the inclusion of these structures in the segmentation. It would not be a difficult 
task to define atrophy for different regions of the brain as desired either using manual 
segmentation or other segmentation software to divide the brain tissue up into a 
number of regions, which I go on to do in Chapter 6. Obtaining an accurate measure 
of atrophy in those with the m.3243A>G point mutation may provide an early warning 
that significant changes are occurring that are not immediately obvious through 
qualitative visual inspection. There are a number of reasons for this, with the main 
reason being that the brain can lose a significant amount of volume, up to around 
10% if loss is spread globally, before the atrophy would be visually classed as being 
of note. The longitudinal data presented in Figure 31 provides evidence that it could 
be the first few percent of brain volume loss that could be the most important in terms 
of being able to provide earlier intervention and also how quickly brain volume is lost 
once the rapid atrophy process has begun. 
The percentage of brain volume lost in these patients with MELAS is an important 
value as it takes the changes well outside volumetric changes that are seen due to 
dehydration and weight loss. A study into a healthy group of runners before, during, 
and after a 9 week, 4487 km ultra-marathon, found that even after running in these 
extreme conditions for several weeks, the athletes only showed a maximum of a 6% 
brain volume loss, which was quickly restored are hydration levels and weight were 
regained after the race (Freund et al., 2014). The clinical relevance of the volume 
changes seen in patients with MELAS is that there are processes occurring that are 
outside of normal changes caused by environmental factors, and therefore are likely 
to be permanent. However, the major limitation of this work is that it is cross-sectional 
in nature and so the longitudinal element of the analysis is not possible, which would 
provide individualised analysis of brain volume changes over time 
There do exist possible automated evaluations of atrophy, such as the structural 
brain change analysis tool (SIENA) in FSL (Smith et al., 2002), however due to the 
lack of high resolution 3D anatomical scans for the carrier and MELAS patient groups 
it was not possible to investigate the accuracy, reliability, or usability of these, 
however as they use previous scans of each individual as the baseline it may be 
possible to use these to not only provide a quantitative measure of volumetric loss, 
but also to pinpoint specific regions that have atrophied more, or less, than the rest. I 




and so any future work to look at these must make sure that any statistically 
significant results can be clearly linked to clinically relevant changes. 
The grey matter, white matter, and grey to white matter ratio results further 
demonstrate the high level of variability between individuals carrying the m.3243A>G 
point mutation in the carrier group, while the MELAS patient group clearly show the 
effects of atrophy with both grey and white matter volumes being reduced compared 
to the control group. The only previous quantitative volumetric work that I identified in 
the systematic review by Virtanen et al. (2011) kept all of the participants grouped 
together in a single group, with no information about who had a history of stroke-like 
episodes, and so the atrophy from those who had suffered from stroke-like episodes 
may have dominated their results and only indicated significant reductions in both 
grey and white matter compared to their control group. In themselves these 
measures do not provide much additional information other than the fact that carriers 
tend to have less grey matter and more white matter than the control group, but do 
indicate that further investigation is required into specific regions to ascertain whether 
there are some that are more, or less, affected than others and their potential 
implications. I have taken this work forward and it will be discussed in the next 
chapter. 
I have brought the predilection of reporting cerebellar atrophy in the absence of 
cerebral atrophy into question here as the results here indicate that there is 
cerebellar atrophy when there is also cerebral atrophy. There are a number of 
reasons why this may be the case and they are all related to the fact that the features 
of the cerebellum are usually around the same order of magnitude as the size of the 
voxels. This causes issues as there will be significant partial volume effects, which 
may be exacerbated by the fact that viewing software usually smooths the image. 
To better understand the relationship between cerebral and cerebellar atrophy higher 
resolution MRI imaging protocols will be required so that the cerebellar volume can 
be more accurately assessed. If cerebral and cerebellar atrophy are intrinsically 
linked, this potentially makes identifying atrophy in the cerebellum using standard 
MRI protocols and visual inspection clinically important as it could provide an easily 
identifiable indicator of global atrophy as the observed level of atrophy in this cohort 




5.6 Conclusions and Further Work 
The simplicity of the apparent correlation between TICV and presentation of stroke-
like episodes could be a potentially powerful clinical tool. The next step for this work 
is to greatly expand the m.3243A>G carrier and MELAS patient groups to ascertain 
whether this trend is seen throughout the wider population with the m.3243A>G point 
mutation. 
The quantitative atrophy measurement that I have defined and developed allows for 
the monitoring of atrophy using simple percentage relations rather than requiring 
statistical hypotheses to test against to assess the significance of changes, and is 
therefore more easily carried out and understood. It would be feasible to automate 
the calculation of the TPV/TICV measurement, which would facilitate the longitudinal 
investigation of atrophy progression and which would also be an initial step in the 
standardisation of quantitative atrophy assessment. 
Analysis of the global grey and white matter volumes yielded little specific information 
about the carrier group, therefore this group is investigated in much more detail in the 
next chapter. 
I have shown that visual inspection of atrophy is not straightforward due to the effect 
of overall volume on the visibility of atrophy, and that quantitative assessment of 
atrophy of both cerebellar and cerebral tissues is required to not only understand the 
relationship between them, but also to assess whether the visible changes in the 
cerebellar volume can be used as an indicator of associated global atrophy. 
While the findings within this chapter have provided some clear differences between 
the control, carrier, and MELAS patient groups, the major limitation here is that there 
are no longitudinal high-resolution scans available for any of the individuals within 
this baselining cohort yet to allow a much more in-depth study of similarities and 
differences in the disease progression between individuals. The lack of longitudinal 
data in addition to the relatively small group size, particularly of the MELAS group 
when patients with obvious lesions have been removed, is also a limiting factor in this 




Chapter 6. Regional analysis of volumetric and cortical thickness 
data 
6.1 Introduction 
The work I carried out in Chapter 5 showed that there are differences between the 
control, carrier, and MELAS patient groups in the global volume measures that 
required further investigation. One possible option was to carry out voxel-based 
morphology (VBM) analysis between the different groups, but as with the work in 
Chapter 5, there is no clinical baseline. Therefore I tested the following hypotheses: 
1) that there are specific regional differences between patients with MELAS and 
controls caused just by the presence of the m.3243A>G point mutation that are not 
related to having a history of stroke-like episodes; and 2) that despite the regional 
specificity of the presence of lesions there are in fact global changes to the brain. 
The VBM work that has been done by Tsujikawa et al. (2016) and Haast et al. (2018) 
did not systematically assess the volumes of the regions of the brain they were 
quoting as being statistically significantly different. Without quantitative results to go 
on it is impossible to build up a clinical picture of the actual differences that are 
present that are clinically significant, and instead all that is possible is to provide a list 
of the areas that have been highlighted. 
To my knowledge, no-one has attempted this type of analysis on brain MRI data in 
mitochondrial carriers and patients with MELAS, which makes this an important study 
to carry out so that mitochondrial disease research may benefit more fully from a 
multidisciplinary approach. 
6.2 Aims 
The aims of the work carried out in this chapter are as follows: 
1. Ascertain whether there are differences in overall cortical thickness for each 
lobe between the control, carrier, and MELAS patient groups. 
a. Cortical thickness was chosen over grey matter volume in each region 
as it is a far simpler task to verify cortical thickness measurements in 




2. Break the lobes down into sub-regions to ascertain whether there are specific 
regions showing cortical thinning in carriers, or if the cortical thinning is spread 
evenly across the lobe, and therefore across the entire cortex. 
3. Devise and utilise a methodology that is easily repeatable. 
6.3 Methods 
6.3.i Carrier and Patients with MELAS 
17 participants, the same as used in Chapter 5, from the mitochondrial disease 
cohort were used for the TICV and TPV analysis. 10 of these were classed as 
carriers with no history of stroke-like episodes, while 7 were classed as patients with 
MELAS with a history of stroke-like episodes. Carrier and MELAS patient details can 
be found in Chapter 3. 
6.3.ii MRI Scans 
Cohort participant scans were taken on a 3 T Siemens MRI scanner. The scan 
parameters used are Gradient echo, 3D anatomical, TR = 50 ms, TE = 30 ms, FA = 
15°, with 1 mm x 1 mm x 1 mm voxels. 
6.3.iii Regional Segmentation 
Volumetric and cortical thickness measurements were carried out using the 
FreeSurfer 5.4 software (Dale et al., 1999; Fischl and Dale, 2000; Fischl et al., 2002; 
Fischl et al., 2004). This version of the software was used for all analysis within this 
section as studies into previous FreeSurfer versions have found significant 
differences in the outputs available and the accuracy of these (Gronenschild et al., 
2012). 
The cortical parcellation was carried out using the Desikan-Killiany Atlas, which splits 






Figure 36. Visual representation of the Desikan-Killiany Cortical Parcellation Atlas in 
an inflated brain  
These 35 cortical areas can then be combined to provide data by lobe (Frontal, 
Parietal, Temporal, and Occipital). This is valid for both cortical volumetric 
measurements of the grey matter volume, and also for the cortical thickness 
measurements. 
All of the FreeSurfer segmentation is carried out using the command line prompt. All 
of the control, carrier, and MELAS patient files were converted to .nii for the FSL 
segmentation and were used in this format for this analysis. Each file was run 
through the full FreeSurfer cortical reconstruction process using the following 
command: 
recon-all –subject ‘output file name’ –i  input_file.nii –all 
Where the ‘output file name’ is used to name the folder where all of the output files 
for a specific input file will go. These were set to match throughout, so Control1.nii 
would be output to folder Control1. 
Manual assessment of the cortical thickness measurements output by FreeSurfer 
across random sections of each region was carried out to ascertain the accuracy and 
validity of the automated measurements. 
The volumetric and cortical thickness values then had to be extracted from their 
output text files, which are located in the ‘stats’ folder within the output folder for each 
individual. The relevant stats files are ‘aseg.stats’, ‘lh.aparc.stats’, and 
‘rh.aparc.stats’. The ‘aparc.stats’ files contained a list of all of the regions and the 
associated measures, which then have to be transferred into Excel and reordered by 




allocated, and Table 24 shows all of the sub-cortical segmentation measures from 
the aseg.stats output file. 
 
Table 23. Output regions from the FreeSurfer aparc.stats files grouped by lobe. 
Frontal Parietal Temporal Occipital
superiorfrontal superiorparietal inferiortemporal lateraloccipital
caudalmiddlefrontal inferiorparietal middletemporal lingual
rostralmiddlefrontal supramarginal superiortemporal cuneus


































































Table 25. Table showing the cortical thickness (the average of the right and left 












































































































































































































































































































































































































































































































































































































































































Controls vs Carriers Controls vs MELAS Carriers vs MELAS 
No significant 
difference 
p = 0.149 
Controls > MELAS 
p < 0.0005 
Carriers > MELAS 
p < 0.0005 
 
Parietal Lobe 
Controls vs Carriers Controls vs MELAS Carriers vs MELAS 
No significant 
difference 
p = 0.124 
Controls > MELAS 
p < 0.0005 
Carriers > MELAS 
p = 0.003 
 
Occipital Lobe 
Controls vs Carriers Controls vs MELAS Carriers vs MELAS 
No significant 
difference 
p = 0.554 
Controls > MELAS 
p = 0.002 
Carriers > MELAS 
p = 0.014 
 
Temporal Lobe 
Controls vs Carriers Controls vs MELAS Carriers vs MELAS 
Controls > Carriers 
p = 0.018 
Controls > MELAS 
p < 0.0005 
Carriers > MELAS 
p = 0.001 
Table 26. Tables showing the outputs of a paired t-test for each lobe, and between 
each of the control, carrier, and MELAS groups. 
Table 26 shows that there is no significant difference in cortical thickness between 
the control and carrier groups in the frontal, parietal, or occipital lobes, but that there 
is a significant difference in the temporal lobe. All lobes show significant differences 





Figure 37. z scores of the cortical thickness by lobe of the carrier and MELAS patient 
groups, corrected for head size, age, and gender. 
Figure 37 shows that in the carrier group the frontal, parietal, and occipital lobe 
cortical thicknesses are slightly thinner than the control group, but are still within the 
normal cortical thickness distribution. The carrier group temporal lobe cortical 
thickness is much thinner than would be expected as it is more than three standard 
deviations smaller than the control group. The MELAS patient group has much 
smaller cortical thicknesses than the control group across all lobes. The raw values 
show that there is approximately a 10% difference in cortical thickness in all lobes 
between the carrier and MELAS patient groups, which demonstrates that whatever 
the atrophy mechanism is, it globally affects the cortex and not just the cortex that is 





Figure 38. z scores for the cortical thickness of each sub-region, averaged across the 
sub-region, of the frontal lobe. 
Figure 38 shows that most of the sub-regions of the frontal lobe are within normal 
ranges for the carrier group, but the precentral and paracentral gyri are both a great 
deal thinner in the carrier group than the control group (control (total) > carrier (total), 
precentral: p < 0.0005, paracentral: p = <0.0005). None of the other frontal lobe 
regions showed a significant difference between the control and carrier cortical 
thicknesses, although the superiorfrontal region was approaching significance (p = 
0.05). The MELAS group results show that cortical thicknesses are greatly reduced 
across the frontal lobe, except for the frontal pole, which appears to be preserved, 
and also to some extent the pars orbitalis, which does not reach significance when 
compared to the control group (p = 0.081). There are also no significant group 





Figure 39. z scores for the cortical thickness of each sub-region, averaged across the 
sub-region, of the parietal lobe. 
The cortical thickness in the parietal lobe of carriers, as shown in Figure 39, also 
shows a variation across sub-regions, with the postcentral gyrus and superior parietal 
region both being, on average, significantly thinner than in the control group (p < 
0.0005 and p = 0.006 respectively). There do not appear to be any sub-regions that 
are preserved in the parietal lobes of patients with MELAS after the onset of stroke-
like episodes. Again, there are no significant differences between the left and right 
hemispheres, although the inferior parietal region approaches significance (p = 
0.064) and thus requires a larger sample size to reduce the uncertainty in the mean 






Figure 40. z scores for the cortical thickness of each sub-region, averaged across the 
sub-region, of the occipital lobe. 
The cortical thickness in the occipital lobe of carriers is mostly well within the normal 
distribution, as shown in Figure 40, however there does appear to be a predisposition 
of the carrier group left hemisphere cuneus and pericalcarine regions to show 
thinning that are not seen in the right hemisphere. The hemisphere differences are 
statistically significant for the cuneus (p = 0.031) and the pericalcarine region (p = 
0.028). The cortical thicknesses of the MELAS group clearly show that all regions 
have undergone significant thinning after the onset of stroke-like episodes (all 
occipital regions in the MELAS group are significantly thinner than the control group, 





Figure 41. z scores for the average cortical thickness of each sub-region of the 
temporal lobe. 
Figure 41 shows that even in carriers that the cortical thickness is much thinner than 
in the control group particularly in the temporal pole, the entorhinal cortex, and the 
fusiform gyrus. The temporal pole does not appear to thin much further in the MELAS 
patient group, but all of the other temporal sub-regions do show significant thinning 
















Control > Carrier 
0.009 
Control > MELAS 
 <0.0005 




Control > Carrier 
0.01 
Control > MELAS 
 <0.0005 






Control > Carrier 
0.043 
Control > MELAS  
<0.0005 
Carrier > MELAS 
0.036 
Fusiform 
Control > Carrier 
<0.0005 
Control > MELAS  
<0.0005 
Carrier > MELAS 
0.057 
Entorhinal 
Control > Carrier 
0.001 






Control > Carrier 
<0.0005 















Table 27. Results of the 2-sample t-test for all of the areas of the temporal lobe. 
Table 27 shows all of the statistical results for group comparisons across the 
temporal lobe. The full set of comparisons are shown as the patterns are unlike any 
of the other lobes, which all follow approximately the same pattern of the carrier 
group showing no significant difference to the control group, except in the highlighted 
regions, while the MELAS group shows significantly thinner cortex than either the 
control, or the carrier, group. 
6.5 Discussion 
The analysis method I chose to carry out regional assessment of the carrier and 




in the MRI literature as it does not utilise VBM to carry out the comparisons. There 
are a number of examples of VBM studies, including Tsujikawa et al. (2016) and 
Haast et al. (2018), in which carrier and/or MELAS patient groups are compared 
statistically to a control group. Within previous studies, both volumetric and also 
qualitative observation, a number of areas are identified as being different between 
the groups, but there is often little effort to ascertain the clinical relevance of these 
and to establish at what point the difference becomes clinically significant. My 
approach takes a step back from testing a specific statistical hypothesis and instead 
provides a robust, repeatable method to carry out quantitative measurements on the 
brains of both controls and carriers that provides an output that may be more easily 
related to the clinical significance of the results, and may also inform the formulation 
of more specific statistical hypotheses in which the hypothesis goes beyond ‘mean ≠ 
0’ for use in future studies. 
The results, even in this relatively basic format, already challenge some of the 
assumptions that exist both within the research and the clinical communities. If we 
first consider Figure 37, it shows that there is a very large difference in cortical 
thickness between the carrier and MELAS patient groups, and that this is global and 
not centred in the regions of previous stroke-like episodes (see Table 4). Only one of 
the patients with MELAS had a reported stroke-like episode centred in the frontal 
lobe, and removing their data from the MELAS patient frontal cortical thickness made 
very little difference to the resulting z score, showing that their result was not biasing 
the overall result. Up to now, it has often been assumed that the frontal lobe is 
relatively well spared, but my results indicate that while the underlying white matter 
may be relatively spared until later in the disease progression, there are significant 
changes to the grey matter once a stroke-like episode has occurred.  
Figure 37 also shows that even in carriers, the temporal lobe is severely affected, 
which suggests that there are intrinsic differences between the brains of carriers and 
controls. This finding formed the rationale for my investigation of the sub-regions of 
the individual lobes to ascertain whether the smaller cortical thicknesses were 
throughout the lobe, or centred in any particular areas. 
Figure 38 shows the results from the breakdown of the frontal lobe. Despite the 
assumption that the frontal lobe is relatively spared, these results clearly indicate that 




are both greatly thinned compared to the control group. The presence of this thinning 
fits in neatly with clinical observations of carriers of the m.3243A>G point mutation 
who are very often slow in both their movements and speed of mental processing. It 
is also interesting to note that the frontal pole, even in the brains of patients with 
MELAS who have a lot of atrophy, is preserved. This region has been identified 
through neuroimaging studies to be responsible for monitoring the expected 
outcomes from an ongoing action (Boorman et al., 2009; O’Doherty, 2007; Daw et 
al., 2006; Koechlin, 2002). 
Figure 39 shows that two of the five parietal sub-regions, the postcentral gyrus and 
the superior parietal cortex, are much thinner than in the control group. All regions of 
the parietal cortex are then further thinned in the MELAS patient group compared to 
the carrier group. 
Figure 40 shows the results for the sub-regions of the occipital lobe. The occipital 
lobe appears to show a large difference between the left and right hemispheres, with 
the left showing much thinner cortex than the right. Hemispherical differences are 
something that have not traditionally been addressed in neuropathological research 
due to the widespread practice of only fixing the left hemisphere of any donated 
brains, while the right hemisphere is frozen, but my results indicate that there may be 
significant differences between the left and right occipital lobes and that these 
differences may provide valuable information on the mechanisms that either lead to 
the cortical atrophy, or perhaps even the mechanisms involved in the onset of stroke-
like episodes. These results indicate that handedness may be an influencing factor 
for occipital thickness, and also that the lack of significant thinning seen between 
carriers of the m.3243A>G point mutation and healthy controls perhaps indicates that 
the occipital cortex may already be critically thin and susceptible to influences of 
abnormal activity, particularly in the adjoining regions of the temporal lobe. 
The temporal lobe, unlike the other lobes, is heavily affected in both carriers and 
patients with MELAS. These results provide a solid region of interest not only in 
patients with MELAS, but also in carriers to ascertain whether the cortical thinning in 
the temporal lobe is linked to whether there will be an onset of stroke-like episodes. 
The carriers frequently only show significant thinning in one hemisphere, but there is 
no specific pattern to whether this is the left or the right. In this small sample size and 




on to develop stroke-like episodes, the results from this analysis are limited to 
defining regions of interest for future work, using both MRI and neuropathology to 
begin to tie together the data from the different disciplines. 
All of the m.3243A>G carriers and patients with MELAS in this study were adults, 
with the youngest being 25, so one of the key questions that would need to be 
addressed is whether the thinner cortex is due to an early onset atrophy of the grey 
matter that is not related to the onset of stroke-like episodes, or if those regions of 
cortex did not develop fully in the first place.  
With the results from this analysis, it gives the opportunity to devise very specific 
cognitive tests to use in addition to the volumetric results of an individual to begin to 
pin down exactly how big a change is required in cortical thickness before it becomes 
clinically significant, with clinically measurable changes in performance or behaviour. 
This type of ‘back to basics’ approach to attempting to gain an understanding of how 
carrier and MELAS patient brains is generally lacking in current mitochondrial 
disease MRI literature with methodology and approaches being chosen seemingly at 
random. The heterogeneous nature of mitochondrial disease means that the current 
scatter-gun approach to measurement and analysis is unlikely to yield any results 
that are of real value to the clinical community as without a clinical baseline or a 
standard, well-defined, methodology the outputs are highly likely to contain 
contradictory data simply due to different assumptions being made and different 
analysis methods being used. 
My work here has highlighted the absolute requirement for a set of standard 
measurement protocols to be defined to allow a much more rapid progression of 
understanding to be achieved as data from multiple studies will be much more readily 
compared and/or combined and clinical significance can actually be defined so that 
meaningful statistical analysis may be carried out. 
6.6 Conclusions 
The results from this section have highlighted that assumptions cannot be made 
about volumetric and cortical thickness measurements from qualitative inspections of 
MRIs. I have shown that there are numerous quantitative differences between 
carriers and controls in very specific regions of the brain, which have not yet been 
explored or explained. It is possible that changes in one, or more, of these regions 




limited by it only covering a single time point, and also that it only used adult 
m.3243A>G carriers and patients with MELAS as there are many questions relating 
to whether the carriers show cortical thinning, or if they have a cortex that was never 
any thicker. These are questions that only a longitudinal multi-disciplinary study can 





Chapter 7. Tract-based spatial statistical analysis in individuals with 
the m.3243A>G point mutation 
7.1 Introduction/Hypothesis 
There is a growing amount of evidence to show that white matter tract properties are 
affected by neurological disease (Turken et al., 2008; Kim et al., 2015; Rieckmann et 
al., 2016). These changes can include thickening, or thinning, of the myelin around 
the white matter tract, and change to the tract itself, both in terms of diameter, 
directionality, and branching (Bourbon-Teles et al., 2017; Barakovic et al., 2018). 
Fractional anisotropy (FA) provides a gross measure of some of these parameters as 
it shows the level of anisotropy, in other words the higher the value, the more 
directional the properties of the tissue. In a completely isotropic material the fractional 
anisotropy will be zero. 
With the evidence from temporal lobe epilepsy studies (Chiang et al., 2016; Imamura 
et al., 2016) showing changes in white matter tracts, it is not a large step to consider 
the effects on the white matter tracts of stroke-like episodes and the electrical and 
cellular activity leading up to these, and in particular in the lead up to the first stroke-
like episode. There has only been one study to date that has looked at FA in patients 
with the m.3243A>G point mutation, and this found significant differences between 
controls and patients, particularly in the inferior longitudinal fasciculus (Virtanen et al., 
2014).  
The hypothesis being test in this section of the work is: 
1. That there are significant differences in the fractional anisotropy between each 
of the two groups, carriers, and patients with MELAS, demonstrating physical 
differences in the white matter tract connectivity and directionality. 
This work forms a basis for further hypotheses to be developed that can utilise more 
in-depth white matter tract analysis to assess the connectivity between specific 
regions of interest, as identified in the preceding chapters of this thesis, with a 
particular focus on the connections to and from the regions showing much smaller 





No controls were available from locally held brain MRIs. Some control DTI scans 
were sourced but there were significant differences in the scan sequences used and 
due to the unknown amount of variation (Styner et al., 2002; Vollmar et al., 2010; 
Biberacher et al., 2016) this would introduce I decided that the analysis for this 
section of the study should be limited to the carrier and MELAS groups as they were 
all scanned on the same scanner using an identical protocol. 
7.2.i MRI DTI Scanner Protocol 
Participant scans were taken on a 3 T Siemens MRI scanner. The scan parameters 
used were 2D Echo Planar, TR = 9000 ms, TE = 95 ms, FA = 90°, with 2 mm x 2 mm 
x 2 mm voxels, two b-values (0, 1000), 64 directions, and two averages. 
7.2.ii TBSS Protocol 
The full details of the TBSS protocol can be found in Appendix B, with only the key 
stages highlighted within this section. 
The DTI files were converted from DICOM to NIfTI and as there were two averages 
taken, these were split into two separate files so that the number of b-values and b-
vectors matched the number of images within the file to be analysed. 
Each DTI file was then corrected for eddy currents, and the b-vectors rotated 
appropriately. 
The b0 image was then skull-stripped to create a binary mask image that is used to 
define the brain area over which the rest of the analysis is run. 
The diffusion tensors are then reconstructed by running the DTIFIT tool. This outputs 
a number of files including an FA file. The FA files for each scan are then collected 
into a single folder for further processing ensuring that each group has a distinct 
naming convention as this greatly simplifies future stages of the processing. 
There are four stages of pre-processing that have to occur before TBSS can be run 
to output the associated statistics of the groups being compared. These stages are 
pre-processing, after which the ‘slicesdir’ folder should be opened and the images 
inspected to ensure that the process has run correctly (if it has not these images are 




post-registration to bring the subjects into MNI152 space, and finally the thresholding, 
which is defined by inspecting the mean_FA_skeleton, although it is usually around 
0.2, which should remove highlighted regions outside of the white matter tracts. 
To run TBSS a general linear matrix (GLM) needs to be generated. This is achieved 
using the GLM option in the main FSL GUI. The two cases analysed were for the 
carrier FA to be greater than the MELAS FA, and vice versa. 
The number of permutations used in this analysis was 5000, however this should be 
considered the minimum for each of the larger datasets and if time and processing 
facilities permit, larger n values should be used for large datasets such as these. 
7.3 Results 
While all groups were compared against all others looking for FA both higher and 
lower, only those group comparisons that showed any significant differences have 







Figure 42. TBSS output showing the regions in which carriers have a significantly 
higher FA than patients with MELAS. The mean FA skeleton is shown in green. The 
regions indicate a significant difference between the Carrier and Patient groups with 
a confidence limit of over 95%. 
The carrier group was shown to have significantly larger FA than both the control and 
the MELAS patient groups, with no significant difference being found between the 
control and MELAS patient groups. The difference between the carrier and control 
group is concentrated along the cingulum, with a couple of regions of arcuate fibres 
in the para- and pre-central gyrus region. The differences between the carrier and 
MELAS patient group are much more widespread and although the difference in FA 
is seen in the cingulum again, there is also evidence that both the superior and 
inferior longitudinal fasciculi also have altered FA values, as well as in arcuate fibres 
across the brain. 
7.4 Discussion 
The only previous TBSS analysis of patients with the m.3243A>G point mutation and 
controls found significant differences in the FA of the inferior longitudinal fasciculus 
between a combined carrier and MELAS patient group and a control group (Virtanen 




were not included, so the prevalence of stroke-like episodes is unknown. In my study 
the carrier and MELAS patient groups were split and analysed against both a control 
group and each other. This was to separate out the effects on the white matter of 
stroke-like episodes. 
The results showed that the carrier group had significantly larger FA values than both 
the control and MELAS patient groups. This may indicate that carrying the genetic 
mutation m.3243A>G causes white matter tracts to develop with greater levels of 
directionality than in controls, and that this is reduced and disrupted in the event of 
stroke-like episodes. 
However, there are a number of factors that have to be taken into account when 
considering these results. The first is that the analysis was carried out using DTI 
scans, which are well known to be limited when it comes to tracing crossing fibres 
(Raffelt et al., 2017) and so there may be differences between the control and 
MELAS patient groups within areas where fibres are crossing that are not detected 
using this method. The sample sizes for the carrier and MELAS patient groups are 
also small, so again details of differences may not be readily apparent. 
Further resolution to these results could be obtained from in depth white matter tract 
analysis, but perhaps a better option would be to carry out DKI scans and analysis to 
gain more information about the white matter tract features. In addition to this, it 
would also be useful to carry out scans to allow for the measurement of white matter 
tract diameters and degree of myelination as it will be this type of analysis that will 
start to provide information about the white matter microstructure, which has been 
shown in other diseases to be altered by abnormal electrical and chemical activities 
(Rodriguez-Cruces and Concha, 2015; Hubbard et al., 2017). 
7.5 Considerations for Future Work 
Although the work carried out in this chapter has provided some interesting initial 
results, it was not possible to utilise the technique to its full potential due to the scans 
being captured before the analysis technique was fully understood. 
TBSS is, as defined in its name, a statistical technique and so larger scan sets than 
have been used in this study, are highly recommended. The presence of lesions in 
the scans of some of the patients with MELAS meant that they had to be removed 




It is also key to collect each of the DTI scans using the same MRI scanner for 
everyone to be included in the analysis, and to ensure that identical DTI scan 
protocols are used. This also includes any control group. Even though there are 
some freely available DTI scan sets for healthy controls, there are too many 
unknowns in the collection process, and attempting to combine scan sets from 
different scanners, even if they do use the same protocol, is not recommended. I did 
attempt to use some available control DTI scans, but ran into issues with the 
orientation of the scans, along with differences in the scan protocols, that led to 
outputs that were not possible to sensibly interpret. 
Understanding what is captured, and what the limitations are, within a DTI scan is 
also important. White matter tracts that travel in approximately straight lines will 
dominate the data, which could easily lead to a false picture being painted of what is 
happening within the white matter. Crossing tracts, and tracts that change direction, 
are better identified using DKI scans, but they have the issue of taking longer to 
capture, and also being more complex to analyse. 
It must also be understood that DTI analysis is a group analysis, and in its current 
form is not suitable for assessing individuals against group characteristics. This is 
perhaps one of the most limiting factors about this type of analysis as although group 
trends may be identified, individual differences may not. 
In summary, to overcome the challenges above, the analysis technique needs to be 
understood prior to the scanning taking place to ensure scan sets will be numerous 
enough to provide enough power to the study. The level of detail of a DTI scan and 





Chapter 8. 7 T MRI ultra-high-resolution scanning and quantitative 
T1 mapping of post mortem brain sections 
8.1 Introduction 
It became very apparent early in this PhD that although MRI scanning is a very 
powerful investigative technique due to it being non-invasive and suitable for use in 
vivo, to be able to get more information out of the scans, the tissue being imaged 
needs to be better characterised and understood. Standard anatomical MRI scans 
only provide limited information, so to delve deeper a completely novel approach 
needs to be taken. 
To better understand the underlying tissue, and potentially even the processes that 
lead to abnormal electrical activity and subsequent degeneration, it seems like a 
natural step to turn to neuropathology and to attempt to combine the outputs of 
neuropathological staining and very high-resolution MRI scans. Until very recently, 
this hasn’t been practically feasible because MRI scanners could not scan at a high 
enough resolution, and neuropathological techniques required tissue slices so thin 
that MRI scans just could not image them. 
The development of the CLARITY technique, allowing staining of up to 500 µm thick 
slices, opens up the possibility of being able to quantitatively investigate parameters 
such as protein deficiencies, cell death, cellular make-up, neuronal density, vascular 
characteristics to be measured through the use of optimised antibody staining (Lee et 
al., 2014; Poguzhelskaya et al., 2014; Spence et al., 2014; Tomer et al., 2014) at a 
cellular level, and to carry out ultra-high-resolution MRI scanning of these same 
sections. 
Despite having a reasonable understanding of how the standard formalin fixation 
process affects tissue properties in that the T1 relaxation times decrease significantly 
compared to fresh tissue (Schmierer et al., 2008; Schmierer et al., 2010; Birkl et al., 
2016; Yong-Hing et al., 2005; Pfefferbaum et al., 2004; Tovi and Ericsson, 1992; 
Blamire et al., 1999), and T2 relaxation times develop a temperature dependence 
(Birkl et al., 2016; Dawe et al., 2009), the impact of the first stage of the CLARITY 
process of mounting tissue samples in hydrogel on the tissue properties that define 




It is unfortunate that this section of the study was again opportunistic in nature as 
post mortem samples became available that were ear-marked for future CLARITY 
staining, but they had already undergone the first stage of the process, namely 
mounting in hydrogel. 
The original rationale behind this section of the work was to begin to put together a 
set of protocols that would allow neuropathological staining of specific cell types, or 
activity, to, ultimately, be linked to specific MRI characteristics in vivo. The complexity 
of achieving this is outlined in the rest of the introduction, and the specific findings of 
this study detailed in the results and discussion sections. 
Carrying out MR imaging of unfixed post mortem brains would be ideal, but there are 
a number of issues associated with this. Firstly, if the brain is removed from the skull 
it will not retain its shape unless it is placed in some sort of carriage system 
(Schmierer et al., 2008). Secondly, the brain tissue will begin to decay (D’Arceuil and 
de Crespigny, 2007), which will also affect the MRI metrics and downstream 
neurohistopathological studies. It is clear that there are advantages to imaging both 
unfixed and fixed brains, but this can only be accomplished successfully if the 
conditions the brain is being imaged in are fully understood. In particular, the 
understanding that imaging post mortem fixed brains and brain tissue cannot be 
directly mapped onto in vivo imaging is key (Birkl et al., 2016). 
While there has been some in depth imaging studies of healthy post mortem brains 
and also of patients with multiple sclerosis, there have not, to date, been any post 
mortem imaging studies carried out on patients with m.3243A>G point mutations. 
There have also not been any imaging studies to look at the effect of embedding 
brain sections in hydrogel, which is part of the CLARITY (Phillips et al., 2017) 
process, to ascertain what effect that has on the imaging parameters. This is 
important as the process of mounting a brain section in hydrogel significantly alters 
the tissue properties by removing the lipids from the section. 
There are recently published papers that have looked in depth at various elements of 
multiple sclerosis, including cortical atrophy (Popescu et al., 2015), and myelination 
and cellular characteristics (Schmierer et al., 2008). The techniques utilised in these 
studies are directly applicable to the brains of patients with mitochondrial disease and 
could potentially yield a large amount of information about the underlying 




which they occur. In addition to these studies in multiple sclerosis, there is other 
developmental work in which high resolution MRI can be used to image individual 
layers of the cortex in vivo (Waehnert et al., 2016). Applying this technique to the 
brains of patients with m.3243A>G could provide vital information in differentiating 
how the cortex of a patient has been affected before, during and after the formation 
of a lesion, and also generally throughout their lifetime. 
Combining MRI with CLARITY is something that has only been done in a couple of 
studies, and only in one of relevance to this PhD. Spence et al. (2014) used a 
combination of in vivo MRI with post mortem CLARITY to investigate grey matter 
atrophy in multiple sclerosis.  
It is clear from the rather complex picture of atrophy progression in patients with 
mitochondrial disease discussed in Chapter 5 that this type of multi-disciplinary 
methodology is likely to be the only way to build up a comprehensive picture of the 
longitudinal progression of mitochondrial disease. Previous histopathological work 
indicates observed features in MELAS, a phenotype frequently associated with the 
m.3243A>G point mutation, as being multifocal necrosis (Sparaco et al., 1993; Brown 
and Squier, 1996; Tanji et al., 2001), loss of neurons (Sparaco et al., 1993; Tanji et 
al., 2001), vacuolation (Sparaco et al., 1993), astrogliosis (Brown and Squier, 1996; 
Lax et al., 2016), calcification (Tanji et al., 2001; Lax, 2011) and disruption to the 
vascular network and blood-brain barrier (Lax et al., 2016; Lax, 2011). Clearly there 
are a number of processes involved and the order and causality of these is a long 
way from being identified and pathological investigations are limited to post mortem 





Figure 43. Documented characteristics of lesions seen in patients with mitochondrial 
disease. A.I. shows normal cellular layers in the temporal cortex while A.II. and A.III. 
show loss of neuronal cells and tissue necrosis. B.I. and B.II. show severe 





Therefore, the combination of multiple investigation techniques is the only way of 
taking the large body of neuropathological knowledge forwards to the next stage. 
This will begin by starting to tie together pathological observations made in 
volumetric samples, as opposed to thin slices, using the CLARITY neuropathological 
processing technique and initially combining that with MR images taken of the same 
post mortem volumetric samples. In the long term it is envisaged that high resolution 
MRI of fresh post mortem brains from patients with m.3243A>G can then be linked to 
the fixed tissue MRI and CLARITY observations, with the final step being the 
application of this information to provide details of MRI features that indicate the 
beginnings and progression of very specific changes within the brain, which may aid 
diagnosis, prognosis and the development of treatments. 
The level of detail attainable in immunofluorescent staining of thick sections of post 
mortem tissue prepared using CLARITY is extremely high (Figure 44). 
 
Figure 44. Images of a mouse cerebellum obtained using the CLARITY technique 
combined with immunofluorescent staining and also the use of confocal microscopy 




In order to relate the cellular level observations back to in vivo brains it would be 
ideal if this type of imaging could be registered with a non-invasive imaging modality, 
such as MRI, to gain a better understanding of the processes in the brain as they 
happen. 
All imaging work to date using MRI to investigate the brains patients with the 
m.3243A>G point mutation has been whole brain, in contrast to diseases such as 
multiple sclerosis in which many studies have focussed upon various deep grey 
matter structures (Haider et al., 2014; Debernard et al., 2015; Van de Pavert, 2017), 
and low resolution, of the order of 1mm3 voxels, compared to neuropathological 
techniques, which allows imaging on the scale of just a few microns (Phillips, 2015). 
There has also been no work carried out correlate the anomalies seen on MRI scans 
in these patients with the underlying neuropathological changes, particularly in 
relation to observations of assumed cortical laminar necrosis, which has been 
commented on in MRI papers even though this is a purely neuropathological finding. 
For this reason, there are still a number of different theories for the cause and 
proliferation of stroke-like episodes and little real understanding of the mechanisms 
involved. 
While the previous work in this thesis has shown a number of potentially informative 
changes that occur in the brains of patients with the m.3243A>G point mutation and 
subsequent changes that occur after stroke-like episodes, the lack of understanding 
of the types of cellular changes that lead to changes in the brain that then lead to 
abnormal signals that are picked up on an MRI scan means that as things stand MRI 
is of relatively limited use in the assessment of the cellular state of the brain. 
The introduction of 9 T clinical scanners opens up the option of carrying out higher 
resolution structural scans and also of achieving greater contrast between brain 
tissues, but also the opportunity to utilise other MRI scan types that can provide 
additional information about the brain tissue in each area, such as quantitative T1 
mapping. To inform which of these are the most relevant scans to carry out, it is 
suggested that carrying out MRI scans on post mortem tissue, in conjunction with 
neuropathological techniques, and registering the output images can begin to provide 
details on the cellular changes that lead to each type of anomaly observed. As it is 
likely that multiple types of scan will be required to gain specific combinations of 




opportunity to use long scan times and ultra-high-resolution imaging techniques to 
optimise the types of scan required without initially having any patient involvement. 
The aims of this piece of work were: 
• To develop and assess a very high-resolution MRI scanning sequence for post 
mortem brain sections already mounted in hydrogel. 
• To assess how closely MRI and neuropathology structural image resolutions 
could potentially be matched. 
• To investigate the methods required for high resolution structural MRI scans 
and CLARITY and to ascertain whether they are compatible for carrying out 
imaging, and registration of those image, on the same section. 
• To optimise a scan sequence to carry out quantitative T1 mapping of the post 
mortem brain sections and identify whether this may be a useful technique for 
investigation of the cortex both post mortem and ante mortem. 
• To discuss the future potential insights that the combination of these 
techniques may provide. 
8.2 Methods and Materials 
The post mortem brain sections used in this work are as detailed in Table 5 in 
Chapter 3. 
The MRI scanner used was a pre-clinical 7 T Agilent (Varian) scanner using a 28 mm 
birdcage coil (Rapide Biomedical). 
Prior to each scan being carried out, including between samples scanned on the 
same day, the scanner was calibrated by carrying out a manual shim to optimise the 
signal, checking the position of the peak frequency and adjusting as necessary to 
centre on 50 kHz, using a single pulse (SPULS) scan, and checking the power of the 
pulse to ensure transmission and detection is optimal. Should the frequency and/or 
power be abnormal this was an indication that there was something wrong with the 
overall setup and functioning of the scanner. 
Each post mortem sample was placed in a 20 mm diameter falcon tube filled with 
phosphate-buffered saline (PBS) solution after trials were carried out to assess the 
effect of imaging with this solution around the sample. The samples were not secured 




face uppermost. The falcon tubes then had a collar placed around them so they fitted 
into the centre of the coil and would not move during the scanning process. The 
sections were then inserted into the scanner with the centre of the section at the 
centre of the coil. To assess the position of each slice, SCOUT scans were run, each 
taking around 10 s, with adjustments of the section in between these, until the 
section was in the correct position for the main scan to be carried out. 
8.2.i Structural Imaging 
The scan sequence used for the structural imaging was a gradient echo multi-slice 
(GEMS) sequence using the following parameters: 
Parameter Value 
Repetition Time (TR) 799.84 ms 
Echo Time (TE) 10.04 ms 
Flip angle (α) 20° 
Averages 92 
Slices 20 
Gap 0 mm 
Slice thickness 0.5 mm 
Resolution 512 x 512 pixels 
Field of view 20 x 20 mm 
Pixel size 39 x 39 µm 
Table 28. Table of GEMS scan parameters used to obtain the structural T1 MRIs of 
post mortem brain sections. 
The output files for these scans were standard .nii files and so the images were 




8.2.ii    Quantitative T1 mapping 
For the quantitative T1 mapping a Gradient echo multi-slice inversion recovery 
(GEMSIR) Look-Locker scanning sequence was used. Inversion recovery sequences 
are the gold standard for quantitative T1 mapping, but in this case the GEMSIR Look-
Locker sequence was chosen because it allowed the measurement of T1 values from 
a single inversion recovery. The magnetisation is inverted, and then is sampled a 
number of times using multiple relaxation times during its recovery. As this type of 
scan sequence is sensitive to the flip angle (α), α was kept as small as possible as 
the sensitivity decreases with α. The GEMSIR Look-Locker scan sequence had been 
pre-defined on the Agilent (Varian) scanner and was not designed as a bespoke 
sequence for this work. 
Parameter Value 
Repetition Time (TR) 8.37 ms 
Echo Time (TE) 4.2 ms 
Flip angle (α) 8° 
Averages 20 
Dummy slices 2 
Slices 2 
Gap 0.5 mm 
Slice thickness 0.5 mm 
Resolution 128 x 128 pixels 
Field of view 20 x 20 mm 
Pixel size 156 x 156 µm 
Sweep width 50 kHz 
Receiver gain 10 dB 
Table 29. Scanner settings to run the GEMSIR Look-Locker scan to measure the 




In addition to the scan settings, an array is also required to be defined: 
Start inversion time (TI): 5.00 ms 
End inversion time (TI): 2000.00 ms 
The array values were chosen so that a balance of measurements between the 
negative and positive magnetisation states was taken during the inversion recovery, 
hence the exponential nature of the array values. A representation of this is shown in 
Figure 45. The processing of the data requires that the inversion of the magnetisation 
is taken into account, which was done in this case by using an algorithm in which the 
data was analysed to find the null point, which was also visible by eye as the point at 
which the contrast of the images was inverted, to restore the polarity (Bakker et al., 
1984; Nekolla et al., 1992; Clare and Jezzard, 2001). Polarity restoration also 
reduces any potential noise-induced systematic errors (Tofts, 2003). 
 
Figure 45. Basic representation of a perfect magnetisation inversion recovery to 
demonstrate the array requirement to contain an exponential set of inversion times to 
cover both the negative and positive magnetisation regions equally during the scan. 
For the quantitative T1 mapping scans the scanner room was kept at a constant 
temperature (21.8 ± 0.4 °C) throughout the scans and all of the samples were 





After the scan had completed it was then necessary to generate the T1 map from the 
measurement files captured within the NMRJ software on the scanner computer. In 
this process the sequential images were opened to check their quality. Due to the 
long T1 of the PBS dominating the image if automatic thresholding was selected, the 
threshold was set at 100 ms to optimise the contrast of the brain tissue in the images. 
Using the ‘Math’ tab functions to generate .nii files for M0 and S0, it was then 
possible to generate NIfTI libraries of each quantitative T1 scan and output single 
slice quantitative T1 maps in the .nii file format. Scale bars for the images could only 
be generated using the NMRJ software, and the colour scales could also only be 
altered with ease within the NMRJ software. 
8.3 High Resolution Structural Imaging 
At the time of writing, the most recent high-resolution MRI post mortem human brain 
section studies have reported single slice pixel sizes of 300 x 300 µm (Castillo et al., 
1996; Smith et al., 2012). After optimisation of the scan sequence, pixel sizes of 39 x 
39 µm were achieved, using a slice thickness of 125 µm. The slice thickness could 
be reduced further but was limited by the control computer for the scanner and also 
the time taken for each scan, which was around 12 hours per section. 
Only a representative sample of images has been included here to demonstrate the 
features that can be seen across the group of post mortem samples. 
Figure 46 shows an example of a post mortem section from a non-lesioned region of 
the temporal lobe. This image clearly shows the intact cellular structure of this region, 
but also shows a very low contrast between the grey and white matter within the 





Figure 46. Ultra-high-resolution MRI scan with 39µm x 39µm x 125 µm voxels using a 
brain section from a non-lesioned area of brain from a patient with the m.3243A>G 
point mutation after mounting it in hydrogel. 
The reporting of no visible lesions on the post mortem brain section did not 
necessarily correlate with a lack of structural change in the post mortem brain 
section, as is demonstrated by Figure 47, in which microvacuolation can clearly be 






Figure 47. Ultra-high-resolution MRI scan with 39 µm x 39 µm x 125 µm voxels using 
a brain section from a non-lesioned area of brain from a patient with the m.3243A>G 
point mutation after mounting it in hydrogel. 
Other post mortem sections showed very clear evidence of being lesioned, and this 
was even more apparent after carrying out the MRI scan as there are regions 
underneath the top cortical layers that have disintegrated entirely. It is not clear from 
these images whether the disintegration is of one of the cortical layers, or the 





Figure 48. Ultra-high-resolution MRI scan with 40 µm x 40µ x 125 µm voxels using a 
brain section from a lesioned area of brain from a patient with the m.3243A>G point 
mutation after mounting it in hydrogel. 
8.4 Quantitative T1 mapping 
The output quantitative T1 maps were given a multi-coloured scale as this showed 
very clearly the boundary between the white (yellow and dark green) and grey (light 
green, blue, and red) matter in the post mortem section. Although the structural 
image did not provide good contrast between the two tissue types, quantitative T1 
mapping does provide very good contrast, as seen in Figure 49. There appears to be 
some evidence of differentiation between the cortical layers, but these are not clearly 
defined in these sections. It should be noted that individual pixel sampling was 
carried out on each image to verify which part of the scale they sit on. In Figure 49, 





Figure 49. Quantitative T1 map showing the variation of T1 (in seconds) in a post 
mortem section of fixed brain tissue after mounting in hydrogel from a non-lesioned 
area of brain from a patient with the m.3243A>G point mutation. 
The effect of neurodegeneration can also be clearly seen in the quantitative T1 map 
of the lesioned section shown in Figure 48. Where the brain tissue has degenerated, 
there is literally nothing left and these areas have been filled with hydrogel and so 
have the same T1 value as the surrounding fluid. 
 
Figure 50. Quantitative T1 map showing the variation of T1 (in seconds) in a post 
mortem section of fixed brain tissue after mounting in hydrogel from a lesioned area 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The T1 values for Patient 1 in Table 30 are clearly larger than for all of the other 
samples and this is due to these sections only being fixed and not being mounted in 
hydrogel. The physical differences between the two processes of fixation and 
mounting in hydrogel are large as the fixation process leaves all of the original 
material in situ, but through the application of formalin bonds are formed that stabilise 
the tissue and reduce T1 values from those of unfixed tissue, whereas when tissue is 
mounted in hydrogel all of the lipids are stripped out of the section, which has the 
effect of shortening the T1 values even further making it difficult to obtain high-quality 
very high-resolution MRI scans. 
8.5 Discussion 
To date there has been very little work carried out that attempts to identify 
neuropathological correlates for MRI features. This has mostly been because of the 
lack of techniques for the staining of thick tissue sections combined with limited 
spatial resolution of MRI scanning. With the development of the CLARITY technique 
for the processing, staining and imaging of thick brain slices of up to 500 µm, 
compared to the usual 5-10 µm in standard neuropathological staining techniques, 
along with up to 9 T MRI scanners becoming more prevalent, particularly in the form 
of pre-clinical scanners, the opportunity to finally begin to carry out multimodal 
imaging and analysis of post mortem tissues is finally here. 
Figure 48 and Figure 50 clearly show the end state of the lesion process and it could 
be argued that these regions are perhaps of the least utility due to the significant 
degeneration and tissue loss. Once brain tissue has reached this point there is little 
point in correlating the features with in vivo scans as entire cortical layers have 
already been completely destroyed and so any correlation in these specific areas will 
be between whatever substance is now filling that gap. In the case of the in vivo brain 
it will be CSF, in the post mortem sections it will be formalin solution, air, or a buffer 
solution. It is of far more interest, and use, to study the cellular changes occurring in 
regions where lesions are not obvious, but there are changes actively occurring, as in 
Figure 47, but even in this case we only know that there was no visible lesion 
recorded during the post mortem and not whether there would have been a lesion, or 
any other visible MRI changes, identified on an MRI scan. This highlights the first 
issue that the development of this multi-disciplinary technique faces, which is the lack 
of longitudinal image and data collection throughout the life of a patient, through to 




The second issue highlighted by the sections that were available to scan as part of 
this piece of work is that they had already been mounted in hydrogel, which was 
initially seen as desirable as this reduced the number of CLARITY processing steps 
that had to be carried out on each section post-MRI and was believed to increase the 
chances of a successful image registration. Unlike the fixation process, in which the 
changes caused to the brain tissue by the process are relatively well documented, 
the effects of mounting brain sections in hydrogel are not well understood from an 
MRI perspective. In fixed brain tissue, the T1 values of grey and white matter are 
similar, although much shorter, than an in vivo brain, which means that the grey 
matter T1 value will be larger than for white matter (Tofts, 2003). My work has shown 
that mounting a brain section in hydrogel not only significantly shortens the T1 values, 
which makes optimising a sequence much more difficult and also limits the resolution 
compared to a fixed section with longer T1 values, it also affects grey and white 
matter to different extents so that the grey matter in a section will end up with T  
values lower than those of the white matter and so the contrast is not only reduced, 
but also inverted compared to both fixed post mortem brain sections and in vivo 
brains. 
The fact that my brain sections had already been mounted in hydrogel is clearly a 
very large limiting factor to this work, but despite that it was still possible to optimise a 
very high resolution 7 T MRI scan sequence to provide output images with very good 
signal to noise ratios, and considering the very short T1 values a reasonable contrast 
between grey and white matter. To take this work forwards effectively would require 
optimisation of a high-resolution scan sequence using fixed brain tissue sections as 
this could not only provide greater contrast images, but also the potential for either 
reduced scanning times or increased resolution. 
Attempting to register MRIs with neuropathological images initially appeared to be 
something that could be achieved, despite the disparity in the resolution of the 
images. However, a closer inspection of the CLARITY protocols highlighted a 
number of issues, but by far the biggest issue was the amount of movement of each 
section that occurred during the processing. With the development of possible 
techniques for carrying out CLARITY on 500 µm thick sections of brain tissue, there 
would have been a possibility to carry out MR imaging at this point, thus reducing the 
amount of movement between the MR imaging and the neuropathological imaging. 




caused by the mounting in hydrogel now precludes this, but there are far greater 
challenges to overcome due to the standard procedures for the rest of the 
processing. 
CLARITY antibody staining, unlike standard thin section staining that is carried out 
with tissue mounted on a slide, is carried out with the sections floating freely in 
solution to allow the antibodies to penetrate the entire section. Therefore, attempting 
to get a stained brain section onto an imaging slide in the same orientation and 
without significant warping or physical distortion is virtually impossible unless there is 
a large feature within the slice that is, at an absolute minimum, around 80 µm in size 
for the MR imaging to be able to resolve, according to the Nyquist theorem. In 
practice there are additional image processing methods that have been developed 
for coregistration to pathology that may provide options to develop and optimise 
registration protocols for the brain to take this work forwards (Orczyk et al., 2012; 
Antunes et al., 2018). 
Despite the very clear need for neuropathological correlates for MR imaging, I have 
identified that the practicalities of achieving the gold standard of fully registered MR 
and neuropathological images is currently not trivial to achieve and much 
development of CLARITY processing techniques would have to be carried out to 
achieve this. Even without this gold standard there is a great deal of work that could 
be carried out to being to more fully investigate the cellular changes within post 
mortem brain sections that could involve ultra-high resolution of fixed brain sections 
followed by standard neuropathological techniques that could begin to provide 
neuropathological correlates for observed MRI changes. 
Quantitative T1 mapping, although it suffers from the same T1 value reduction issues 
as the structural imaging, may provide an easier method to gain further insights into 
the brains of patients with mitochondrial disease, both through the high resolution 
quantitative T1 mapping of post mortem brain sections, but also ‘reverse engineering’ 
these to provide more information about the in vivo brain, particularly in relation to 
any changes that are observed within the cortex, which I showed in Chapter 6 to be 
significantly affected by the onset of stroke-like episodes.  
The reason I have identified quantitative T1 mapping as potentially useful source of 
information is because the T1 values of tissue are directly related to properties of the 




and also the concentration of macromolecules (Gowland and Stevenson, 2003). The 
benefit of using T1 values over T1-weighted images is that T1-weighted images have 
a lot more contributing factors in order to produce grey scale contrast images. 
Quantitative T1 mapping not only provides a better contrast between tissue types, it 
also provides the quantitative difference between them as well, which means that 
differences between controls, carriers, and patients with MELAS can be quantified 
and also potentially investigated further using other MR techniques, such as looking 
at metabolite ADCs. Quantitative T1 mapping of in vivo brains could also provide a 
clinical baseline, much in the same way as TPV and cortical thickness has been used 
in chapters 5 and 6, so that clinically significant changes in T1 values could be 
identified and used in conjunction with other brain measures in longitudinal studies to 
ascertain the order and the extent of observable MR changes during the progression 
of mitochondrial disease in anyone carrying the m.3243A>G point mutation to gain a 
much more in depth understanding of the range of individual differences and perhaps 
begin to pinpoint any regions where protective mechanisms appear to be in effect. 
In this chapter I have begun a discussion on the way forward for a multi-disciplinary 
approach to investigating mitochondrial disease with a view to achieving a much 
greater mechanistic understanding that may underpin future therapeutic strategy 
development. While it is one thing to discuss the methods required, it is another to 
put in place the systematic data collection required to achieve the greatest 
understanding, and until both standardised methods and a systematic approach are 






Chapter 9. Final Discussion 
9.1 MRI studies of the brain 
This study was begun with a very small amount of published work on volumetric 
analysis using MRI in relation to adult individuals with the m.3243A>G point mutation 
and mitochondrial disease, which was a difficult starting point considering the 
complex, multisystemic, and unpredictable nature of mitochondrial disease. 
Therefore I had to develop testable hypotheses from a range of different sources 
whilst also keeping in mind that there may be quantitative information available that 
had not yet been identified. There was also the issue of a lack of standardised 
methods, patient selection, or patient grouping when carrying out quantitative 
volumetric work on MRI scans of the brains of people either just carrying a 
mitochondrial mutation through to those with a fully definable phenotype. The 
published studies also generally do not provided clinical details of patients, so it is 
often unclear how, or why they have been grouped as they have. 
The complexity of mitochondrial disease, along with its multisystemic nature, make a 
systematic approach absolutely vital in order to obtain enough comparable data to be 
able to draw useful, and accurate, conclusions. Therefore the main aim of this thesis 
was to establish validated and justified methods to carry out an initial systematic 
volumetric analysis of both carriers and patients with MELAS to allow the formulation 
of more specific testable hypotheses both for further investigation within later work for 
this thesis, and also for future work in the form of highlighting specific regions of 
interest for the development of neuropathological correlates of structural MRI scans 
as well as regions to investigate further using both structural and functional MRI 
techniques. 
9.1.i Volumetric 
During the course of this thesis, I developed a number of protocols to systematically 
process T1-weighted high-resolution structural brain MRI scans. I began by carrying 
out the time-consuming accuracy validation for these high-resolution anatomical T1-
weighted scans, which allowed me to justify and validate the use of FSL 5.0 for the 
global segmentation of tissues within this study as the comparison with the 
segmentation results of manual segmentation were matched closely (Chapter 4). 




MRI segmentation volumes and actual volumes defined through pathological 
dissection so this work does not necessarily imply that the selection of segmentation 
software provides the ‘correct’ volumes, but does provide justification for making that 
selection based on the observable and measurable properties of the MRI scans 
available. One of the overarching comments for all of the segmentation work is that 
all of these segmentation protocols require scans to be high resolution, and also high 
contrast, thus leading to scans using protocols such as SPACE are not suitable for 
these analysis methods, although they may be favoured by radiologists due to the 
increased contrast between brain tissue and pathology, and this is an important 
takeaway point from this study to inform any future volumetric work (Okada et al., 
2011). 
The method developed for global segmentation provides a straightforward 
methodology, which if combined with additional work to standardise scans between 
scanners and sites, could provide the basis for a much larger database for the study 
of individuals with mitochondrial disease. The systematic review (Chapter 2) 
highlighted the lack of standardised reporting, which leads to the loss of valuable 
information that is perhaps not deemed important enough to make it into a 
publication with a strict word limit, and the differences in the reported information 
makes it extremely difficult to combine or compare studies. 
The global segmentation showed that, within the cohort of individuals with the 
m.3243A>G point mutation, TICV was strongly correlated with a clinical history of 
stroke-like episodes, and that this could potentially be used as a surrogate measure 
of susceptibility to the onset of stroke-like episodes in younger carriers of the 
m.3243A>G point mutation. The initial assumption that head circumference could 
potentially provide a much simpler surrogate measure in adults was quickly called 
into question after carrying out correlation calculations. The use of adult head 
circumferences to assess the percentile a person sits in is also problematic as there 
is currently no accepted percentile definition. 
The TPV measurements showed that patients with MELAS showed high levels of 
atrophy compared to both the control and carrier groups, which supports the 
anecdotal clinical evidence of a link between high levels of atrophy and a clinical 
history of stroke-like episodes. The rate of atrophy was also touched-upon with a 




scans were available (although they were not part of the main cohort). The results 
from this study showed that atrophy can be very fast, decimating the brain tissue 
volume with around a 25% reduction over 8 - 10 years. While other generic lifestyle 
factors known to cause accelerated brain shrinkage, such as drinking alcohol, 
smoking, and diabetes, are important to consider, the mechanisms are very different 
as the rate of atrophy only increases slowly over decades, and even then the volume 
loss is only around half of that seen in patients with mitochondrial disease. 
This fact makes identifying those susceptible to stroke-like episodes, and therefore 
also this rapid atrophy, an important endeavour if this process is to be understood to 
allow preventative treatments to be developed. To date, the atrophy associated with 
neurodegeneration in patients with mitochondrial disease has only been monitored 
visually, but this does not provide an accurate assessment of either the rate, or the 
true volume loss. 
The very small, again opportunistic, longitudinal study of atrophy scans indicates that 
understanding the mechanisms for the onset of rapid atrophy are likely to be closely 
linked to the onset of stroke-like episodes as the brain volumes were normal for the 
head size and age at the first scan, but there is currently no information to suggest 
whether there is a causal relationship between the two, so the only way to increase 
characterisation of these changes is to being to carry out longitudinal, quantitative 
monitoring of brain volumes. 
Looking at the results for GM and WM volumes in Figure 32 and Figure 33 it is clear 
that despite the individual differences, there are clear differences between the control 
and carrier groups, even in the absence of obvious neurological symptoms that 
equate to carriers of the m.3243A>G point mutation having a smaller percentage of 
GM, and higher percentage of white matter, in the make-up of their brain tissue. 
The regional analysis of GM in the form of cortical thickness allowed me to carry out 
a systematic investigation of brain regions and to identify which regions are 
significantly thinner in carriers as well as in patients with MELAS. Perhaps one of the 
most surprising results is the observation that the precentral, paracentral, and 
postcentral gyri are significantly thinner in carriers than in controls and this results 
does fit with clinical reporting of movement disorders and a slow mental processing 
speed across both carriers and patients with MELAS. One area that has the cortical 




this region warrants further attention to ascertain if there is some sort of 
compensatory mechanism in place protecting this particular area. Other than the 
areas already mentioned, the occipital and parietal lobes are not significantly different 
between controls and carriers. This is in stark contrast to the temporal lobe, in which 
a number of regions are significantly thinner in carriers of the m.3243A>G point 
mutation compared to controls. These differences are most pronounced in the 
entorhinal cortex, fusiform gyrus, and temporal pole. It is important to note that these 
changes are seen even in the carriers who have no reported symptoms. However, 
even from this starting point of being significantly thinner in carriers than in controls, 
the temporal lobe undergoes further thinning, of around 10%, along with all of the 
other lobes after the onset of stroke-like episodes. Therefore, the existence of these 
differences between carrier and control brains are unlikely to be directly related to the 
onset of stroke-like episodes without some other type of mechanism being present as 
well.  
As has already been mentioned, this study was only able to take a snapshot of the 
brains of everyone who had scans. This means that this study is not able to provide 
any information regarding the starting state of the brain of each person, or to provide 
an insight into any changes that happen over time that may provide key information 
about any causal processes that lead to some people with the m.3243A>G point 
mutation going on to develop stroke-like episodes and rapid atrophy. 
The complex nature of mitochondrial disease and the extremely large individual 
variations suggests that the only way to get a true perspective on neurological 
disease progression is to carry out quantitative analysis, not only of brain volumes, 
but also on other quantitative measures that can be made of the brain, such as 
quantitative T1 values, connectivity analysis, functional analysis using fMRI, along 
with non-scanning quantitative measures such as cognitive function tests. This 
clearly places a large assessment and analysis burden against carrying out this type 
of monitoring, but the inaccessibility of the brain and the rapid neurodegeneration 
suffered by MELAS patients is unlikely to be any better understood until this type of 





TBSS is a method for carrying out analysis across the whole of the brain to assess 
whether there are significant variations in FA between either different groups, or 
between different time points for an individual. 
The TBSS analysis that was carried out looked at the differences between the carrier 
and MELAS groups. The control group utilised in the other sections of the study 
could not be used as they did not have a DTI scan taken as part of their scanning 
protocol. While this limited the group comparisons that could be made, it also 
highlighted the importance of having understanding of the analysis techniques prior 
to recruiting participants and collecting the scans for analysis. The aims of the 
analysis also need to be clearly defined as in this study it was only possible to 
compare the carrier group to the group with MELAS, which could only provide 
information on generic differences between the two and it was not possible to extract 
any information on individual differences and the extent to which these may have 
affected the group comparison. 
While the results gave a couple of regions of interest that appear to be significantly 
different between groups, there were indications, in the form of many small regions of 
significantly different FA, distributed globally throughout the brain that potentially 
many regions may show altered FA but these are specific to individuals and only 
small patches of these are highlighted in the groupwise analysis. 
With the increased understanding of what this technique is and what it shows, there 
are obvious improvements that can be made in improving future scan collection and 
analysis. The two biggest factors that will have an impact upon the outputs are: 
• Increase in the numbers of participants in each group to much better ascertain 
whether there are any true group differences between controls, carriers, and 
patients with MELAS. 
• Carry out longitudinal DTI scans of all three groups so that changes within an 
individual brain can be assessed over time. This will provide information on: 
o FA changes that occur in a healthy brain to inform what size of change 




o FA changes that are observed in carriers who will eventually fall into 
one of two categories, those who do not go on to develop stroke-like 
episodes and rapid atrophy, and those do, 
o FA changes associated with the rapid atrophy and ongoing stroke-like 
episodes in patients with MELAS. 
This method allows for generic analysis to be carried out across the whole brain, but 
more detailed analysis of white matter tracts and connectivity is also possible, and 
highly recommended, as specific regions of interest are defined in the volumetric 
analysis, and also potentially in future fMRI work. This again will require careful 
assessment of the scan requirements for each type of analysis prior to the capture of 
the scans, or possibly even prior to the recruitment of the participants. 
9.1.iii Ultra-high-resolution MRI scanning 
As this project has developed it has become clear that complete answers about any 
aspect of mitochondrial disease are highly unlikely to come from a single imaging 
modality. Perhaps the most obvious pairing to make is that of neuropathological 
staining and MRI, but until recently there have been practical issues preventing co-
registration of imagery. 
Every imaging and analysis modality in this research area is moving towards 
quantitative analysis, but the development of complementary techniques is still very 
much in its infancy. 
This study identified an opportunity to carry out initial development of an ultra-high-
resolution MRI scanning protocol on a 7 T pre-clinical scanner that would potentially 
allow registration with a CLARITY image that would be generated after the MRI 
scanning had completed and after subsequent staining of a target of interest had 
been carried out. 
During the work there were a number of key issues that were highlighted that are 
very important if this work is to be taken forward and the desired multi-modal imaging 
is to be achieved: 
• The MRI scans must be carried out prior to the tissue sections being mounted 
in hydrogel as the stripping out of the lipids reduces the T1 values to such an 




this also has the knock-on effect that the images are not easily relatable to any 
in vivo scans, 
• The treatment of the tissue sections during the rest of the CLARITY process 
currently requires the tissue section to be free to move within various 
solutions. This movement away from the original position in which the MRI 
scan is done creates a huge challenge in the image registration process and 
either features need to be identified that will allow some sort of algorithmic 
registration to be carried out, or development of a CLARITY process that 
allows the tissue section to remain flat and in the MRI scan position. 
The challenges of achieving this type of image registration should not be 
underestimated as it has recently been found that there is an entire PhD studentship 
dedicated to this exact subject. 
Despite the challenges identified within this section of the study, good progress was 
made in understanding the capabilities and limitations of using a 7 T pre-clinical 
scanner to generate ultra-high-resolution MRIs of post mortem tissue. The pixel 
resolution achieved was 39 µm2, which is almost small enough to begin to think 
about attempting to register the images against neuropathological images, but the 
thickness of the image slice was too large, at 125 µm. These limits were mostly 
imposed by the effects of the hydrogel on the tissue sample and the reduction of T1 
values to a fraction of those found in fixed tissue and it should be expected that these 
limits can be relatively easily surpassed using fixed tissue samples with similar 
scanning protocols. 
The full effects of mounting the tissue samples in hydrogel did not become apparent 
until quantitative T1 mapping was carried out on each section. This highlighted the 
reduction in T1 values and also that the grey and white matter had been affected very 
differently by the process, which ultimately led to an inversion of the expected 
relationship between the T1 values in each type of matter. This, again, highlights the 
importance of carrying out quantitative measurement and analysis as it provides a 
much greater level of detail, and therefore a greater potential contribution to the 
understanding of an observation or process, than qualitative analysis. 
The quantitative T1 mapping also showed the benefits of carrying out quantitative 




between the different cortical layers, as well as seeing a clear boundary between the 
grey and white matter, which was not always obvious in the qualitative MRIs. 
Multi-disciplinary investigation of tissue samples was last attempted in the early 90s, 
but neither the neuropathological methods nor the MRI scan protocols were at a 
stage where the desired outputs could be achieved. These are now in place and it is 
time to bring multiple disciplines together and align the aims and outputs to increase 
the amount of information it is possible to extract from the captured data. 
9.2 Implications of this study 
The implications of this study are that just being a carrier of the m.3243A>G point 
mutation is enough to lead to significant differences in the brain compared to healthy 
controls. Some of these changes affect every single person with the mutation, and so 
these are unlikely to be directly correlated with the later development of stroke-like 
episodes, unless there are threshold values. The changes in the brains of carriers of 
the m.3243A>G point mutation are not always what would be expected, for example 
the higher values for FA found in this study, the percentage of the brain cavity filled 
with brain tissue, and the significantly thinner cortex in the pre-, para-, and post-
central gyrus that has not been reported previously. This study has shown the 
potential for structural MRI analysis to provide novel information about the effects of 
carrying the m.3243A>G point mutation, as well as demonstrating the devastating 
speed of atrophy that generally accompanies the occurrence of stroke-like episodes 
and the absolute importance of the opportunity to either delay or prevent the onset by 
identifying a predictive biomarker. Head size, in the form of TICV, appears to be a 
potentially easy to measure predictor of disease severity in carriers of the 
m3243A>G, and therefore also of potential susceptibility to stroke-like episodes. 
However, perhaps the biggest implication of this study is that we are only just 
beginning to identify and pursue the techniques required to gain a solid 
understanding of the mechanisms associated with mitochondrial disease and why the 
disease is so heterogeneous in nature even within a single genotype. 
9.3 Study Limitations 






Chapter 4 – Accuracy of segmentation software 
This work, although providing justification for the choice of software used in this 
specific study, is perhaps not valid for scans from other scanners, or using alternative 
MRI protocols for anatomical imaging of the brain. The study also only compared the 
segmentation results produced by a single individual. For a more robust validation, 
the manual segmentation would need to be carried out my multiple people. This 
study also only considered two of the possible options for global segmentation. 
Although these are the two pieces of software most often used for global 
segmentation, it could be argued that FreeSurfer should also have been included, 
and also the validation extended to validation the regional volumes produced by 
FreeSurfer, however time constraints led to this option not being taken. 
The major consideration to be taken forwards is that there is currently no 
segmentation software, or method, that has been fully validated and confirmed to 
accurately and repeatably represent the actual tissue differences within the brain. 
This lack of validated segmentation method is compounded by the lack of a standard 
MRI scanning protocol for anatomical scans, and the increasing use of alternative 
protocols for enhanced tumour and lesion contrast in place of the preferred MPRAGE 
scan protocols that are optimised for healthy tissue classification. 
Chapter 5 and 6 – Global and Regional segmentation 
The volumetric work in this this section of the study set out a straightforward protocol 
to follow to measure and analyse brain volumes. The initial concept of grouping 
together all participants carrying the m.3243A>G point mutation was quickly seen to 
be inadequate and that there are significant differences between those with 
diagnoses of MELAS, and those without. This indicates that much more thought and 
preparation needs to go into the selection of study participants to be able to gain the 
most information from the work carried out. 
This phase of work specifically used hypotheses that allow for the use of smaller 
sample sizes with the aim of providing more clinically relevant results. This approach 
was successful for this study, but more subtle, but still clinically significant differences 
may have been missed due to the lack of power. 
The inclusions of patients with lesions led to them having to be removed from much 




while taking into account the effects of the presence of the lesions due to 
misclassification of those areas. 
The lack of 3D anatomical MRI scan history for any of the participants of this study 
meant that the results from the analysis carried out had to be compared between 
participant groups. This lack of history means that vital information about the starting 
point of each person was not available, so a true measure of their changes could not 
be assessed. To begin to put together more meaningful change observations, 
longitudinal scans will need to be taken from the point of identification of the genetic 
diagnosis so that in addition to group comparisons, individual comparisons with their 
previous scans can also be made. 
Chapter 7 – TBSS 
There are a number of learning points that came out of this section of the study. The 
first is that the use of DTI scans is not straightforward and that both the scan 
protocols and the analysis methods have to be carefully selected along with having a 
sound understanding of how the analysis methods treat the recorded data. 
This method could provide a particularly powerful longitudinal analysis method as 
one of the analysis options is to specifically compare the current measure of 
fractional anisotropy against previously recorded measures for an individual. This, 
like the volumetric methods, could provide valuable information about how the brain 
of an individual changes over time, which then allows more insight to be gained on 
the variation in progression patterns, symptom onset, and also overall severity. 
There are techniques that allow much more detailed analysis of white matter tracts to 
be undertaken, but these have a significant time burden associated with them and 
also require very specific regions of interest to be identified to optimise the analysis 
techniques. The identification of the temporal pole as a key region of interest in both 
carriers and patients with MELAS, provides the first definitive area that could be 
investigated as it is known that it is affected in all carriers of the m.3243A>G point 
mutation, but what is unknown is whether there are additional connectivity, or 
network, differences that may facilitate development of stroke-like episodes. 
There is also an ongoing debate about whether it is better to use DTI or DKI scans. 




to identify which method could provide the most useful information about the brains 
of people with the m.3243A>G point mutation. 
Chapter 8 – Ultra-high-resolution 7 T MRI of post mortem brain sections 
It is clear that the greatest limitation in this work was the fact that the brain sections 
that were available had already been mounted in hydrogel, which had removed the 
lipids from the sections. This significantly altered the physical properties of the tissue 
making it difficult to obtain the highest quality MRI scans. If the scans were to be 
carried out prior to mounting in hydrogel the resolution limits of the ultra-high-
resolution scanning would be increased, and it would also be possible to get much 
more useful information about the cortical layers using higher resolution quantitative 
T1 mapping. To date, the capabilities of a 7 T pre-clinical MRI scanner have not been 
pushed to their limits, but in the future higher field scanners should be considered 
should these limits need to be pushed further to obtain the resolution required to 
achieve true image registration with CLARITY stained tissue sections. 
To fully take this work forwards the cellular targets for the neuropathological staining 
would need to be defined and the CLARITY process optimised. 
The biggest challenge for researchers in this area is currently finding a way to 
achieve image registration between the CLARITY images and MRIs. The CLARITY 
process, as it stands, requires the section to be suspended in solutions containing 
the required antibodies, and the MRI scans are taken prior to this, so the key problem 
to solve to take this forwards is how to reorient, or prevent movement of, the section 
to allow the images to be fully registered to each other. Once this problem is 
resolved, this will provide an incredibly powerful analysis technique to potentially 
allow analysis at the post mortem cellular level to be ultimately applied to in vivo 
imaging to understand and assess real-time changes in cellular function. 
9.4 Concluding remarks 
In conclusion, the methods presented in this thesis form a starting point for a 
standardisation of MRI processing that can be used across the mitochondrial disease 
population, while the data has expanded upon current knowledge by systematically 
looking at the structural properties of the brains of individuals harbouring the 
m.3243A>G point mutation and may have allowed the identification of TICV as a 




greater level of understanding larger sample sizes, longitudinal studies, and an 
emphasis on quantitative measurement and analysis that are clinically significant, are 
required in all areas with a multi-disciplinary approach being identified as the most 
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Appendix A – Global Segmentation Procedure Details 
A.1 Segmentation of global tissue volumes 
Segmentation of the MRI scan images to produce the global tissue volumes was 
carried out using the FSL FMRIB’s Automated Segmentation Tool (FAST) (Zhang et 
al., 2001) as justified by the work carried out in Chapter 4 regarding the accuracy of 
the volumetric outputs. 
Stage 1: Skull stripping was carried out using the FSL Brain Extraction Tool (BET) 
(Smith, 2002) using the following settings: 
 
Figure 51. Screen capture of the FSL BET GUI (reproduced here with the permission 
of the FMRIB FSL Development Group, Oxford University). 
Input file = original .nii file 




Fractional intensity threshold was optimised to provide the most accurate removal of 
the skull, leaving the entire brain cavity intact. It was found that for all of the high-
resolution scans this should be set to 0.5. 
The extraction protocol used was: Robust brain centre estimation (iterates bet2 
several times), where bet2 is the basic brain extraction tool algorithm. 
The extracted brain file was then examined using FSLView to assess the accuracy of 
the brain extraction to ensure that all of the brain was present. The brain-extracted 
image would then be further used in the segmentation process using the FSL FAST. 
 
Figure 52. Screen capture of the FSL FAST GUI (reproduced here with the 
permission of the FMRIB FSL Development Group, Oxford University). 
Leave all settings as is, except increase number of iterations to 5. 




pve_0 = CSF 
pve_1 = GM 
pve_2 = WM 
The segmentation for each individual was then assessed using FSLView, loading up 
the extracted brain file and overlaying each of the segmented classifications on top to 
ensure that the segmentation was ok. 
The volumetric measurement for each of these is then extracted using the command 
line prompt: 
fslstats file_pve_0.nii.gz –M –V 
To obtain the volume in mm3 of each tissue type, the first and third of the returned 





Appendix B – TBSS Protocol Details 
TBSS Protocol 
Pre-processing for 17 NCL patients 
Select only the first average of the scan taken by using the following commands in 
the FSL terminal: 
fslroi input_file.nii.gz output_file.nii.gz 0 65 
Select the second average: 
fslroi input_file.nii.gz output_file.nii.gz 65 65 
Open bval and bvec files in Excel and take out second average ‘a’ values (they are 
the same for both averages). 
Create a new folder for each input .nii file with a copy of the bval and bvec file. 
Carry out eddy current correction: 
eddy_correct input_file.nii ecc.nii 0 
Rotate bvecs: 
fdt_rotate_bvecs input.bvec rot.bvec ecc.ecclog 
Note that bvecs must be rotated for each individual DTI .nii file as the eddy current 
correction will be different for each one. 
Open the FSL GUI. 
Run brain extraction (BET): 
Input file is ecc.nii (BET will only take the b0 scan to run the BET on), leave output 
file to populate automatically, set the fractional intensity to 0.25, use the ‘Robust 
brain centre estimation’, and check the ‘Output binary mask image’ option in the 
‘Advanced’ section. 
Open FSLView and carry out a manual check of the brain extraction to ensure that 




brain. If either case is encountered modify the fractional intensity value (lower value = 
more volume included, higher value = smaller volume included). 
Run DTIFIT: 
Select ‘FDT Diffusion’ 
In the dropdown menu at the top of the box select ‘DTIFIT Reconstruction diffusion 
tensors’ 
Select ‘Specify input files manually’. 
Diffusion weighted data = ecc.nii 
BET binary brain mask = ecc_brain_mask.nii 
Output basename: Automatically populates 
Gradient directions = rot.bvec 
B values = file_name.bval 
Once DTIFIT has been run on all of the files required, collect all of the FA files into a 
single folder ensuring that each group (i.e. controls, carriers, patients) have a 
different identifier at the beginning of the FA filename. 
Pre-TBSS processing stages 
From within the folder of FA files run the follow: 
tbss_1_preproc *.nii.gz 
This creates a new folder called ‘FA’, along with another called ‘origdata’ that will 
contain all of the original FA files. 
Once tbss_1 has run, open the FA folder, then open the ‘slicesdir’ folder. If the 
processing has been successful all of the strips will show DTI images. If any do not 
show images and are blank, this indicates that there has been a problem with the 





Then run  
tbss_2_reg –T 
to align all of the FA images to the FMRIB58_FA standard space. 
tbss_3_postreg –S 
to bring all of the subjects into MNI152 space. 
View the skeleton output in the stats folder (mean_FA) to assess what the most 
suitable threshold is for the next stage. This is used to remove noise from outside the 
white matter. The threshold can most often be set at 0.2. 
tbss_4_prestats 0.2 
to apply the thresholding. 
Pre-TBSS DTI Batch Processing 
Each .nii DTI file should be in its own folder with a copy of all.bvec and all.bval. The 
script then carries out eddy current correction, b vector rotation, brain extraction on 
the b0 scan, and finally the DTIFIT process. This will output a number of files but the 
FA is the file required for TBSS. 
Shell script to automate the pre-TBSS DTI processing: 
#!/bin/sh 
eddy_correct file_in.nii ecc.nii 0 
fdt_rotate_bvecs all.bvec rot.bvec ecc.ecclog 
bet ecc.nii ecc_brain.nii –R –f 0.25 –g 0 –m 








To run TBSS a general linear matrix (GLM) needs to be generated. This can be 
carried out by opening the FSL GUI and using the GLM option in the Misc tab. It is 
easiest to create this within the ‘stats’ folder of the current analysis folder. 
The group sizes used in the statistical analysis were as follows: 
Carriers (10) – Patients (8) = Total 18 
In all cases two EVs were used with group 1 being the first named group above, and 
group 2 being the second named group. 
Four contrasts were used for each analysis with values as shown in brackets and the 
control-carrier group used as an example: 
1. Carrier FA > MELAS FA (1, -1) 
2. MELAS FA > Carrier FA (-1, 1) 
3. Carrier mean FA (1, 0) 
4. MELAS mean FA (0, 1) 
The matrix should be then be saved in the stats folder as e.g. CaME for the above 
example, which then generates a number of files that will be used in the next stage. 
The final step is to run ‘randomise’ to carry out the analysis using the following 
command line, where ‘n’ is the number of permutations: 
randomise -i all_FA_skeletonised -o tbss -m mean_FA_skeleton_mask -d 
GLM_matrix_name.mat -t GLM_matrix_name.con -n 5000 –T2 -V 
The number of permutations used in this analysis was 5000, however this should be 
considered the minimum for each of the larger datasets and if time and processing 
facilities permit, larger n values should be used for large datasets such as these. 
 
